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ABSTRACT 
The dystrophinopathies are a group of disorders characterised by cellular absence of 
the membrane stabilising protein, dystrophin. Duchenne muscular dystrophy is the 
most severe disorder clinically. The deficiency of dystrophin, in the muscular 
dystrophy X-linked (mdx) mouse causes an elevation in intracellular calcium in 
cardiac myocytes. Potential mechanisms contributing to increased calcium include 
enhanced influx, sarcoplasmic reticular calcium release and\or reduced sequestration 
or sarcolemmal efflux. This dissertation examined the potential mechanisms that may 
contribute to an intracellular calcium overload in a murine model of muscular 
dystrophy. The general cardiomyopathy of the mdx myocardium was evident, with the 
left atria from mdx consistently producing less force than control atria. This was 
associated with delayed relaxation. The role of the L-type calcium channels mediating 
influx was initially investigated. Dihydropyridines had a lower potency in contracting 
left atria corresponding to a reduced dihydropyridine receptor affinity in radioligand 
binding studies of mdx ventricular homogenates (P<0.05). This was associated with 
increased ventricular dihydropyridine receptor protein and mRNA levels (P<0.05). 
The function of the sarcoplasmic reticulum in terms of release and also sequestration 
of calcium via the sarco-endoplasmic reticulum ATPase were investigated. A lower 
force of contraction was evident in mdx left atria in response to a range of stimulation 
frequencies (P<0.05) and concentrations of extracellular calcium (P<0.05). However, 
in the presence of 1 nM Ryanodine to block sarcoplasmic reticular calcium release, 
increased stimulation frequency caused similar forces to those obtained in control 
mice suggesting enhanced calcium influx via L-type calcium channels in mdx. Rapid 
cooling contractures showed a reduced contracture in mdx compared to control in 
response to cooling. This suggests some dysfunction in SR storage, which may be 
associated with the delayed relaxation time. Concentration-response curves to 
inhibitors of the sarco-endoplasmic reticulum showed no difference in function of the 
enzyme responsible for calcium uptake into the sarcoplasmic reticulum. Although 
sarco-endoplasmic reticulum ATPase mRNA was upregulated, no functional benefit 
was evident. This study indicates that a deficiency of dystrophin leads to upregulation 
of L-type calcium channels that contribute to increased calcium influx, with no 
functional change in sarcoplasmic reticular sequestration. Upregulation of the influx 
pathway is a potential mechanism for the calcium overload observed in mdx cardiac 
muscle.  
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RT-PCR Reverse-transcriptase – polymerase chain reaction 
RyR  Ryanodine Receptor 
SD  Standard Deviation 
SEM  Standard Error of the Mean 
SERCA  Sarco-endoplasmic reticulum Ca2+-ATP-ase 
SR  Sarcoplasmic Reticulum 
TPSS  Tyrodes Physiological Salt Solution 
µM  Micromolar 
VRL   Verapamil 
vs  Versus 
 vii
CONTENTS 
ABSTRACT .....................................................................................................ii 
CERTIFICATION OF DISSERTATION...........................................................iii 
ACKNOWLEDGEMENTS ..............................................................................iv 
GLOSSARY OF ABBREVIATIONS ................................................................v 
CONTENTS ...................................................................................................vii 
LIST OF TABLES..........................................................................................xii 
LIST OF FIGURES .......................................................................................xiii 
LIST OF PUBLICATIONS ............................................................................xvi 
CHAPTERS .....................................................................................................1 
CHAPTER 1 – INTRODUCTION .....................................................................1 
1.1 DYSTROPHINOPATHIES .........................................................................................1 
1.2 THE HISTORY OF DUCHENNE MUSCULAR DYSTROPHY.........................................2 
1.3 CALCIUM HANDLING IN CARDIAC TISSUES............................................................5 
1.4 REQUIREMENTS FOR FURTHER STUDY OF CARDIAC DYSFUNCTION IN 
DYSTROPHINOPATHIES ...............................................................................................6 
1.5 AIMS AND OBJECTIVES .........................................................................................9 
1.6 CONTRIBUTIONS ...................................................................................................9 
1.7 SIGNIFICANCE.....................................................................................................10 
CHAPTER 2 – LITERATURE REVIEW.........................................................11 
2.1 PROGNOSIS AND DEVELOPMENT OF DYSTROPHINOPATHIES ................................11 
2.2 DYSTROPHIN AND THE DYSTROPHIN-ASSOCIATED GLYCOPROTEIN COMPLEX ....15 
2.3 CARDIAC DYSFUNCTION IN DYSTROPHINOPATHIES.............................................19 
2.3.1 Cardiac manifestations ..............................................................................19 
2.3.2 The role of cardiac dystrophin...................................................................22 
2.4 ANIMAL MODELS OF DYSTROPHINOPATHIES AND RELATED CONDITIONS ............24 
2.4.1 The GRMD dog.........................................................................................25 
2.4.2 The mdx mouse..........................................................................................26 
2.4.3 Other animal models of muscular dystrophy.............................................28 
2.4.3.1 Feline X-linked muscular dystrophy..................................................28 
2.4.3.2 Dystrophic Syrian hamster ................................................................28 
2.4.3.3 The cardiomyopathic hamster ...........................................................29 
 viii
2.5 CURRENT RESEARCH AND THERAPEUTIC STRATEGIES ........................................30 
2.5.1 Myoblast transfer.......................................................................................30 
2.5.2 Gene therapy..............................................................................................31 
2.5.3 Exon skipping............................................................................................33 
2.5.4 Utrophin upregulation ...............................................................................33 
2.5.5 Drug therapy..............................................................................................34 
2.5.5.1 Glucocorticoids..................................................................................34 
2.5.5.2 β-adrenergic agents...........................................................................35 
2.5.6 Summary of current and future therapeutics .............................................36 
2.6 CARDIAC CALCIUM CYCLING.............................................................................37 
2.6.1 The action potential ...................................................................................38 
2.6.1.1 L-type calcium channels ....................................................................39 
2.6.1.1.1 Dihydropyridines .......................................................................42 
2.6.1.1.2 Phenylalkylamines .....................................................................42 
2.6.1.1.3 Benzothiazepines........................................................................43 
2.6.2 The sarcoplasmic reticulum.......................................................................44 
2.6.2.1 SR calcium release.............................................................................44 
2.6.2.2 SR calcium sequestration...................................................................45 
2.6.3 Regulation of responsiveness to calcium in the heart ...............................47 
2.7 POTENTIAL SITES OF DYSFUNCTIONAL CALCIUM HANDLING IN DYSTROPHIC 
HEARTS ....................................................................................................................48 
2.7.1 The L-type calcium channel ......................................................................50 
2.7.2 SR mechanisms .........................................................................................51 
2.7.2.1 The ryanodine calcium release channel ............................................52 
2.7.3 Calcium leak..............................................................................................52 
2.7.4 Calcium binding and associated proteins ..................................................53 
2.7.5 Calcium efflux ...........................................................................................54 
2.8 INSIGHTS FROM SKELETAL MUSCLE ....................................................................54 
2.8.1 Calcium influx in dystrophin-deficient skeletal muscle............................57 
2.8.2 Sequestration mechanisms in dystrophin-deficient skeletal muscle .........58 
2.8.3 Activation of calcium-dependent proteolytic enzymes .............................58 
2.9 REQUIREMENTS FOR FURTHER STUDIES ..............................................................59 
 ix
CHAPTER 3 – MATERIALS AND METHODS ..............................................61 
3.1 ETHICAL CONSIDERATIONS.................................................................................61 
3.2 EXPERIMENTAL ANIMALS ...................................................................................61 
3.3 APPARATUS CALIBRATION AND PROTOCOL OPTIMISATION .................................61 
3.4 DISSECTION OF CARDIAC TISSUES.......................................................................62 
3.4.1 Papillary muscles.......................................................................................63 
3.5 TISSUE BATH EXPERIMENTS................................................................................63 
3.5.1 Concentration response curves for Bay K 8644 and nifedipine ................64 
3.5.2 Rapid cooling contracture experiments .....................................................65 
3.5.2.1 Preliminary studies ............................................................................65 
3.5.2.2 Comparison of mdx and C57 left atria ..............................................65 
3.5.3 Force-frequency experiments ....................................................................66 
3.6 MICROELECTRODE AND CONTRACTILITY EXPERIMENTS .....................................68 
3.7 RADIOLIGAND BINDING EXPERIMENTS................................................................68 
3.7.1 Assay development....................................................................................68 
3.7.2 Experimental protocol ...............................................................................69 
3.8 REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (RT-PCR) 
EXPERIMENTS ...........................................................................................................70 
3.8.1 Preliminary experiments............................................................................70 
3.8.2 Experimental protocol ...............................................................................70 
3.8.3 Primer design.............................................................................................72 
3.9 DATA ANALYSIS .................................................................................................73 
3.10 DRUGS AND CHEMICALS ...................................................................................73 
CHAPTER 4 – RESULTS..............................................................................75 
4.1 MORPHOMETRY..................................................................................................75 
4.2 CALCIUM INFLUX MECHANISMS..........................................................................75 
4.2.1 Calcium channel agonist and antagonist concentration-response curves..76 
4.2.1.1 Basal measurements ..........................................................................76 
4.2.1.2 Response to the calcium channel antagonists....................................77 
4.2.1.3 Response to Bay K 8644 ....................................................................82 
4.2.2 Microelectrode and contractility experiments ...........................................83 
4.2.2.1 Basal measurements ..........................................................................83 
4.2.2.2 Response to the calcium channel antagonists....................................84 
4.2.3 Radioligand binding experiments..............................................................88 
 x
4.2.3.1 Assay development.............................................................................88 
4.2.3.2 Comparison of mdx and C57 ventricular homogenates ....................90 
4.2.4 RT-PCR .....................................................................................................92 
4.2.4.1 Comparison of mdx and C57 dihydropyridine mRNA.......................92 
4.3 SR CALCIUM RELEASE ........................................................................................94 
4.3.1 Rapid cooling contractures ........................................................................96 
4.3.1.1 Basal measurements ..........................................................................96 
4.3.1.2 Rapid cooling contractures................................................................97 
4.3.2 Force-frequency relationships ...................................................................97 
4.4 CALCIUM SEQUESTRATION AND/OR REUPTAKE.................................................101 
4.4.1 Cyclopiazonic acid ..................................................................................101 
4.4.2 SERCA RT-PCR .....................................................................................103 
CHAPTER 5 – DISCUSSION ......................................................................105 
5.1 FUNCTIONAL DIFFERENCES BETWEEN MDX AND C57 CARDIC TISSUES..............105 
5.2 CONTRACTILITY AND MICROELECTRODE STUDIES ............................................107 
5.2.1 Concentration-response curve to Bay K 8644.........................................107 
5.2.2 Effects of the calcium channel antagonists .............................................108 
5.3 RADIOLIGAND BINDING STUDIES ......................................................................112 
5.4 DIHYDROPYRIDINE RECEPTOR RT-PCR ...........................................................114 
5.5 UPREGULATION OF THE L-TYPE CALCIUM CHANNEL ........................................115 
5.6 DIFFERENCES IN CALCIUM HANDLING BETWEEN VENTRICLES AND ATRIA ........118 
5.7 FUNCTION OF THE SARCOPLASMIC RETICULUM ................................................119 
5.7.1 Altered relaxation ....................................................................................120 
5.8 FORCE-FREQUENCY EXPERIMENTS ...................................................................120 
5.8.1 Response to ryanodine.............................................................................121 
5.8.2 Response to caffeine................................................................................122 
5.8.3 Response to dantrolene............................................................................123 
5.9 RAPID COOLING CONTRACTURES ......................................................................124 
5.10 CPA CONCENTRATION-RESPONSE CURVE.......................................................125 
5.11 SERCA RT-PCR ...........................................................................................126 
CHAPTER 6 – IMPLICATIONS AND CONCLUSIONS...............................128 
6.1 CONCLUSIONS FROM THE CURRENT STUDY.......................................................128 
6.2 IMPLICATIONS OF THE FINDINGS .......................................................................129 
6.3 FUTURE RESEARCH DIRECTIONS .......................................................................131 
 xi
6.3.1 Longitudinal study...................................................................................131 
6.3.2 Calcium channel antagonists ...................................................................132 
6.3.3 Patch clamp and L-type calcium current .................................................132 
6.3.4 The sodium/calcium exchanger as a potential contributor to calcium 
overload ............................................................................................................133 
6.3.5 Calcium binding proteins ........................................................................133 
6.3.6 Myofilament sensitivity to calcium.........................................................134 
6.4 CONCLUSION ....................................................................................................134 
REFERENCES ............................................................................................136 
APPENDICES..............................................................................................160 
APPENDIX A – OXYGEN CONSUMPTION ASSAY AND APPARATUS DEVELOPMENT ...160 
The requirement for oxygen usage studies.......................................................160 
Oxygen consumption methodology..................................................................161 
Depolarisation and L-type calcium channel blockade......................................162 
Oxygen consumption data ................................................................................163 
Preliminary experiments...................................................................................163 
Comparison of oxygen consumption in mdx and C57......................................164 
APPENDIX B - PATCH CLAMP ASSAY AND APPARATUS DEVELOPMENT IN OUR 
LABORATORY .........................................................................................................167 
APPENDIX C - PATCH CLAMP ASSAY AND APPARATUS DEVELOPMENT AT THE 
UNIVERSITY OF ADELAIDE .....................................................................................171 
 xii
LIST OF TABLES 
Table 1.1 Landmarks in the History of Duchenne Muscular Dystrophy ......................4 
Table 2.1 Etiology of Duchenne and Becker Muscular Dystrophy and X-linked 
dilated cardiomyopathy................................................................................................12 
Table 2.2 Pharmacological agents that affect calcium handling in cardiac myocytes .... 
......................................................................................................................................46 
Table 4.1 Number and masses of mice used throughout the dissertation ...................75 
Table 4.2 Effect of L-type calcium channel antagonists on time to 90% relaxation 
(TR90) in the tissue bath studies ...................................................................................82 
Table 4.3 Contractile parameters in response to Bay K 8644.....................................83 
Table 4.4 Basal electrophysiological parameters ........................................................88 
Table 4.5 Comparison of Ca2+ channel antagonists effects on contraction time course 
mdx and C57 left atria ..................................................................................................88 
Table 4.6 Strain potency ratios for L-type calcium channel data................................94 
 
 
 
 
 
 xiii
LIST OF FIGURES 
Figure 1.1 Calcium handling pathways in cardiomyocytes ..........................................6 
Figure 2.1 Muscle groups affected by DMD ..............................................................13 
Figure 2.2 Schematic model of the dystrophin-glycoprotein complex as a 
transsarcolemmal link between the subsarcolemmal cytoskeleton and the extracellular 
matrix ...........................................................................................................................16 
Figure 2.3 The dystrophin-glycoprotein complex and muscular dystrophies that arise 
due to primary defects in different members of the complex ......................................18 
Figure 2.4 Prevalence of clinical cardiac involvement in DMD, BMD and carriers 
according to age ...........................................................................................................21 
Figure 2.5 A comparison of human and murine action potentials ..............................39 
Figure 2.6 The subunits of the L-type calcium channel..............................................40 
Figure 3.1 Rapid cooling contracture protocol ...........................................................66 
Figure 3.2 A typical force-frequency chart in the absence of any drug......................67 
Figure 4.1 An indicative contraction from a C57 mouse ............................................77 
Figure 4.2 The effects of nifedipine on left atria, and the effects of extracellular 
calcium.........................................................................................................................78 
Figure 4.3 The effects of verapamil on left atria, and the effects of extracellular 
calcium.........................................................................................................................79 
Figure 4.4 The effects of diltiazem on left atria, and the effects of extracellular 
calcium.........................................................................................................................80 
Figure 4.5 Response to Bay K 8644 in isolated mdx and C57 left atria .....................81 
Figure 4.6 The effects of nifedipine on left atrial force of contraction and action 
potential duration .........................................................................................................85 
 xiv
Figure 4.7 The effects of verapamil on left atrial force of contraction and action 
potential duration .........................................................................................................86 
Figure 4.8 The effects of diltiazem on left atrial force of contraction and action 
potential duration .........................................................................................................87 
Figure 4.9 Determination of incubation time..............................................................89 
Figure 4.10 Determination of antagonist concentration for non-specific binding......89 
Figure 4.11 Determination of incubation temperature................................................90 
Figure 4.12 Saturation binding curve showing the mean of all experiments from mdx 
and C57 ventricular homogenates in response to increasing concentrations of 3H-
PN200-110 ...................................................................................................................91 
Figure 4.13 Kd and Bmax for the binding data...........................................................92 
Figure 4.14 RT-PCR results from mdx and C57 dihydropyridine receptor mRNA 
from ventricles and left atria ........................................................................................93 
Figure 4.15 Max and linear range gel electrophoresis photos inverted so that mRNA 
bands are black.............................................................................................................93 
Figure 4.16 DHPR Gel electrophoresis with colours inverted so bands are black .....94 
Figure 4.17 Rapid cooling contractures from left atria of mdx and C57 ....................95 
Figure 4.18 Basal contractility of mdx and C57 left atria at increasing frequencies ..96 
Figure 4.19 Force-frequency relationship in the presence of ryanodine.....................98 
Figure 4.20 Force-frequency relationship in the presence of dantrolene....................99 
Figure 4.21 Force-frequency relationship in the presence of caffeine......................100 
Figure 4.22 Left atrial force of contraction and time to 90% relaxation in response to 
cyclopiazonic acid......................................................................................................102 
Figure 4.23 SERCA mRNA expression as pixel intensity per unit area...................103 
 xv
Figure 4.24 SERCA gel electrophoresis of mRNA with colours inverted so that bands 
are black .....................................................................................................................104 
Figure A.1 Oxygen consumption protocol................................................................162 
Figure A.2 Determination of oxygen consumption in the absence of tissue ............165 
Figure A.3 Comparison of the effects of KCl, nifedipine and diltiazem on oxygen 
consumption with and without tissue.........................................................................166 
Figure A.4 Contractility of mdx and C57 mice for all of the oxygen consumption 
experiments ................................................................................................................166 
Figure C.1 Superimposed current records from mdx cardiomyocytes......................172 
Figure C.2 A calcium current IV curve from a 12 week old mdx.............................173 
 
 xvi
LIST OF PUBLICATIONS 
Full publications arising from this thesis include: 
1. Peter J. Woolf, Sai Lu, Sean M. Holroyd, Lindsay Brown and Andrew J. 
Hoey (2003) Calcium influx and sequestration in dystrophin-deficient cardiac 
muscle. Submitted to Journal of Molecular and Cellular Cardiology. 
 
Abstracts arising from this thesis include: 
1. Peter J. Woolf, Sai Lu and Andrew J. Hoey (2002) Regulation of calcium 
influx in dystrophic cardiac muscle. Proceedings of the Australian Health and 
Medical Congress, Melbourne, Australia. 
 
2. Peter J. Woolf, Sai Lu and Andrew J. Hoey (2002) Regulation of calcium 
influx in cardiomyocytes from mice with Duchenne Muscular Dystrophy. 
Proceedings of the Australian Society for Medical Research, Brisbane, 
Australia. – Runner up for Queensland Premier’s Award for Medical Research 
(Pre-Doctoral Category). 
 
3. Peter J. Woolf, Sai Lu, Richard B. Ryan & Andrew J. Hoey (2001) 
Characteristics of the dihydropyridine receptor in cardiac muscle. Proceedings 
of the Australasian Society of Clinical and Experimental Pharmacologists and 
Toxicologists, Dunedin, New Zealand. 
 
4. Andrew J. Hoey, Sai Lu, Peter J. Woolf, Richard B. Ryan (2001) Cardiac 
dysfunction in mice with Duchenne muscular dystrophy.  Proceedings of the 
Queensland Health and Medical Research Scientific Meeting, Brisbane, 
Australia. 
 
5. Peter J. Woolf, Sai Lu, Richard B. Ryan & Andrew J. Hoey (2001) Changes 
in cardiac dihydropyridine calcium channel receptors from dystrophin 
deficient mice. Proceedings of the International Society for Heart Research, 
Brisbane, Australia. 
 
6. Andrew J. Hoey, Peter J. Woolf, Sai Lu & Richard B. Ryan (2001) Cardiac 
dysfunction in the mouse model of Duchenne muscular dystrophy. 
Proceedings of the International Society for Heart Research, Brisbane, 
Australia. 
 
7. Peter J. Woolf, Sai Lu & Andrew J. Hoey (2000) The electrophysiological 
and contractile effects of calcium channel antagonists on the left atria of 
muscular dystrophy (mdx) mice. Proceedings of the Australasian Society of 
Clinical and Experimental Pharmacologists and Toxicologists, Newcastle, 
Australia.  
Chapter 1 - Introduction 
 1
CHAPTER 1 - INTRODUCTION 
 
1.1 Dystrophinopathies 
Duchenne Muscular Dystrophy (DMD) and its allelic variant Becker Muscular 
Dystrophy (BMD) are genetic neuromuscular disorders caused by a mutation on the X 
chromosome (Xp21), a gene that encodes for the protein dystrophin. A complete loss 
of dystrophin leads to the most severe form of the muscular dystrophies, DMD, while 
a partial loss of dystrophin (the protein is either truncated or expressed partially) leads 
to the less severe BMD. Similarly, X-linked cardiomyopathy is due to a mutation at 
the same chromosomal site. Together these conditions are known as 
dystrophinopathies, since the dystrophin gene is affected in all the disorders. Several 
animal models have been identified with X-linked dystrophinopathies, including the 
mdx (Muscular dystrophy X-linked) mouse and GRMD (Golden retriever muscular 
dystrophy) dog. To date, the exact roles of dystrophin are not completely defined, but 
it is understood to be involved in cell membrane structural organisation, control of 
calcium regulation and signal transduction.  
 
The absence of dystrophin in muscle leads to impaired sarcolemmal integrity, along 
with alterations in signal transduction that lead to a loss of intracellular calcium 
homeostasis. Such a disruption in intracellular calcium homeostasis, leading to 
intracellular calcium overload, is a significant feature of dystrophin-deficiency. 
Increased intracellular calcium levels have been measured in at-risk foetuses, 
premature infants with DMD, in whom necrosis was absent (Bertorini et al., 1984; 
Emery & Burt, 1980), DMD affected individuals (Bertorini et al., 1982; Bodensteiner 
& Engel, 1978) and animal models of DMD (Mallouk et al., 2000). This calcium 
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overload is one of the earliest pathological manifestations and is generally accepted as 
a contributing factor to the pathogenesis of dystrophinopathies (Wrogemann & Pena, 
1976). This calcium overload has been implicated in activation of calcium-dependent 
proteolytic enzymes. Proteolysis leads to cellular necrosis, subsequent fatty 
infiltration and fibrosis. These processes of fatty infiltration and fibrosis contribute to 
a hypertrophy of cardiac and skeletal muscle without any functional advantage, and 
eventually loss of tissue function. 
 
The clinical features of DMD due to the absence of dystrophin, manifest 
progressively. The major clinical features of DMD include a slowed development of 
motor skills, a loss of ambulation from 10-15 years of age, and progressive skeletal, 
cardiac and smooth muscle deterioration. Death usually occurs in the early twenties 
due to cardiac or respiratory failure. The partial expression of dystrophin as in BMD, 
results in a spectrum of both skeletal and cardiac muscle involvement, ranging from 
Duchenne-like symptoms and prognosis to near normal skeletal and cardiac muscle 
function, with some BMD patients being ambulatory into their eighties. In contrast, 
patients with X-linked dilated cardiomyopathy do not usually develop skeletal muscle 
myopathy, with selective impairment of the myocardium progressing to dilated 
cardiomyopathy. 
 
1.2 The History of Duchenne Muscular 
Dystrophy 
Edward Meryon was the first to describe DMD in 1851. Meryon described eight 
affected boys in three families and detailed family trees of affected individuals, 
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tracing the condition in cousins to three sisters. Meryon observed muscle fibres 
microscopically, reporting diffuse sarcomeres and breakdown of the sarcolemma.  
 
Meryon concluded that the disease was familial and not a disease of the affected 
nervous system, but his work became overshadowed by that of Duchenne (Emery, 
1993; Hoffman, 2001).  
 
DMD was named after the after French neurologist Duchenne de Boulogne who wrote 
extensively about the disease in the mid 1800s. His studies built up a picture of the 
condition affecting muscle tissue directly, rather than as a secondary (neurogenic) 
effect of a disturbance of the nervous system. Duchenne correctly identified DMD as 
not involving the spinal cord. Duchenne correctly defined the disease as being 
progressive in terms of loss of mobility. He observed that the lower limbs were 
affected initially followed by the upper limbs. Duchenne used a needle-harpoon 
technique to take muscle biopsies from patients with Duchenne muscular dystrophy 
over many years. Studying the biopsies, Duchenne observed an increase in interstitial 
connective tissue in affected muscles with the production of fibrous and adipose 
tissues in the latter stages of the disease. Duchenne observed that the onset of the 
disease was in childhood, affected boys more often than girls, and could affect several 
members of the one family. Duchenne’s name remains eponymous with DMD, for his 
early work in identifying the pathogenesis of the disease (Emery, 1993). Extensive 
research into Duchenne muscular dystrophy has since been undertaken (Table 1.1) 
which is improving the longevity and quality of life of sufferers considerably. 
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 Table 1.1 Landmarks in the History of Duchenne Muscular Dystrophy 
 
Nineteenth century DMD recognised as a specific clinical disorder  
 
1959-60 Elevated serum creatine kinase levels reported in patients and 
female carriers (Ebashi et al., 1959; Okinaka et al., 1959).  
 
1978-82 DMD mapped to Xp21 by X/A translocations (Verellen et al., 
1978) and DNA markers (Murray et al., 1982). 
 
Early 1980s DMD shown to be allelic (Kingston et al., 1983). Prenatal 
diagnosis of DMD developed (Wassner et al., 1982). 
 
1985  Gene-specific probes (Kunkel et al., 1985). 
 
1987-88 cDNA cloned and sequenced (Koenig et al., 1987). Protein 
product (dystrophin) identified (Hoffman et al., 1987). 
Dystrophin localisation and functional studies began (Sugita et 
al., 1988). 
 
1989-90 Myoblast transfer experiments in mice (Partridge et al., 1989) 
and humans (Karpati, 1990) commenced. 
 
1990-91 Direct gene transfer (Wolff et al., 1990) attempted. 
 
1995 Adhalin has a role in DMD (Mendell et al., 1995). 
 
1996-97 Recombinant vectors deliver therapeutic genes (Petrof et al., 
1996). Cloning of the DMD gene (Davies, 1997). 
 
1997 Stem cells identified as potential therapeutics (Smith & 
Schofield, 1997). 
 
1998 Sarcoglycans (Urtasun et al., 1998) and dystroglycans 
(McDearmon et al., 1998) play a role in DMD. 
 
1999 Antisense oligonucleotides improve expression of dystrophin 
(Wilton et al., 1999) 
 
Table adapted from Emery (1993). 
 
Alterations in calcium handling are not uncommon in cardiac diseases. Given the 
aetiology of DMD, it could be expected that calcium handling will be significantly 
altered in dystrophic hearts. 
 
Chapter 1 - Introduction 
 5
1.3 Calcium Handling in Cardiac Tissues 
Calcium handling in cardiac tissues is considerably different to that in skeletal 
muscle. In the myocardium, calcium influx occurs via voltage gated L-type calcium 
channels while T-type calcium channels provide only a minor contribution in 
cardiomyocytes. Influx via the L-type calcium channel triggers calcium-induced-
calcium-release (CICR), a mechanism whereby inflowing calcium flows across the T-
tubule membrane and binds to ryanodine receptors on the SR membrane, causing 
them to open, thus resulting in release of calcium from the sarcoplasmic reticulum 
(SR). Calcium binds to troponin causing the actin and myosin filaments to interact 
allowing development of contractile force. Calcium is then actively sequestered back 
into the SR by the sarco-endoplasmic reticulum ATPase (SERCA). The sarcolemmal 
sodium/calcium exchanger (NCX) also assists in returning calcium to resting 
intracellular levels by extruding calcium out of the cytoplasm into the extracellular 
fluid. Mitochondrial calcium plays a minor role in the myocardium. 
 
As an intracellular calcium overload is observed in dystrophin deficient muscle, 
dysfunction of any of the calcium handling mechanisms described above may be 
implicated in the loss of calcium homeostasis. There is currently a paucity of 
knowledge regarding calcium regulation in dystrophin-deficient myocardial tissues, 
with the only available information being drawn from studies on dystrophic skeletal 
muscles and a very small number of studies using dystrophic cardiac tissues. 
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Figure 1.1 Calcium handling pathways in cardiomyocytes. Calcium flows in from the 
extracellular space through L-type calcium channels where the dihydropyridine receptors (DHP) 
act as voltage sensors. The influx of calcium triggers calcium-induced calcium release from the 
sarcoplasmic reticulum via the Ryanodine sensitive receptors. This released calcium and the 
calcium influxed via the L-type calcium channels binds to the cardiac troponin to produce 
contraction of the muscle. Calcium is then sequestered back to the SR by sarco-endoplasmic 
reticulum calcium ATP-ase (SERCA). Calcium efflux occurs simultaneously via the Na+/Ca2+ 
exchanger (NCX) and the sarcolemmal Ca2+-ATPase (SL Ca++-ATPase).  
 
1.4 Requirements for Further Study of Cardiac 
Dysfunction in Dystrophinopathies 
The improved management of the skeletal, and hence respiratory aspects of DMD, has 
caused cardiac pathophysiology to become an increasingly important determinant of 
the sufferers' functional capacity and life span (Eagle et al., 2002). Therefore research 
into cardiac implications in dystrophinopathies and particularly DMD, is becoming 
increasingly important, but as yet, is in its infancy. 
SERCA Ca2+ 
NCX 
Na+ Ca++ 
SL 
Ca++ATPase 
Ca2+
Influx 
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The therapeutic regimes currently used to treat cardiomyopathy rely on modifying 
neurohumoral activation and positive inotropes that increase intracellular calcium 
levels. Calcium channel blockers are also well established in the treatment of certain 
cardiovascular disorders including hyperplasia and arrhythmias. However, 
intracellular calcium overload is a prominent pathological feature of dystrophic 
muscle cells and is likely to have a pathogenic role in cardiac tissue necrosis in DMD. 
It would therefore appear that, theoretically, the application of conventional 
medications, such as positive inotropic drugs that enhance intracellular calcium levels, 
could be deleterious. Yet this does not appear to have been taken into account when 
treating DMD/BMD-associated cardiac manifestations, as no studies have questioned 
the suitability of the positive inotropic drugs for treatment of DMD-induced 
congestive heart failure (CHF). Furthermore, it remains unknown whether there are 
DMD-induced specific changes in the responsiveness of dystrophic hearts to agents 
that modulate intracellular calcium.  
 
There is evidence that treatment with calcium channel blockers could reduce necrosis 
in dystrophic skeletal muscle (Duarte et al., 1992; Hotchkiss et al., 1995; Yoshida et 
al., 1997) although the outcomes of clinical trials and experiments in a sarcoglycan 
deficient cardiomyopathy (Cohn et al., 2001) are inconclusive. In cardiomyocytes, the 
majority of the cardiac dystrophin has been found to be associated with the diadic 
junction region of the transverse tubule (T tubules) membrane system, which is also 
the area where the dihydropyridine receptor (DHPR) component of the L-type 
calcium channels is located (Bers, 1991). Therefore, dystrophin has been suggested as 
having a role in anchoring or modulating the activity of the cardiac DHPR. As 
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dystrophin is deficient in DMD/BMD, it is feasible that alterations of L-type calcium 
channels may contribute to the increase in intracellular calcium levels in DMD. 
However, no study has been conducted to examine the function of the cardiac L-type 
calcium channels in any model of DMD. Thus, the affinity and function of the cardiac 
L-type calcium channels need to be investigated. 
 
The sarcoplasmic reticulum as the major storage site of calcium in the cardiomyocytes 
may be implicated in dysfunctional calcium handling. Similarly, mechanisms of 
sequestration such as SERCA and the intraluminal SR calcium binding proteins, and 
the release of calcium from the SR are potential contributors to the intracellular 
calcium overload. SERCA has been implicated in cardiomyopathies where a delayed 
relaxation has been observed. A delayed relaxation has been observed in dystrophin-
deficient myocardium (Sapp et al., 1996) but as yet the mechanisms remain to be 
elucidated. The calcium binding proteins have been shown to be downregulated in 
dystrophic skeletal muscle (Culligan et al., 2002) causing a calcium leak from the SR. 
Whether the calcium binding proteins play a role in the cardiomyopathy observed in 
dystrophinopathies remains to be determined.  
 
Futile calcium cycling such as SR leak calcium cycling leads to physiological 
consequences such as altered metabolism in dystophin-deficient skeletal muscle 
(Even et al., 1994; Braun et al., 2001). It is unknown whether dystrophin-deficiency 
related alterations in calcium handling lead to altered oxygen usage in myocardium. 
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1.5 Aims and Objectives 
The broad objectives of this research were to characterize myocardial calcium 
handling in a murine model of dystrophin-deficiency. More specifically, the 
objectives were: 
1. To examine the electrophysiological characteristics of dystrophic myocardium in 
response to three major classes of L-type calcium channel antagonists and 
concurrently ascertain their effect on force of contraction; 
2. To determine the density and function of the dihydropyridine receptor on the L-
type calcium channel. 
3. To examine SERCA function and regulation in dystrophic myocardium.  
 
1.6 Contributions 
Preliminary experiments in our laboratory demonstrated impaired calcium regulation 
in cardiac muscle in young and old mdx from both sexes (Lu & Hoey, 2000a & 
2000b). Similarly, an altered relaxation time was observed in left atria from mdx in 
our laboratory (Lu and Hoey, 2000a & 2000b) and in another study (Sapp et al., 
1996). Experiments in the current study examined the function of the cardiac L-type 
calcium channels by utilizing three classes of calcium channel antagonists. 
Experimental results provided clear evidence of a reduced affinity of sarcolemmal L-
type calcium channels from atria of mdx mice to dihydropyridine compounds. Further 
studies examined the affinity and density of the DHPR, along with its mRNA levels. 
These studies showed a reduction in the affinity of the DHPR for [3H]-PN 200-110, 
along with an increase in receptor density in mdx ventricles, and a two-fold increase 
in mRNA for the DHPR in both atria and ventricles of mdx. These data suggest that 
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dystrophin-deficiency results in a conformational change in the DHPR, and 
upregulation of the receptor. It remains unknown, however, whether this upregulation 
is primarily a consequence of dystrophin deficiency or is secondary to the intracellular 
calcium overload. Studies that examined sequestration function revealed no change in 
the function of SERCA, even though SERCA mRNA was upregulated. The 
upregulation of the SERCA mRNA may be a consequence of intracellular calcium 
overload, but due to post-transcriptional mechanisms is not observed as a functional 
change.  
 
1.7 Significance 
The observed persistent abnormal calcium handling in both atria and ventricles of mdx 
may lend further support to the hypothesis that the mdx is a useful model for the study 
of dystrophin-deficiency-related cardiac disease. The finding that L-type calcium 
channels are upregulated could provide a further insight into the mechanisms 
underlying dysfunction of the calcium regulation in dystrophic hearts, and may offer 
alternative treatment options for delaying the onset of CHF in DMD.  
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CHAPTER 2 – LITERATURE REVIEW 
2.1 Prognosis and Development of 
Dystrophinopathies 
Duchenne muscular dystrophy is caused by a mutation on the short arm of the X 
chromosome, at the Xp21 allele. Since the gene is X-linked, transmission of DMD is 
maternal, although approximately one third of DMD cases arise as spontaneous (de 
novo) mutations. Studies have shown the incidence of DMD ranges from 
approximately 1 in 3950 live male births in the United States (Boland et al., 1996) 
and in the 1980’s at 1 in 5400 live male births in Australia (Cowan et al., 1980). The 
most common incidence quoted is 1 in 3500 live male births (Emery, 1991). 
Spontaneous mutations occur frequently at an incidence of about 1 in 12000 births 
due to the large size of the dystrophin gene (2.4 MB), and as high as 62% of cases 
may have no previous familial history (Alcantara et al., 1999). The rare X-linked 
dilated cardiomyopathy also occurs due to a mutation in the dystrophin gene at the 
Xp21 allele. Although both DMD and BMD have been recognised for more than 100 
years, the aetiology was not completely understood until the identification of the 
primary biochemical defect in 1987 (Hoffman et al., 1987). Table 2.1 presents a 
comparison of Duchenne and Becker muscular dystrophies and X-linked 
cardiomyopathies along with cardiac manifestations of these diseases. 
 
In DMD, the protein product of the dystrophin gene, also known as dystrophin, is 
absent from all muscle types – striated skeletal and cardiac, and smooth (Boland et 
al., 1996; Serio et al., 2001), as well as some neuronal cell types (Lidov et al., 1990; 
Anderson et al., 2002). Loss of dystrophin has several pathophysiological 
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consequences, and there are many independent mutations that lead to dystrophin-
deficiency in humans, dogs, cats and mice (Hoffman & Dressman, 2001). Long before  
 
Table 2.1: Etiology of Duchenne and Becker Muscular Dystrophy and X-linked dilated 
cardiomyopathy 
 
Type Incidence Protein  
defect 
Non-cardiac clinical 
features 
Heart 
block 
*Cardiac 
Arrhythmias 
Cardiomyopathy 
Duchenne 1 in 3500 
live male 
births 
Dystrophin Onset of severe 
muscle weakness, 
proximal-girdle 
distribution at 2 to 5 
y in a male; loss of 
ambulation by 11y; 
calf 
pseudohypertrophy; 
mild cognitive 
impairment; Serum 
CK 10 to 100 times 
normal; death in 
twenties 
+ + + + + 
Becker 10 times 
less 
frequent 
than 
DMDa 
Dystrophin Onset of mid-
moderate muscle 
weakness, proximal-
girdle distribution 
from childhood-
adulthood in male; 
ambulation beyond 
16; calf 
pseudohypertrophy; 
Serum CK 10 to 100 
times normal; 
normal to reduced 
lifespan 
+ + + + + 
X-linked  
dilated  
cardiomyopathy 
Very rare Cardiac 
dystrophin 
only 
No  skeletal muscle 
weakness but some 
cramping, exertional 
myalgias, 
myoglobinuria, calf 
pseudohypertrophy; 
mild myopathic 
changes may be 
present in muscle 
biopsy; Serum CK 1 
to 100 times normal 
- + + + + 
Each of these dystrophies is X-linked, with the defect localised to Xp21. a – De La Porte et al., 
1999 * Clinical significance based on prevalence and severity; +, mild, + +, moderate,  
+ + +, severe, CK – creatine kinase. Adapted from Cox and Kunkel, 1997. 
 
the visible onset of the disease, high serum creatine kinase (SCK) levels (Hoffman et 
al., 1987) and high intracellular calcium in muscle cells are present in affected 
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individuals. A study using electron microscopy revealed that the first ultrastructural 
change was dilation of the sarcoplasmic reticulum (SR) with subsequent alterations in 
myofibrils and mitochondria, concurrent with rupture of the sarcolemma in the 
skeletal muscles from DMD patients (Watkins & Cullen, 1987). Histologically, DMD 
is characterized by a progressive myopathy resulting in myofibre death, reactive 
fibrosis, fatty infiltration of muscle tissue, and ultimately, complete loss of muscle 
function.  
 
 
Figure 2.1 Muscle groups affected by DMD (Figure adapted from McCance & Huether, 1990 pg 
1376). 
 
Proximal muscle groups (See Figure 2.1 for muscle groups affected in DMD), which 
tend to contain some of the large myofibres, bear more weight and so are affected first 
in DMD. Compared with concentric types of exercise, eccentric exercise (lengthening 
contractions), where the myofibrils contract but the myofibre is extending, probably 
generate the most shear force on the membrane and cause the most damage to the 
compromised dystrophin-deficient fibres (Hoffman & Dressman, 2001). The lack of 
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dystrophin seems to be associated with a lack of intracellular calcium homeostasis. In 
skeletal muscle, sarcolemmal tears are thought to be responsible for the initial 
excessive influx of calcium, with leak channels eventually manifesting in the primary 
sarcolemmal tears. The first manifestations of the loss of dystrophin in smooth and 
cardiac muscle is as yet unknown, although a similar mechanical stabilisation role for 
dystrophin in the myocardium has been shown recently (Hainsey et al., 2003). 
 
One of the first outward clinical signs of DMD is a delayed achievement of motor 
milestones, usually evident by 18 to 20 months of age and apparent in most cases 
before the age of 5 years. Symptoms include difficulty with walking and stair 
climbing, weak reflexes, a waddling gait and toe walking. Pseudo-hypertrophy 
(enlargement) of the gastrocnemius muscle is the most obvious and consistent feature 
in the early stages of DMD, caused by muscle fibre hypertrophy and an excess of 
adipose and connective tissue (Murphy et al., 1986). Permanent muscle contractures 
occur in the legs and heels due to shortening of muscle fibres and fibrosis of the 
connective tissue, causing an inability to use those muscles. Gower's sign (from a 
prone position, the child ‘climbs' the lower extremities to stand upright) is also a 
common feature. Muscle involvement is always progressive, bilateral and 
symmetrical (Fig 2.1). Without intervention, 95% of boys with DMD are wheelchair 
bound by the age of 12 years. Once wheelchair bound, scoliosis and joint contractures 
tend to develop rapidly. Extreme muscle weakness and subsequent postural changes 
cause abnormal bone development, which causes skeletal deformities of the chest and 
other areas. Involvement of the intercostal muscles, diaphragm and cardiac muscle 
contributes to deterioration of respiratory and cardiac function respectively (Emery, 
1993). Death usually occurs before reaching 20 years of age, often from respiratory 
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failure (Newsom-Davis, 1980), while at least 30-40% of mortality can be attributed to 
cardiac failure (Radda, 1999). Intellectual impairment occurs in approximately 19% 
of boys with DMD, evidently from a loss of the smaller neuronal dystrophin in that 
subset of boys, and impairment does not worsen as the disorder progresses (Hinton et 
al., 2000).  
 
2.2 Dystrophin and the Dystrophin-Associated 
Glycoprotein Complex 
The dystrophin gene is the largest known gene at 2.4 MB consisting of 79 exons. It 
encodes the rod-shaped cytoskeletal protein dystrophin (Koenig et al., 1988) that has 
a molecular weight of 427kD, comprising 3600 amino acids, making it one of the 
largest known proteins. Dystrophin is composed of four domains: an amino-terminal 
actin-binding domain; a central rod domain that contains spectrin-like repeats; a 
cysteine-rich domain suggestive of calcium-binding motifs; and a unique carboxy-
terminal domain that penetrates the plasma membrane and interacts with dystrophin-
associated glycoproteins. Dystrophin lies along the inner surface of the plasma 
membrane in skeletal, cardiac and smooth muscle cells, and acts as a link between the 
actin cytoskeleton, the plasmalemma, and the surrounding basal lamina (Fig 2.2). In 
DMD, the complete absence of dystrophin leads to disruption of the transmembrane 
complex and a loss in the integrity of the plasmalemma (Cox & Kunkel, 1997) 
causing fibre necrosis (Ervasti & Campbell, 1993). The underlying mechanisms that 
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Figure 2.2: Schematic model of the dystrophin-glycoprotein complex as a transsarcolemmal link between the subsarcolemmal cytoskeleton and the extracellular 
matrix (From De La Porte et al., 1999). 
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lead to fibre necrosis are not well understood and seem to be specific for each muscle 
type.  
 
There are several proteins associated with dystrophin that together form the 
dystrophin-associated glycoprotein complex (DAGPC). The DAGPC aids dystrophin 
in its ability to stabilize the plasma membrane against mechanical stress (Ervasti & 
Campbell, 1993) although alternate functions (eg, the organization of membrane 
proteins, signal transduction and calcium regulation) have been proposed (Ahn & 
Kunkel, 1993). Two actin-binding proteins, dystrophin and α-actinin, are known to 
link membrane-associated elements to the cytoskeleton. Dystrophin and its associated 
proteins have also been implicated in playing a role in receptor and/or channel 
localization (Sadeghi et al., 2002). Dystrophin has further been postulated to bind the 
contractile filaments to the internal membrane system, thereby ensuring a link 
between the membranes that release calcium and the contractile proteins that are 
activated by this calcium (Slater, 1987; Hoffman et al., 1987; Tay et al., 1989). 
 
Several of these associated proteins have now been shown to underlie the 
pathogenesis of other types of muscular dystrophy. The DAGPC in striated muscle 
includes the α-, (156 kDa) and β-dystroglycan (43 kDa) and the α-, (adhalin, 50 kDa) 
β-, (43 kDa) γ-, (35 kDa) and δ-sarcoglycan (35 kDa) along with sarcospan (25 kDa; 
Crosbie et al., 1997) (De La Porte et al., 1999; Hainsey et al., 2003). The syntrophin 
complex consists of α-syntrophin (59 kDa), β1-syntrophin (59 kDa) and β2-syntrophin 
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(59 kDa) and links sodium channels of the membrane to the actin cytoskeleton (Fig 
2.3; De La Porte et al., 1999; Brown, 1997).  
 
 
Figure 2.3: The dystrophin-glycoprotein complex and muscular dystrophies that arise due to 
primary defects in different members of the complex (From Cox & Kunkel, 1997) LGMD = Limb 
Girdle Muscular Dystrophy, XLDCM = X-linked dilated cardiomyopathy, CMD = Congenital 
Muscular Dystrophy. An arrow indicates the disease state that arises from a dysfunction in that 
section of the dystrophin-glycoprotein complex. 
 
Dystrophin, the syntrophin complex, α-dystroglycan, and a muscle form of 
dystrobrevin (78 kDa) are peripheral membrane proteins, whereas the sarcoglycan 
complex and β-dystroglycan are integral membrane proteins. The sarcoglycans are a 
group of single-transmembrane proteins that form a subcomplex within the DAGPC. 
Mutations within the genes encoding α, β, γ, and δ sarcoglycans have been shown to 
possibly cause four to six known types of autosomal recessive Limb Girdle Muscular 
Dystrophies (LGMD; Fig. 2.3), while mutation of the γ-sarcoglycan is the basis 
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underlying the cardiomyopathy observed in the cardiomyopathic hamster (Sakamoto 
et al., 1997). The sarcoglycanopathies are characterized by relatively well-preserved 
dystrophin immunostaining, but a marked deficiency of the entire sarcoglycan 
subcomplex. The α-2 chain of laminin, formerly called merosin, is an extracellular 
matrix protein that directly binds to the DAGPC via the α-dystroglycan, a process that 
has been shown to be calcium dependent (McDearmon et al., 1998). A primary defect 
in the laminin α-2 chain underlies a form of congenital muscular dystrophy associated 
with leukodystrophy-like lesions in the brain that are detectable by MRI (magnetic 
resonance imaging) (Cox & Kunkel, 1997; Brown, 1997). The DAGPC has been 
shown to bind to F-actin for stabilisation (Rybakova & Ervasti, 1997) and is 
drastically reduced in patients with DMD. Loss of the DAGPC, even when truncated 
dystrophin is present, leads to severe muscular dystrophy (Matsamura et al., 1993). 
 
2.3 Cardiac Dysfunction in Dystrophinopathies 
2.3.1 Cardiac Manifestations 
Although the overt clinical symptom in DMD/BMD is skeletal muscle wasting, both 
conditions are frequently associated with myocardial impairment (Boland et al., 1996; 
Hunsaker et al., 1982; Melacini et al., 1996), manifesting predominantly as 
cardiomyopathy and congestive heart failure (CHF) (Cox & Kunkel, 1997). Primary 
cardiac involvement in the muscular dystrophies should not be surprising given that 
cardiac and skeletal muscles are both striated. The most common cause of death in 
BMD patients is heart failure (Finsterer & Stollberger, 2003). Even carriers who are 
heterozygous for a loss of dystrophin show cardiac dysfunction due to dystrophin-
deficiency. Because X-chromosome inactivation is sporadic (arbitrary) in the 
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myocardium, there is a patchwork of dystrophin positive and dystrophin negative 
cardiomyocytes. Therefore, cardiac disease in adult female carriers of the X-linked 
dystrophinopathies is often observed due to the structural abnormality in some of the 
cells (Melacini et al., 1998; Davies et al., 2001; Nolan et al., 2003). The incidence of 
cardiac abnormalities associated with this partial loss of cardiac dystrophin is quite 
high. In a study of cardiac abnormalities in 129 carriers of DMD/BMD only 38% 
showed completely normal cardiac parameters (Hoogerwaard et al., 1999). Therefore 
most carriers present with some degree of cardiac abnormality due to the sporadic loss 
of dystrophin in the myocardium. 
 
Cardiac dysfunction in DMD has been shown to be early in onset and progressive in 
its nature throughout life (Backman & Nylander, 1992). During the progression of 
DMD the incidence of cardiomyopathy becomes increasingly prevalent such that 
more than 90% of patients eventually manifest significant cardiac defects (Megeney 
et al., 1999). Dilated cardiomyopathy is a feature of DMD and BMD (Gnecchi-
Ruscone et al., 1999; Bia et al., 1999) and cardiac dysfunction is a more frequent 
cause of death in patients with BMD than patients with DMD (Melacini et al., 1993; 
Vrints et al., 1983), although progression of myocardial damage is not identical in the 
two myopathies (Saito et al., 1996). The incidence of arrhythmia has been shown to 
be higher in boys with DMD and significant decreases in heart rate variability are 
observed more often than the normal population, along with almost all DMD patients 
presenting with some degree of ECG abnormalities (Ishikawa et al., 1999). Persistent 
tachycardia is usually an early manifestation of cardiomyopathy seen in almost all 
DMD patients over 10 years of age (Gardner-Medwin, 1980), and it has been shown 
that ventricular arrhythmias correlate with the degree of myocardial dysfunction 
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(Ishikawa et al., 1999). Congestive heart failure ultimately manifests, with cardiac 
failure being a leading cause of mortality (30-50% of DMD patients die from cardiac 
failure; Ishikawa et al., 1999), along with respiratory failure.  Figure 2.4 shows the 
clinical cardiac manifestations of DMD and BMD progressing with age. 
 
It has been speculated that cardiomyopathy may be secondary to skeletal myopathy 
(Megeney et al., 1999), although this remains controversial with subsequent studies 
suggesting that cardiomyopathy is completely independent of skeletal muscle 
degeneration (Zhu et al., 2002). The cardiomyopathy in X-linked cardiomyopathy 
arises without any skeletal muscle involvement showing that an X-linked loss of 
dystrophin can directly cause cardiomyopathy. Although cardiac degeneration is 
progressive, there appears to be little correlation between its severity and skeletal 
muscle involvement, physical condition, vital capacity, respiratory status (Ishikawa et 
al., 1999) or dystrophin absence in the vasculature (Hainsey et al., 2003).  
 
Figure 2.4: Prevalence of clinical 
cardiac involvement in DMD, BMD and 
carriers according to age. Clinical 
involvement is defined as arrhythmia, 
cardiomyopathy, and regional wall 
abnormalities as determined by ECG, 
echocardiography or both (Cox & 
Kunkel, 1997). 
 
 
 
Chapter 2 – Literature Review 
 22
 
2.3.2 The Role of Cardiac Dystrophin 
If cardiomyopathy is taken in its widest possible context to include both primary and 
secondary lesions of the myocardium, then this term is appropriate in dystrophin-
deficiency and recognises that muscular dystrophy is a generalised myopathy (Hunter, 
1980). The role of dystrophin in cardiac development has been studied previously. In 
the rat heart dystrophin is undetectable on the 15th embryonic day, the stage at which 
the heart is able to generate action potentials and beat spontaneously. Development of 
the first functions of the myocardium therefore does not require the presence of 
dystrophin (De La Porte et al., 1999). A small quantity is detected on the 17th 
embryonic day, a stage where cardiac work increases, and expression of dystrophin 
increases during the perinatal period. Because its expression rises before cardiac work 
begins, dystrophin may be necessary for rapid and large contractions of the 
myocardium. Adult levels of dystrophin are reached 2 weeks postnatally (Tanaka & 
Ozawa, 1990).  
 
Cardiac dystrophin is normally localised at the membrane surface of the Purkinje cells 
(Bies et al., 1992). At the ultrastructural level, the dystrophin-deficient heart exhibits 
disordered abnormalities of the Z bands, SR dilation, and changes of the nuclei 
(Wakai et al., 1988), along with an increase in the number and a change in the 
structure of mitochondria (Sapp et al., 1996). It has been shown recently that 
dystrophin plays a mechanical role in cardiomyocytes similar to its role in skeletal 
muscle by linking the submembranous actin cytoskeleton to the extracellular matrix 
through its direct interaction with the DAGPC (Hainsey et al., 2003). Earlier, Cziner 
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and Levin (1993) proposed that dystrophin was required to physically reinforce the 
sarcolemma against axial stress, and this postulation has since been supported by 
Saito et al., (1996). Dystrophin abnormality has also been observed in cardiac 
myocytes acutely injured by exposure to isoprenaline (Miyazato et al., 1997), 
showing dystrophin abnormality can occur in the absence of an X-chromosomal gene 
defect. Therefore it appears that dystrophin abnormality may occur due to mechanical 
strain resulting from high force contractions. 
 
The function of α-actinin is to anchor parallel filaments of F-actin throughout the 
cytoskeleton in all tissue types, as well as to anchor antiparallel actin filaments in 
muscle tissue, forming the Z line in skeletal and cardiac muscle and the cytoplasmic-
dense bodies in smooth muscle. An early abnormality in dystrophin-deficient mice is 
the scattered focal streaming of Z lines (Torres & Duchen, 1987). Several types of ion 
channels may also associate with α-actinin (Sadeghi et al., 2002). Within adult mouse 
cardiac tissue, the L-type calcium channel was found to colocalise with dystrophin at 
both the Z and M lines, whereas α-actinin was found to colocalise with the channel 
only over regions of the Z line. Together, these data suggest a regulatory role for the 
actin binding proteins α-actinin and dystrophin, acting on the calcium channel by 
either direct or indirect interactions (Sadeghi et al., 2002). Approximately 40% of 
dystrophin is tightly bound to the contractile apparatus (Braun et al., 2001). The loss 
of that particular dystrophin fraction appears to be causative in the development of 
cardiac insufficiency. Another group has identified that cardiac dystrophin is 
distributed between two distinct pools, a soluble cytoplasmic pool and a membrane 
bound pool (Peri et al., 1994) however they do not speculate on the roles of these 
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pools. The authors speculate that the distinct properties of cardiac dystyrophin suggest 
unique roles for the protein in cardiac versus skeletal muscle (Peri et al., 1994). 
 
A highly significant correlation between dystrophin and other calcium regulating 
proteins has been recognised (Gurusinghe et al., 1991). In particular, a major portion 
of the dystrophin sequence has been found to contain repeating units of approximately 
100 amino acid residues. These repeating units were found to exhibit significant 
homology to troponin I (Gurusinghe et al., 1991). Troponin I binds to the calcium 
binding proteins calmodulin and troponin C. The regions of highest homology were 
characterised by patterns of high localisation of charged amino acids and thus could 
represent a possible calmodulin or troponin C surface accessible binding site 
(Gurusinghe et al., 1991). The expression of cardiac troponin has been found to be 
unchanged in both patients with DMD and mdx mice (Hammerer-Lercher et al., 
2001). Subcellular localisation studies have indicated that dystrophin is associated 
with the diadic junction, providing further support that dystrophin could be involved 
in controlling intracellular calcium homeostasis (Hoffman et al., 1987).  
 
2.4 Animal Models of Dystrophinopathies and Related 
Conditions 
There are a number of animal models that have been identified to examine the 
progressive pathophysiology of Duchenne muscular dystrophy and experimental 
therapeutics for the disease. The mdx (muscular dystrophy X-linked) mouse has 
become the most popular animal model due to its relative inexpensiveness, its short 
gestation period and small size. Cats and mice show a more benign disease than 
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humans, with muscular hypertrophy as one of the more obvious symptoms (Hoffman 
& Dressman, 2001). The golden retriever or GRMD dog (Kornegay et al., 1988) is 
probably the best model of DMD in terms of its similarity to the pathophysiology 
observed in the human male (Cooper et al., 1988). However this model is quite 
expensive, has considerable variability in its phenotype and controversy surrounds the 
use of dogs for medical research. Various other species of animals with muscle 
weakness exist and have been studied, including the hamster, cat (Ytterberg, 1991), 
chicken (Dawson, 1966), sheep (Paulson et al., 1966), mink (Hegreberg et al., 1974), 
duck (Rigdon, 1964), cow (Poukka, 1966), and even a zebra fish (Bolanos-Jimenez et 
al., 2001), but none of these have been shown to be strictly comparable to human 
muscular dystrophy.  
 
2.4.1 The GRMD Dog 
The GRMD dog was first described by Kornegay et al., in 1988. Creatine kinase 
levels are elevated from the first week of life onwards, but symptoms usually manifest 
at approximately 8 weeks when muscular weakness develops and then worsens 
progressively over subsequent months. As in humans, muscular weakness is 
paralleled by a progressive loss of muscle tissue and development of fibrosis. 
Dystrophin-deficiency affects the entire musculature and in particular there is a 
reduction in respiratory capacity. As in DMD, the muscle necrosis is inadequately 
compensated by regeneration and the resulting loss of muscle mass is accompanied by 
fibrous and fatty infiltration and diffuse calcification of the muscles, matched by rapid 
development of clinical muscle weakness and contractures during the first few months 
of life (Partridge, 1991). Cardiomyopathy is a significant feature of dystrophin-
deficiency in the GRMD dog (Moise et al., 1991) and death usually occurs around 
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one year of age (Valentine et al., 1992; De La Porte et al., 1999). 
 
2.4.2 The mdx Mouse  
The mdx is a naturally occurring mutation that was found in a colony of C57BL10 
ScSn mice (Bulfield et al., 1984); hence these mice (C57) have become the control for 
mdx. The mdx mouse mutation is a premature stop codon at exon 23 of the dystrophin 
gene and hence it resembles the genetic defect of boys with DMD quite closely. 
Muscle fibres in old mdx show variation in size with many atrophied and split 
(Pastoret & Sebille, 1995). Progressive and degenerative changes observed in mdx 
resemble DMD closely and imply that there are basic pathological similarities 
between the murine and human diseases (Pasoret & Sebille, 1995; Lefaucher et al., 
1995). The female mdx in breeding colonies are homozygous, so that inbred strains of 
the mdx continually exhibit the Xp21 mutation and subsequent dystrophin-deficiency. 
Bulfield et al., (1984) initially reported the mdx mouse mutation and provided 
evidence for dilation of the SR as an early change in affected myofibrils, a change 
similar to those observed in boys with DMD. They also observed the development of 
electron-dense bodies in the mitochondria and disruption of the plasmalemma and 
basal lamina, which again mimics the pathophysiology observed in boys with DMD. 
The pathology of skeletal muscle in mdx shows necrosis, regeneration and the 
persistence of central nuclei (Torres & Duchen, 1987). However, after marked 
necrosis from 21 days of age (McGeachie et al., 1993) the mdx shows skeletal muscle 
recovery from approximately 40 days of age due to the upregulation of a dystrophin-
related protein, utrophin, which effectively prolongs the life span of these mice and 
decreases skeletal muscle atrophy. Utrophin is a close homologue of dystrophin (69% 
across 3500 amino acids) (Keep et al., 1999), so there is speculation that upregulation 
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of utrophin may be able to functionally compensate for the lack of dystrophin (Fisher 
et al., 2001). Utrophin upregulation thus far has not been shown to be able to prevent 
life-threatening myocardial dysfunction (Fanin et al., 1999) although further studies 
are warranted as this study examined one DMD and one BMD case only. Utrophin 
shares sequence similarity with dystrophin but instead is localised to neuromuscular 
and myotendinous junctions in mature skeletal muscle and to intercalated discs and 
microvasculature smooth muscle in the heart (Sewry et al., 2001). Due to changes 
such as these, there is consideration of the similarity of the pathogenesis of dystrophy 
in mdx compared to DMD, with some authors suggesting that mdx is not an 
appropriate model to study skeletal muscle myopathy (Rouger et al., 2002).  
 
Mice deficient in dystrophin have significant tachycardia, decreased heart rate 
variability, and altered autonomic heart rate modulation in comparison to wild-type 
control mice, findings consistent with clinical observations of autonomic dysfunction 
in DMD (Gnecchi-Ruscone et al., 1999; Chu et al., 2002). Mdx mice display 
abnormal electrocardiograms (ECGs) (Bia et al., 1999), decreased atrioventricular 
conduction time and impaired baroreceptor reflex control in conscious animals that is 
consistent with observations in DMD patients (Chu et al., 2002). Conduction 
abnormalities in mdx are associated with morphological changes, including multifocal 
areas of fibrosis, vacuolization and fatty infiltration throughout the entire conduction 
system (Bia et al., 1999). Mdx heart also develops hypertrophy that does not 
contribute to greater contractile force by 6 months of age (Bia et al., 1999).  
 
At 12-14 weeks of age the pathophysiology of the mdx myocardium is evident by 
altered contractile function (Sapp et al., 1996). Cardiomyocytes from 8-10 week old 
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mdx mice have been reported to have a reduced threshold for the development of 
sarcolemmal injury under mechanical stress (Danialou et al., 2001). Mdx myocardium 
exhibit myocardial lesions, characterised by necrosis, macrophage infiltration and 
inflammation along with a diminished number of functional myocardial fibres which 
are replaced with connective tissue (Bia et al., 1999). The mdx mouse therefore shows 
significant similarity in cardiac dysfunction to that observed in boys with DMD. The 
mdx mouse is therefore an appropriate model to study dystrophin-deficient 
cardiomyopathy. 
 
2.4.3 Other Animal Models of Muscular Dystrophy 
2.4.3.1 Feline X-linked muscular dystrophy 
Dystrophin deficiency has also been described in the feline X-linked muscular 
dystrophy (FXMD) cat. It is characterised by muscle hypertrophy and resembles 
DMD in displaying accumulation of calcium, but differs in showing no fatty 
infiltration with only moderate fibrosis, no loss of muscle fibres, and no progressive 
muscle weakness (De La Porte et al., 1999). This model is rarely used in the research 
of dystrophinopathies. 
 
2.4.3.2 Dystrophic Syrian Hamster 
The dystrophic Syrian hamster is known to have δ-sarcoglycan deficiency, thus, it is 
recognised as a good model for clarification of the pathogenesis of 
sarcoglycanopathy. In Syrian hamsters, the muscle lesions closely resemble those of 
the mdx, and the hamsters also have increased resting intracellular calcium levels 
(Camacho et al., 1988). Although signs of skeletal muscle dysfunction are mild, 
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cardiac muscle is preferentially involved, leading to fatal cardiac insufficiency around 
one year of age (Nonaka, 1998).  
 
2.4.3.3 The Cardiomyopathic Hamster 
The cardiomyopathic hamster has a γ-sarcoglycan deficiency that leads to a 
dysfunctional DAGPC and subsequent cardiomyopathy. More heart research has been 
dedicated to this model of cardiomyopathy than the mdx mouse, so this model may 
lend some insight into the cardiac dysfunction observed due to a loss of the DAGPC. 
The lack of membrane proteins in the cardiomyopathic hamster is directly related to 
increased sarcolemmal permeability and subsequent cell rupture (Ikeda et al., 2000).  
An altered calcium homeostasis leading to an intracellular calcium overload plays a 
primary role in the development of necrosis in the cardiomyopathic hamster (Palmieri 
et al., 1981). Initially calcium influx was implicated as a major contributor to the 
cardiac dysfunction. Kuo et al., (2002) observed increased DHPRs in radioligand 
binding, although Howlett & Gordon (1987) observed no increase in the density of the 
DHPRs. Another major calcium transporter, SERCA, was also expressed in normal 
levels in the cardiomyopathic hamster heart (Kuo et al., 2002), while recently an 
abnormal activation and high levels of the mitochondrial sodium/calcium exchanger 
were reported (Kuo et al., 2002). The effects of increased cytosolic calcium have been 
associated with a loss of matrix calcium, resulting in impaired oxidative 
phosphorylation and thus a loss of mitochondrial metabolism, which may be a 
contributor to altered metabolism (Kuo et al., 2002). The elevation in calcium also 
induces opening of mitochondrial permeability pores that in turn lead to caspase 
activation and cell death (Kuo et al., 2002). In conclusion, it would appear that a loss 
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of γ-sarcoglycan alone may lead to a loss of calcium homeostasis in the myocardium 
that may be similar to the pathogenesis in mdx. 
 
2.5 Current Research and Therapeutic Strategies 
Experimental therapeutics of the muscular dystrophies has made impressive advances 
on several fronts. Muscle gene delivery has been successful in rodent models, 
correction of the dystrophin gene mutation has been reported in dog, and several 
reports of progress on myogenic stem cell characterisation are highlighting cell 
transplantation as a possible therapeutic approach. Bone marrow transplantation has 
been shown to regenerate cardiomyocyte dystrophin (Bittner et al., 1999). The 
consequences of primary dystrophin-deficiency are being continually advanced and 
drugs targeting specific biochemical pathways are being tested in several animal 
models. Drug discoveries are continually being implemented in human clinical trials 
(Hoffman & Dressman, 2001). Physical management has long been an approach used 
to increase longevity in human males with Duchenne muscular dystrophy (Dubowitz 
& Heckmatt, 1980) and survival is now significantly prolonged with the use of 
physical medical interventions, therefore the prevention of cardiac complications 
takes on ever-increasing importance (Ishikawa et al., 1995). 
 
2.5.1 Myoblast Transfer 
With rapid advances in the molecular genetics of DMD, myoblast transfer (cell 
transplantation) and gene therapy have both been proposed as potential treatments. 
Myoblasts are muscle precursor cells capable of migrating to the site of muscle 
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damage, fusing with other myoblasts and thus regenerating the muscle. The aim of 
myoblast transfer is to incorporate donor myoblasts (containing dystrophin) into 
dystrophin-deficient tissue. Initial experiments in mdx mice were promising, but 
efficient transfer of myoblasts into human muscles has not yet been successful. The 
major problem is a reduced replicating ability after the age of 2 years (Miller & 
Hoffman, 1994). Also, as with any other transplantation, the injected material is often 
rejected by the recipient. The final difficulty is that such an approach would also not 
influence the brain for the approximately 19% of boys with intellectual impairment.  
 
2.5.2 Gene Therapy 
Successful gene therapy will require the efficient delivery of a dystrophin expression 
vector to the muscles of the body (Chamberlain, 2002). The process of gene therapy 
has been thwarted by the enormous size (2.4MB) and complexity of the dystrophin 
gene. Therefore the generation of mini-genes that can express therapeutic levels of 
functional protein may alleviate part of the problem. This has involved isolating the 
dystrophin gene from DNA and identifying the gene promoter, a sequence of DNA 
that ensures that the gene is ‘turned on’ in the appropriate tissue. The promoter and 
associated gene are then cloned, a process whereby a microorganism such as a virus is 
induced to synthesize millions of copies (hence viral vector). An appropriate delivery 
vector must also be identified, an organism that does not produce an immunological 
or toxic response (Chamberlain, 2002). Results from animal experiments have shown 
that direct injection of the cloned mini-dystrophin gene itself is not efficient, with 
only a low level of expression (Miller & Hoffman, 1994). The rod structure, and its 
length have been shown to be crucial determinants for the function of micro-
dystrophin (Sakamoto et al., 2002). The muscle isoform of dystrophin is encoded on a 
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14Kb mRNA, and cDNA produced has prevented dystrophy in mdx muscles (Cox et 
al., 1993). New adenovirus-based gene delivery systems are being developed, along 
with retroviruses, adeno-associated viruses and plasmids (Chamberlain, 2002). 
However, delivery of the gene to muscle continues to be problematic for the following 
reasons. Firstly, in order to obtain the maximum therapeutic effect, a large proportion 
of myofibres must be formed, yet with muscle as such a large target tissue (30% of 
the body mass), with a unique cellular structure, it is difficult to successfully infiltrate 
the target adequately. Secondly, there is an aggressive immune attack against infected 
cells. Thirdly, adenovirus can only infect neonatal muscle and has not been successful 
at inducing gene expression in more mature tissues (Hoffman et al., 1997).  
 
Even when solutions for systemic delivery and efficiency are found, transgenic gene 
therapy will still suffer from the major shortcoming of being preventive rather than 
curative of existing damage, because it is unlikely to reverse the physiological and 
anatomical lesions at all sites, or be effective at any stage of the disorder. 
Furthermore, neural defects and secondary complications (such as joint contracture 
and scoliosis) will not be rectified (Kakulas, 1997). Recently Yue et al., (2003) used 
adeno-associated virus-mediated microdystrophin gene therapy in the mdx mouse 
heart with successful restoration of the dystrophin-glycoprotein complex achieved 
when tested 10 months after the procedure. This procedure was also able to improve 
the sarcolemma integrity in the mdx heart. These procedures hold promise for future 
therapeutic value, although their implementation in boys with DMD is still in the 
distant future. 
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2.5.3 Exon Skipping 
Mann et al., (2001) reported an antisense-induced exon skipping mechanism that was 
able to produce functional dystrophin in the mdx. These antisense oligonucleotides 
modify processing of the dystrophin at the pre-mRNA level, so that exons are skipped 
and a shorter version of dystrophin is produced in the muscle. The group have since 
refined their technique by identifying sensitive regions of the gene to induce skipping, 
and by reducing the size of the antisense oligonucleotide. This has produced increased 
function of the skeletal muscle of mdx (Lu et al., 2003) and demonstrated increasing 
feasibility of an antisense-oligonucleotide based therapy for the treatment of DMD 
(Mann et al., 2002). 
 
2.5.4 Utrophin Upregulation 
An alternative approach may lie in the identification of proteins similar in tissue 
distribution and function to dystrophin. Upregulation of utrophin has shown beneficial 
effects in animal models (Deconinck et al., 1997; Gillis & Deconinck, 1998; Rafael et 
al., 1998). It has been hoped that the administration of pharmacological agents to 
stimulate transcription and thus increase the specific expression of utrophin may 
compensate for the loss of dystrophin and assist in overcoming the dystrophin 
deficiency. However, research has indicated that upregulation of utrophin in 
dystrophin-deficient cardiomyocytes is unable to prevent the development of life-
threatening myocardial dysfunction in humans (Fanin et al., 1999).  
 
Although these therapies hold tremendous promise and are the future for treating 
dystrophin-deficient conditions, understanding the pathogenesis of the disease is still 
of vital importance. Also, these therapies are still many years from human therapeutic 
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use, so drug therapy to increase life quality and quantity are important. Gene therapies 
will probably not completely correct the loss of dystrophin, with most therapies 
improving prognosis to BMD-like pathology, with partial expression of dystrophin. 
Therefore drug therapy will likely continue to be required to treat dystrophin-deficient 
conditions. 
 
2.5.5 Drug therapy 
DMD is a progressive disease, with patients largely symptom free before five years of 
age. Although the complete correction of the biochemical defect is the clear goal in 
therapeutics for DMD, it should be equally viable to slow or ideally halt disease 
progression with the use of drug therapy aimed at correcting a well-defined 
pathogenesis of the disease with further research.  
 
2.5.5.1 Glucocorticoids 
The pharmacological agents that have shown the greatest success in slowing the 
progression of DMD are the corticosteroids such as prednisone and deflazacort 
(Dubrovsky et al., 1998). The exact mechanism of their beneficial effects remains 
unknown, although it has been reported that prednisone stimulates myogenesis in 
human and rat muscle cells and increases the expression of dystrophin-associated 
proteins (Vandebrouck et al., 1999). Deflazacort has been shown to promote 
myogenic repair and stimulate fibre growth in mdx skeletal muscle (Anderson et al., 
1996), as well as decreasing myocardial lesions and preventing cardiomyopathy in 
mdx (Skrabek & Anderson, 2001). Part of the beneficial effect of the glucocorticoids 
in DMD patients could be attributed to a reduction in calcium influx (Reilly et al., 
1996) and in the size of calcium pools in dystrophic muscle fibres (De La Porte et al., 
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1999), hence reducing calcium-induced tissue injury. The antiinflammatory effects of 
the corticosteroids are also of benefit since chronic inflammation has been shown to 
be associated with dystrophin-deficient skeletal muscle (Porter et al., 2002). Clinical 
trials of glucocorticoids have documented benefits in palliation of DMD (Burrow et 
al., 1991). Kissel et al., (1991) suggest that glucocorticoids improve strength in DMD 
through primarily immunologic mechanisms involving T lymphocytes. In contrast to 
normal muscle where glucocorticoids promote muscle proteolysis, Rifai et al., (1995) 
alternatively proposed that improved strength of dystrophic muscle was mediated by 
inhibition of muscle proteolysis rather than stimulating muscle protein synthesis. 
Glucocorticoids may enhance muscle strength and function for up to two years (Khan, 
1993) and are at present the only valid muscle-sustaining treatment, though some 
patients experience side effects such as Cushingoid symptoms and are advised to 
discontinue treatment.  
 
2.5.5.2 β-Adrenergic Agents 
It was initially speculated that muscular dystrophy was due to a defect in sympathetic 
innervation of skeletal muscle (Dubowitz & Heckmatt, 1980), so sympathomimetics 
were some of the first treatments aimed at rectifying the pathogenesis of muscular 
dystrophy. The β-adrenergic agonists have recently been nominated to potentially 
improve skeletal muscle strength in dystrophinopathies, although it appears that such 
a strategy could have deleterious effects by increasing the mechanical workload on 
the heart and the risk of further myocardial injury (Danialou et al., 2001). Conversely, 
the use of pharmacological interventions that reduce cardiac workload, such as β-
blockers could be beneficial in not only treating established cardiomyopathy, but also 
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preventing the onset of cardiomyopathy in these patients if instituted sufficiently early 
in life.  
 
2.5.6 Summary of Current and Future Therapeutics 
Although gene therapy and stem cells show promise and hope for the future abolition 
of Duchenne muscular dystrophy, at least in its current prognosis, these experimental 
therapeutics remain somewhat distant clinically. The glucocorticoids currently 
provide the best therapeutic strategy, but their exact mechanism of action remains 
unknown, and side effects may be too severe for the continuation of treatment for 
some DMD patients. Therefore, other strategies to inhibit the progression of this 
disease are still required. 
 
The presence of a high concentration of calcium is considered a major pathological 
contributor to muscle necrosis in dystrophic skeletal muscle. The role of calcium is of 
utmost importance in the myocardium. Calcium is involved in the electrical signalling 
of the pacemaker and it is the ion that is released from the sarcoplasmic reticulum to 
bind to the contractile proteins of the myocardium to produce the contraction of the 
cardiac muscle. Calcium is also a very important contributor to arrythmogenesis, an 
affliction that occurs frequently in the cardiomyopathy associated with DMD. 
Intracellular calcium has been shown to be elevated in dystrophic myocardium, 
although the mechanisms responsible remain to be elucidated. To better understand 
the mechanisms contributing to this intracellular calcium overload and therefore the 
potential to direct therapies towards this, there remains a need for further research on 
the regulation of calcium in the myocardium. 
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2.6 Cardiac Calcium Cycling 
Calcium ions are second messengers in signalling pathways in a variety of cell types. 
Calcium regulates muscle contraction, the electrical signals which determine the 
cardiac rhythm; and cell growth pathways in the heart (Marks, 2001). In cardiac 
excitation-contraction coupling at the cellular level action potentials pass over the 
surface membrane and activate voltage sensitive calcium channels that open rapidly, 
allowing extracellular calcium to flow into the cytoplasm (Lamb, 2000). The calcium 
enters the cell and binds to and opens specialised calcium release channels (type 2 
ryanodine receptors; RyR) in the nearby sarcoplasmic reticulum (SR) membrane. The 
calcium flows out of the SR and activates other RyR release channels, thereby 
reinforcing calcium release. This phenomenon is known as calcium induced calcium 
release (CICR) (Fabiato & Fabiato, 1975). SR calcium release is controlled by the L-
type calcium current because independent, elementary events of SR calcium release 
are “recruited” by calcium flowing through single L-type channels, and not by the 
average concentration of calcium within the cell (Wier & Balke, 1999). The rapid rise 
in cytoplasmic calcium concentration activates the contractile apparatus, which 
produces force, before the calcium is subsequently taken up into the SR by the sarco-
endoplasmic reticulum calcium ATPase (SERCA). Calcium is also removed from the 
cytoplasm by the sodium/calcium exchanger (NCX) and the membrane bound 
sarcolemmal Ca2+-ATPase. Both these processes remove calcium from the 
intracellular space to the extracellular space.  
 
With little known about calcium handling in dystrophin-deficient cardiomyocytes, 
each mechanism that involves the movement of calcium is a potential source that may 
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contribute to the intracellular overload. Each of these mechanisms will be discussed 
further in the following sections. 
 
2.6.1 The Action Potential 
The cardiac action potential is characterised by the movement of three predominating 
ions; sodium, calcium and potassium. The upstroke of the action potential (Fig 2.5) is 
due to sodium influx and is known as the depolarising current and is followed by 
calcium influx, responsible for the plateau phase of the action potential in human 
myocardium. However its contribution to a plateau in murine myocardium is rather 
insignificant. Finally the repolarising current or inward rectifier is due to the efflux of 
potassium ions. The only study to observe the ventricular cardiac action potential in a 
model of DMD was Pacioretty et al., (1994) who studied the Xmd (GRMD) dog 
cardiac action potential. Pacioretty et al., (1994) observed a reduction in the transient 
outward current, which should produce delayed repolarisation of the action potential, 
however it must be acknowledged that the canine cardiac action potential is quite 
different from the murine cardiac action potential. Pacioretty et al., (1992) published 
an abstract on the Xmd and mdx action potential characteristics obtained from isolated 
myocytes. The mdx ventricular action potential duration was unchanged in animals 
less than 6 months of age, while the action potential duration is significantly shorter in 
older animals. The abstract does not elucidate on actual ages or methods of cell 
isolation or recordings. The abstract did however speculate that the transient outward 
current may be increased, and the inward calcium current decreased in DMD, without 
providing any evidence to support the speculations. The cellular cytoskeleton 
contributes to the regulation of both voltage- and ligand-gated ion channels, and L-
type calcium channels in cardiac and smooth muscle have been reported as being 
Chapter 2 – Literature Review 
 39
regulated by actin filament organization (Sasaki et al., 1987). This is important in 
dystrophin-deficiency, as actin filament organisation may be disrupted. 
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Figure 2.5 A comparison of human and murine action potentials. A A human ventricular cardiac 
action potential. 4) Resting membrane potential is set by a large K+ permeability due to a 
combination of the leak K+ channel and a voltage-gated K+ channel (called the inward rectifier 
K+ channel) that is open at rest 0) The rising phase of the action potential is due to the cardiac 
voltage-gated Na+ channel. 1-2) As the voltage-gated Na+ channels produce the rising phase and 
then start to inactivate two channels will now be opening, the delayed rectifier K+ channel and 
the L-type Ca2+ channel. This plateau is a balance between the open Ca2+ channels and the open 
K+ channels. 3) Finally the L-type Ca2+ channels inactive and the voltage-gated K+ channels will 
now dominate and the membrane potential will repolarise to resting membrane potential.  Then 
the voltage-gated K+ channels will close, the voltage-gated Na+ channels will switch from the 
inactive to the closed state and the membrane is set back at 4) ready to fire again. B A 
representative murine atrial action potential from a C57 mouse in the absence of drug for 
comparison. The dominant ion channels are still represented, although the contribution of the L-
type calcium channel to the plateau phase is negligible. 
 
2.6.1.1 L-type Calcium Channels 
The mechanism mediating the majority of calcium influx in adult mammalian 
myocardium is the specific voltage-sensitive L-type channel which is often called the 
dihydropyridine receptor after the specific, high affinity blocking agent (Schramm et 
al., 1983). T-type or fast current via the T-type calcium channels is negligible in most 
ventricular cardiomyocytes (Bers, 2002), although it is somewhat more important in 
A 
B 
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skeletal muscle. The L-type Ca2+ channel is the most sophisticated of all surface 
membrane channels consisting of a functional main unit (α1) containing four domains, 
each with six spans, a voltage sensor and a pore loop. It contains at least three other 
subunits and a number of phosphorylation sites at the C-terminal (Fig 2.6).  
 
Figure 2.6 The subunits of the L-type calcium channel. The structure consists of four subunits 
each with six transmembrane spans and a pore loop. From 
http://medweb.bham.ac.uk/research/calcium/SupportFiles/subunit3.htm 
 
Thus it is a voltage – and at the same time receptor-operated channel. Drugs may bind 
to the L-type calcium channel and induce increased opening of the channel. L-type 
calcium channels are located primarily at the sarcolemmal SR junctions where the 
RyR exist. Opening of the channel is usually voltage activated, with depolarisations to 
-40mV causing opening of the L-type calcium channels. Channel inactivation can be 
mediated by voltage or chemical mechanisms. Normally repolarisation of the 
myocytes initiates inactivation so prolongation of the APD (ie delayed repolarisation) 
will delay inactivation, therefore the channels remain open for a longer period of time. 
During excitation-contraction coupling, SR calcium release also contributes to 
inactivation of the current through the L-type calcium channels by a negative 
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feedback mechanism. The total calcium influx through the L-type calcium channel is 
reduced by about 50% when SR calcium release occurs (Bers, 2002). Thus SR 
calcium release and the L-type current can create local negative feedbacks on calcium 
influx (Bers, 2002). When there is high calcium influx or release, further influx of 
calcium is turned off (Bers, 2002). Increased calcium influx through L-type calcium 
channels can in turn produce an increase in SR calcium content that may induce 
arrhythmia (Tweedie et al., 2000).  
 
Because of their central role in excitation-contraction coupling, L-type calcium 
channels are a key target of the therapeutic class of drugs known as L-type calcium 
channel blockers used to regulate chronotropic and inotropic actions. L-type calcium 
channel blockers, a group of organic substances that bind to specific sites at the 
calcium channels, are now well established in the treatment of angina pectoris, arterial 
hypertension and supraventricular arrhythmias. They are not only important 
therapeutics, but are also valuable tools for the study of the function of L-type 
calcium channels. Based on their pharmacological profile they can be divided into 
three classes: (1) dihydropyridines (eg. nifedipine), (2) phenylalkylamines (eg. 
verapamil) and (3) benzothiazepines (eg. diltiazem). Pharmacological observations 
suggested that the three antagonists bind to three separate receptor sites on the α1-
subunit of L-type calcium channels that are allosterically linked (Hockerman et al., 
1997; Nakayama & Kuniyasu, 1996). The three classes differ in their pharmacological 
profile and safety, with differences in their tissue selectivity. Although all these 
compounds exhibit negative inotropic effects, they exhibit different chronotropic 
effects due to different influences on neuro-hormonal activity (Hjemdahl & Wallen, 
1997; Noll et al., 1998). 
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2.6.1.1.1 Dihydropyridines 
The L-type calcium channel represents the major entry pathway of extracellular 
calcium. The DHPR agonist and antagonist molecules interact with distinct sites on 
the α1-subunit of the L-type calcium channel (Tang et al., 1993). Nifedipine is a 
commonly used representative of dihydropyridines (Table 2.2). It selectively inhibits 
the transmembrane influx of calcium ions into cardiac muscle and vascular smooth 
muscle. As a consequence, nifedipine dilates major coronary arteries and arterioles in 
normal and ischaemic regions, inhibits coronary artery spasm, reduces myocardial 
oxygen requirements and decreases peripheral vascular resistance.  
 
Dihydropyridine binding is voltage dependent, and this may explain the higher 
selectivity of this class of drugs for vascular smooth muscle, as it is more depolarised 
and can undergo a more sustained depolarisation than cardiac muscle (Bers & Perez-
Reyes, 1999). Vascularly selective dihydropyridines usually elicit increases in heart 
rate in vivo by a vasodilatation-triggered, baroreceptor-mediated reflex increase in 
sympathetic tone, renin release and elevated plasma catecholamines, resulting in 
indirect cardiostimulation (Hjemdahl & Wallen, 1997; Scholz et al., 1997). The 
radiolabelled [3H]-PN 200-110 acts similarly to nifedipine by blocking the 
dihydropyridine site to block the L-type calcium channel, but is used for ligand-
receptor binding studies.  
 
2.6.1.1.2 Phenylalkylamines  
Verapamil, a representative of phenylalkylamines binds at an internal site on the α1- 
component of the L-type calcium channel (Table 2.2). Its binding is facilitated by the 
repetitive depolarisation of cardiac tissue, a phenomenon described as use-
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dependence. The distinction between voltage- and use-dependence may explain why 
this drug is not as highly selective as nifedipine (its activity increases with a 
maintained level of depolarisation), instead being equipotent for both the myocardium 
and the vasculature (Ferrari et al., 1994). The mechanism of the anti-anginal and 
antiarrhythmic effects of verapamil is related to its specific cellular action of 
selectively inhibiting transmembrane influx of calcium in cardiac muscle and in cells 
of the sinoatrial (SA) and atrioventricular (AV) nodes. Verapamil is also a potent 
smooth muscle relaxant. Its vasodilatory and myocardial contractility depressant 
properties are largely independent of autonomic influences and this is evident by 
normal plasma noradrenaline measurements after verapamil administration.  
 
2.6.1.1.3 Benzothiazepines 
Diltiazem, a benzothiazepine is also a calcium ion influx inhibitor (Table 2.2). Like 
verapamil, diltiazem is prominently frequency-dependent. This largely contributes to 
its anti-arrhythmic and cardiac depressant action (Triggle, 1999). It also decreases 
sinoatrial and atrioventricular conduction in isolated tissues and has a negative 
inotropic effect in isolated myocardial preparations. It is used for the treatment of 
hypertension and angina as it dilates epicardial and subendocardial arteries.  
 
Furthermore, an inhibitory effect on the mitochondrial Na+/Ca2+ exchange (NCE) has 
been claimed for diltiazem that is unique among calcium channel antagonists (Vaghy 
et al., 1982; Schwartz, 1992). This effect may, in turn, decrease oxidative 
phosphorylation and the production of high-energy phosphates (Cox & Matlib, 1993). 
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2.6.2 The Sarcoplasmic Reticulum 
2.6.2.1 SR Calcium Release 
Calcium is released from the intracellular store by release channels located in the 
junctional part of the reticulum adjacent to the T-tubules. They have a tetrameric 
structure with huge cytoplasmic domains, which include associated intraluminal 
calcium binding proteins such as calsequestrin. It is now called the Ryanodine 
receptor (RyR) after the experimentally used channel blocking alkaloid. During each 
contraction cycle the SR is loaded partly by calcium ions entering the cell but mainly 
by calcium ions that have just been released from the actomyosin interaction. 
Reduced SR function is described in various forms of cardiac hypertrophy and heart 
failure (Meyer et al., 2001).  
 
Dysfunction in a small number of SR Ca2+ release channels has been shown to 
profoundly affect cardiac function (Meyer et al., 2001). The cardiac ryanodine 
calcium release channel is stimulated to release calcium by calcium influx via the L-
type calcium channels. In cardiac muscle, calcium release from the SR is stimulated 
by caffeine (mM range), by ryanodine (nM range) and by calcium (µM range), and 
inhibited by higher concentrations of ryanodine (µM range) and ruthenium red 
(Marks, 2001; Ehrlich et al., 1994). Caffeine has a dual action on calcium flow, by 
inhibiting SERCA and inducing opening of the ryanodine receptor (Ritter et al., 
2000). Caffeine also has an effect of increasing myofilament sensitivity to calcium 
(Wendt & Stephenson, 1983). 
 
Ryanodine has been shown not to interfere with SR sequestration (Bers & Bridge, 
1989). Dantrolene acts to inhibit calcium release via the Ryanodine receptors on the 
Chapter 2 – Literature Review 
 45
SR (Table 2.2). Dantrolene is used clinically in the treatment of malignant 
hyperthermia (Bertorini et al., 1991). In malignant hyperthermia, like DMD, there is a 
defective influx and efflux of calcium from the SR. Dantrolene has undergone clinical 
trials in DMD patients over a two-year period with a reduction in serum creatine 
kinase observed (Bertorini et al., 1991). The authors also observed a trend towards a 
“lessening of muscle deterioration” (Bertorini et al., 1991) during the dantrolene trial. 
Therefore drugs that decrease intracellular calcium levels may be of therapeutic value 
in DMD, although more extensive trials need to elucidate mechanisms of action and 
effectiveness in reducing the intracellular calcium overload associated with 
dystrophin-deficiency.  
 
2.6.2.2 SR Calcium Sequestration 
Cytosolic calcium removal is essential for relaxation of the myocardium. The onset of 
relaxation is synchronised with repolarisation. This feature is important 
physiologically because frequency-dependent shortening of the action potential 
abbreviates not only the refractory period but also the contraction-relaxation cycle and 
in turn causes a relative prolongation of ventricular filling time. In rats and mice, 
which have a high level of activity of SERCA and a relatively high [Na+]i, NCX is 
responsible for approximately 10% of relaxation (Barry, 2000). Contributions of each 
of the calcium removal pathways in rodent heart are as follows: 92% of calcium 
sequestration and/or extrusion by the SERCA, 7-10% by the NCX and approximately 
1% by the slow systems (sarcolemmal Ca2+-ATPase and the mitochondrial calcium 
uniporter) (Bers, 2002). SERCA therefore plays the major role in relaxation of the 
myocardium and is regulated by an associated inhibitory protein, phospholamban 
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Table 2.2 Pharmacological agents that affect calcium handling in cardiac myocytes. 
 
 Calcium influx modulators SR calcium flux 
modulators 
1. L-type calcium channel 
modulators 
Stimulators Blockers  
a) Dihydropyridines Bay K 8644 Nifedipene  
b) Phenylalkylamines  Verapamil  
c) Benzothiazepines  Diltiazem  
    
2. SR calcium pump inhibitors   Caffeine, 
Cyclopiazonic Acid 
    
3. RyR stimulators, SR 
calcium channel release 
promoter 
  Ryanodine,  
Caffeine 
    
4. SR calcium channel release 
inhibitor 
  Dantrolene 
 
(PLB). Decreases in the levels of PLB or increases in its phosphorylation status result 
in an increase in the apparent calcium affinity of SERCA, and augment cardiac 
contractile parameters (Sato et al., 2001). The ratio of PLB/SERCA has been accepted 
as a major determinant of lusitropy (Mirit et al., 2000). SERCA regulation is of vital 
importance, as overexpression of SERCA and a higher accumulation of SR calcium 
have been linked with an acceleration of spontaneous cell death caused by protease-
induced apoptosis (Culligan & Ohlendieck, 2002). Alternatively, an underexpression 
or dysfunction of SERCA will lead to an accumulation of cytosolic calcium, a 
dysfunctional SR and a lengthened relaxation time. Relaxation time has also been 
determined to be impaired at higher stimulation frequencies, and when intracellular 
calcium is elevated (Maier et al., 1998).  
 
Specific inhibitors of calcium removal mechanisms are important pharmacological 
tools that may help to elucidate functional differences between normal and 
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dystrophin-deficient cardiac tissues. Cyclopiazonic acid (CPA) is able to inhibit 
SERCA from functioning so that uptake of calcium to the SR is abolished. 
Thapsigargan is a selective inhibitor of SERCA in cardiac muscle. Concentrations 
higher than 50µM of thapsigargin and CPA are required in multicellular preparations 
of rat and rabbit heart to induce significant inhibition of SERCA (Baudet et al., 1993; 
Pery-Man et al., 1993). Both thapsigargin (Nario & Satoh, 1996) and CPA (Pery-Man 
et al., 1993) have been shown to decrease force of contraction, decrease time to peak 
force, attenuate the force-frequency relationship and significantly delay relaxation 
time (Kocic et al., 1998).  
 
2.6.3 Regulation of Responsiveness to Calcium in the Heart 
Cardiac calcium cycling involves movement of calcium ions from the extracellular 
space through L-type calcium channels to the cytosol. This movement of calcium ions 
initiates calcium-induced calcium release (CICR). CICR initiates a massive outflow 
of calcium from the intracellular store, the sarcoplasmic reticulum (SR). All calcium 
ions in the cytosol are able to bind to the contractile proteins to produce shortening of 
the myocardial fibres. Finally removal of calcium to produce relaxation involves 
extrusion of ions to the extracellular space by the sodium-calcium exchanger (NCX) 
and sequestration of calcium back into the SR by the sarco-endoplasmic reticulum 
ATPase (SERCA).  
 
Three features of cardiac calcium handling are unique. First, the voltage sensitivity of 
the RyR is dwarfed by the sensitivity to calcium ions entering the cell through the 
membrane channels. Therefore CICR becomes the major influence in SR calcium 
release. Second, the amount of calcium release and hence the force of contraction 
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depends on autonomic heart rate variability and variations in the availability of 
reticular calcium that account for the force-frequency relationship of the myocardium. 
Third, an increased sarcomere length increases the sensitivity of troponin C to 
calcium, partly accounting for the Starling principle (Metzger et al., 1989). There are 
also differential interactions of calmodulin with the RyR channels that may contribute 
to differences in the calcium dependence of SR calcium release in cardiac muscle 
(Fruen et al., 2000).  
 
Importantly in the pathophysiology of high intracellular calcium and in normal 
conditions, high intracellular calcium favours calcium efflux, whereas positive 
membrane potentials and high intracellular sodium favour the NCX operating in 
reverse mode. The NCX has a reversal potential that depends on the electrochemical 
gradients for both calcium and sodium. At rest, this reversal potential is around -
40mV (Niggli, 1999). A depolarisation of the cell membrane beyond the reversal 
potential is expected to activate calcium influx via the NCX, for example, early 
during the action potential, immediately before the intracellular calcium concentration 
starts to rise. Later during the action potential, the elevation of intracellular calcium 
shifts the reversal potential of the NCX to more positive potentials and the NCX starts 
to remove calcium from the cytosol (Niggli, 1999).  
 
2.7 Potential Sites of Dysfunctional Calcium Handling 
in Dystrophic Hearts 
Calcium homeostasis in cardiomyocytes is maintained via precise control of 
intracellular calcium concentrations in a range from ~ 100nM during diastole to a 
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peak of ~ 1000nM in systole (Marks, 2001). In failing myocardium, cardiac force may 
be insufficient due to modification of the calcium sensitivity of the myofilaments, 
and/or a deterioration of the calcium signals due to dysfunction in one of the calcium 
handling proteins (Niggli, 1999). Studies on failing hearts have found resting 
intracellular calcium to be slightly elevated whereas calcium transients were reduced 
in amplitude and exhibited a slower decay (Niggli, 1999). For efficient excitation-
contraction coupling and relaxation, the cycling of intracellular calcium must be 
rigidly linked to sarcolemmal depolarisation during the action potential (Bers, 2002). 
Thus, a longer opening of L-type calcium channels or an increase in their density, or 
SR calcium overload would therefore produce a greater intracellular calcium 
concentration which should theoretically produce action potential duration 
prolongation (APD). Sustained depolarisation of the cardiomyocyte plasma 
membrane decreases the rate of extrusion of calcium by the NCX. In general, less 
calcium is extruded by the NCX at more positive potentials. This voltage-dependence 
of the NCX is such that a prolonged APD leads to higher intracellular calcium levels 
and decreased calcium extrusion (Marks, 2001). Therefore a dysfunction in one 
mechanism of calcium handling may alter other processes involved in calcium 
regulation causing a cascade effect. 
 
It is not clear yet whether alterations of cardiac calcium signalling are pathogenic to a 
particular disease or an adaptive consequence of deteriorated cardiac function (Niggli, 
1999). It appears probable that calcium channel abnormalities play a role in the 
potential for arrhythmias in DMD (Sadeghi et al., 2002). SR calcium overload has 
also been proposed as a contributing factor to the development of aberrant calcium 
fluxes due to calcium influx via the L-type calcium channel. Thus both the L-type 
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calcium channel and the RyR have been implicated in the dysregulation of calcium 
signalling that may contribute to cardiac arrhythmias (Marks, 2001). In other studies 
of cardiac dysfunction, changes were observed in the expression of calcium handling 
proteins and/or their mRNA and often these changes were paralleled by alterations of 
transport function. In yet other studies, changes of calcium signalling appeared to 
result from a functional modification of a particular transporter and not from a change 
in the amount of expressed protein (Niggli, 1999). Therefore both protein and mRNA 
expression and function should be investigated concurrently to correctly ascertain the 
basis for dysfunctional calcium handling. 
 
Given that a calcium overload of all muscle types seems to be associated with 
myopathy in dystrophin-deficiency, there is a requirement for further study to 
disseminate potential mechanisms of the calcium overload. 
 
2.7.1 The L-type Calcium Channel 
The DHPR are a point of contention in research into dystrophin-deficiency and other 
myopathies associated with a loss of the DAGPC. Studies have shown either no 
change or an increase in DHPR, dependent on the model of dystrophin-deficiency 
used and the age of the experimental animals. Two studies have evaluated the L-type 
calcium channel in mdx. Alloatti et al., (1995) studied currents from the L-type 
calcium channel and Sadeghi et al., (2002) determined interaction of the mdx cardiac 
L-type calcium channel with actinin and dystrophin-binding proteins. Neither study 
showed conclusive evidence for changes in L-type calcium channels in mdx. Sadeghi 
et al., (2002) showed that inactivation was delayed in the cardiac L-type calcium 
channel in mdx neonatal cardiomyocytes. How this related to activity of adult mdx 
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myocytes that exhibit myopathy is unclear. Influx mechanisms as the main source for 
calcium entry into the cell remain a potential cause for intracellular calcium overload 
in dystrophin-deficient conditions.  
 
In cardiac myocytes from mdx mice, inactivation of the L-type calcium channel was 
reduced by a positive shift in the voltage dependence of activation, a likely allosteric 
change in channel conformation that made it more sensitive to stimulation by the β-
adrenergic agonist l-isoproterenol and the dihydropyridine agonist l-Bay K 8644 
(Sadeghi et al., 2002). 
 
Verapamil has been reported to reduce heart lesion in dogs and dystrophic hamsters 
(Reimer et al., 1977; Wrogemann & Pena, 1976; Jasmin et al., 1979), inhibit the 
protein degradation in mdx myotubes (Kamper & Rodemann, 1992), and also inhibit 
calcium-induced efflux of CK (Anand & Emery, 1982) and it thus may be useful in 
treatment of DMD-associated cardiovascular disorders. 
 
2.7.2 SR Mechanisms 
Uptake mechanisms such as SERCA have been shown to be altered in conditions 
where an abnormality of calcium handing is already present. This along with a 
delayed relaxation time exhibited in mdx tissues previously (Alloatti et al., 1995) 
suggests that there may be a role in the cardiac dysfunction for SERCA. A recent 
report indicated a downregulation of SERCA in mdx heart in 5 month old mice 
(Rohman et al., 2003). It is unclear whether SERCA is altered at 12-14 weeks in mdx 
myocardium, and whether potential alterations contribute to cardiomyopathy observed 
in dystrophin-deficiency. Sapp et al., (1996) observed decreased force in mdx left 
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atria compared to control, especially at long test intervals. The authors suggest that 
there may be a leaky SR or dysfunctional SERCA. Since relaxation time has also been 
shown to be delayed in both mdx atria (Sapp et al., 1996) and DMD ventricles, there 
is a possibility that dystrophin-deficiency leads to a dysfunctional SERCA.  
 
2.7.2.1 The Ryanodine Calcium Release Channel 
The ryanodine receptor as the release channel for calcium from the SR remains a 
candidate for dysfunctional calcium handling. Two reports have described cardiac 
ryanodine receptors in dystrophic cardiac tissue. Both studies observed a 
downregultion of the ryanodine receptor as measured by binding sites for 3H-
ryanodine in cardiomyopathic hamsters (Lachnit et al., 1994) and decreased levels of 
ryanodine receptor mRNA in mdx (Rohman et al., 2003). Rohman et al., (2003) used 
5 month old mdx mice for their study, it is unknown whether levels of the ryanodine 
receptor are altered at 12-14 weeks when the cardiomyopathy is first observed, or 
when the changes observed in their study are manifested. 
 
2.7.3 Calcium Leak 
The possibility of an SR calcium leak cannot be discounted in mdx cardiomyocytes. 
Studies have shown that SR calcium stores in ryanodine-treated animals can be 
depleted during prolonged rest periods (Meyer et al., 2001). The leak-induced 
reduction in SR calcium load was associated with a prolongation of relaxation and a 
slower rate of contraction. Cardiac hypertrophy was also evident in the study, and 
atrial natriuretic factor mRNA was increased while SERCA mRNA was decreased 
(Meyer et al., 2001). In dystrophin-deficient conditions a delayed relaxation of the 
myocardium has been observed, but rate of contraction is usually normal. Since 
Chapter 2 – Literature Review 
 53
Meyer et. al. (2001) showed that an SR leak can lead to contractile dysfunction and 
altered SERCA it is important to determine whether such a SR leak develops in 
dystrophic hearts. 
 
2.7.4 Calcium Binding and Associated Proteins 
Several calcium-related signalling molecules, such as calcineurin, calmodulin (CaM)-
kinase, and calcium-dependent protein kinase C (PKC) have been suggested to play 
key roles in myocardial hypertrophic responses (Sato et al., 2001). Calcium regulatory 
proteins such as calcineurin have been shown to be involved in the hypertrophic 
response that precedes heart failure (Marks, 2001). The RyR is a macromolecular 
signalling complex in which signalling proteins, including kinases, phosphatases and 
adaptor or anchoring proteins, are bound to specific binding domains on the 
cytoplasmic portion of the channel (Marx et al., 2000). The RyR is phosphorylated by 
PKA, PKC, PKG and CamKII (Witcher et al., 1992; Takasago et al., 1989; 
Hohenegger & Suko, 1993; Hain et al., 1995). Defective regulation of the RyR in 
heart failure is associated with PKA hyperphosphorylation resulting in increased 
sensitivity to calcium-dependent activation (Marks, 2001). PKA phosphorylation 
affects at least three important targets that regulate cardiac excitation-contraction 
coupling: the L-type channel, phospholamban which regulates SERCA activity and 
the RyR. In failing hearts, PKA mediated phosphorylation of RyR is over-stimulated 
and pathological consequences could include depletion of SR calcium stores required 
for EC coupling as well as aberrant release of SR calcium during diastole which may 
serve as triggers for fatal cardiac arrhythmias (Marx et al., 2000). Calcineurin and p38 
mitogen-activated protein kinase (MAPK) are up-regulated in the hearts of mdx mice 
(Nakamura et al., 2002). Phosphorylated p38 MAPK, phosphorylated extracellular 
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signal-regulated kinase 1/2 and calcineurin are up-regulated in exercised mdx hearts 
compared to exercised C57 or non-exercised mdx hearts. These data suggest that 
physical exercise accelerates the dystrophic process through activation of intracellular 
signalling molecules in dystrophin-deficient hearts (Nakamura et al., 2002). The SR 
calcium load and subsequent release are regulated by calsequestrin, a luminal SR 
protein, with high capacity and low affinity for calcium (Sato et al., 2001). Transgenic 
mice overexpressing calsequestrin show disturbed calcium handling associated with 
cardiac hypertrophy (Meyer et al., 2001).  
 
Skeletal muscle studies in mdx have shown that the calcium binding proteins are 
altered, and not in as great an abundance as in normal skeletal muscle (Culligan et al., 
2002). There is a possible role for dysfunctional SR calcium binding in the 
cardiomyopathy associated with dystrophin-deficiency. 
 
2.7.5 Calcium Efflux 
Finally, efflux of calcium may be affected in dystrophin-deficient myocardium, since 
the primary cause of the cardiomyopathy is a loss of structural integrity of the 
sarcolemma. The NCX may be reduced, dysfunctional, or contributing to the calcium 
overload by operating in reverse mode.  
 
2.8 Insights From Skeletal Muscle 
Dystrophin-deficient skeletal muscle has been studied extensively. The major findings 
in regard to calcium regulation in mdx may offer some insight into the dysfunction in 
cardiac muscle. Dystrophin-deficient skeletal muscles undergo a characteristic pattern 
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of myocyte necrosis and regeneration (Cullen & Mastaglia 1980; Torres & Duchen, 
1987). Structurally, the T-tubules from mdx mice have been examined using electron 
microscopy and shown to be abnormal (Lucas-Heron et al., 1987), and mdx myotubes 
have a depressed SR and/or SERCA function (Bakker et al., 1993). Mdx skeletal 
muscles produce less force than control, and this force decrement was not simply due 
to fibre necrosis (Coulton et al., 1988). Skeletal muscle myotubes (Bakker et al., 
1993) and fibres (Turner et al., 1991; Ruegg & Gillis, 1999; Mallouk et al., 2000) 
have been shown to have a higher resting intracellular calcium than control, although 
some reports have provided evidence against dystrophin-deficiency leading to an 
intracellular calcium overload (Head, 1993; Pressmar et al., 1994; Gillis, 1996; Collet 
et al., 1999). Reports have shown that reducing extracellular calcium can improve 
longevity of mdx myofibres (De Backer et al., 2002). Mdx skeletal muscles are less 
able to regulate intracellular calcium levels in the region near the sarcolemma (Turner 
et al., 1991). This elevation of intracellular free calcium is thought to stimulate the 
breakdown of muscle proteins by activating cellular proteases (Haws & Lansman 
1991; Ruegg & Gillis, 1999).  
 
Mechanosensitive calcium channels (leak calcium channels) are more active in mdx 
skeletal muscles compared to control (Turner 1991; Franco & Laansman 1990; Fong 
et al., 1990), although other reports suggest that leak calcium channels are not 
responsibly for the entirety of the elevated intracellular calcium (Pressmar et al., 
1994). Haws and Lansman (1991) examined mechano-sensitive Ca2+ channel activity 
in mdx skeletal muscle fibres using cell-attached membrane patches at different stages 
of postnatal development. They revealed very high levels of activity in mdx patches, 
and observed that channel density decreased in normal fibres, whereas it remained 
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relatively constant in mdx fibres, as if channels are down-regulated in normal, but not 
mdx fibres during postnatal development (Haws & Lansman, 1991). They suggest that 
an early step in the dystrophic process in skeletal muscle may be an alteration of the 
mechanisms that regulate the expression of functional channels.  
 
Calcium leakage in dystrophic muscle may also be produced by unusual physical 
interactions between acetylcholine receptors and the dystrophic cytoskeleton during 
processes associated with localisation and stabilisation of acetylcholine receptors 
(Carlson & Officer, 1996; Xu & Salpeter, 1997). It is possible that dystrophin is 
required for anchorage of other membrane-associated channels. Dystrophin deficient 
skeletal muscle membranes succumb to exercise-induced membrane ruptures more 
frequently than those of normal fibres (Stevens & Faulkner, 2000). However Dupont-
Versteegden et al., (1994) observed a training effect in soleus from mdx, a finding that 
suggested that exercise is not deleterious to mdx skeletal muscle. A study that allowed 
voluntary exercise in mdx showed that the dystrophin-deficient mice lacked endurance 
compared to control mice (Hara et al., 2002). Overall, the weight of data suggests that 
dystrophin-deficient muscles are less able to continue exercise, and that sarcolemma 
tears originate from exercise-induced contractions. Ruptures of the skeletal muscle 
allow for the insertion of calcium leak channels into the sarcolemma during the 
natural processes of cell membrane resealing. Ion leak channels give rise to localised 
calcium elevations, contributing to a cycle of enhanced protease activity and leak 
channel activation (Culligan & Ohlendieck 2002). Recently the leak channels have 
been suggested to be store-operated transient receptor potential channels 
(Vandebrouck et al., 2002).  
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Finally, Dangain & Neering, (1993) suggested that the developmental changes in 
myofilament sensitivity affect the contractile activity of dystrophic skeletal muscle, 
rather than an alteration in the calcium handling of the muscle. This postulation is in 
question, as Divet & Huchet-Cadiou (2002) found no difference between the calcium 
sensitivity of the contractile apparatus in mdx compared to control, even though the 
mdx maximum calcium-induced tension was significantly smaller. 
 
2.8.1 Calcium Influx in Dystrophin-Deficient Skeletal Muscle 
Although dystrophic skeletal muscle shows a two to three-fold increase in calcium 
influx, according to Ruegg and Gillis (1999) the voltage sensitive calcium channels 
play no role in the intracellular calcium overload. However, both the density of DHPR 
and the current density were shown to be higher in a DMD cell line than normal cells 
by Caviedes et al., (1994) although this finding has not been replicated. Therefore 
current reports in skeletal muscle are contradictory. The cardiac isoform of the DHPR 
mRNA was upregulated in skeletal muscle from transgenic mice following acute 
injury (Pereon et al., 1997) but an increase in protein of the DHPR in skeletal muscle 
has not been shown. The authors attributed this to proteolysis, although it is difficult 
to determine what mechanism is responsible. Insertion of a cDNA plasmid containing 
dystrophin has been shown to correct the defect in calcium homeostasis in mdx 
skeletal muscles (McCarter et al., 1997). 
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2.8.2 Sequestration Mechanisms in Dystrophin-Deficient 
Skeletal Muscle 
Lucas-Heron et al., (1987) observed a decrease in SERCA levels in skeletal muscle of 
mdx compared to C57, and this has since been supported by Divet & Huchet-Cadiou 
(2002) who observed significantly slower SR calcium uptake following exposure to 
caffeine. Lucas-Heron et al., (1987) also observed a decreased level of cardiac 
SERCA when compared to the skeletal muscle of the same species, but no differences 
in SERCA between dystrophin-deficient and normal mice. SR calcium quantity has 
been shown to be equivalent between mdx and normal mice (Divet & Huchet-Cadiou, 
2002). A longer decay time of the calcium transient has been observed mdx adult 
fibres (Gordon & Stein, 1985) and is due to either defective regulation of energy 
metabolism or by functionally altered SR calcium pumps (Tutdibi et al., 1999). 
Alternatively, Turner et al., (1991) suggest that calcium sequestration mechanisms are 
not altered in dystrophin-deficient muscle but are slowed by the higher resting 
calcium. It is probable that the calcium sequestering mechanisms in mdx are 
continually coping with a calcium overload (Tutdibi et al., 1999). Loss of 
calsequestrin-like proteins has also been observed (Culligan et al., 2002). Skeletal 
muscle of mdx has also shown decreased oxidative phosphorylation probably as a 
result of calcium overload of the muscle fibres (Kuznetsov et al., 1998). 
 
2.8.3 Activation of Calcium-Dependent Proteolytic Enzymes 
The marked elevation of calcium in dystrophic muscle may contribute to activation of 
calcium-dependent proteases such as skeletal muscle specific calpains (Culligan & 
Ohlendieck 2002). Alderton and Steinhardt (2000) suggest that “calcium influx 
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through calcium leak channels is responsible for the elevated levels of calcium-
dependent proteolysis in dystrophic myotubes”. Several authors have found an 
increase in the activity of calpains (Spencer et al., 1995; Nagy & Samaha, 1986) that 
have been implicated in the proteolysis of calcium leak channels, constitutively 
activating these channels (Culligan & Ohlendieck 2002). Conversely, protease 
inhibitors have been shown to reduce calcium-induced protein degradation in mdx, 
suggesting that an increase in intracellular calcium mediates this process (Turner et 
al., 1993). 
 
2.9 Requirements for Further Studies 
The current study aimed to determine whether the reported changes in intracellular 
calcium concentration were due to defective calcium handling mechanisms in the 
cardiac muscle of the mouse model of Duchenne muscular dystrophy. The study 
initially examined the function of the L-type calcium channel by measuring the 
potency and affinity of drugs that bind to the α1-subunit of the L-type calcium 
channel of mdx myocardium. The action potential characteristics of mdx were then 
examined, and contractile and repolarisation characteristics in response to drugs that 
act at the L-type calcium channel. 
 
The density and affinity of the DHPR was then measured, to confirm functional 
changes observed in the L-type calcium channel. The mRNA for the DHPR was also 
measured to determine whether regulation factors were altered. 
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The force-frequency relationship was determined in mdx myocardium to ascertain 
whether the ryanodine receptor or SR mechanisms were altered. The force-frequency 
relationship was also determined in the presence of ryanodine, dantrolene and 
caffeine. Rapid cooling contractures measured SR content and active mechanisms 
involved in sequestering calcium. The response of mdx myocardium to an inhibitor of 
SERCA was measured to determine whether sequestration mechanisms were altered 
in dystrophic myocardium. The mRNA of SERCA was also measured to determine 
whether regulation of SERCA was altered in response to dysfunctional calcium 
handling. 
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CHAPTER 3 – MATERIALS AND METHODS  
3.1 Ethical Considerations 
All animal experimentation conformed to NHMRC Animal Ethics guidelines and was 
approved by the University of Southern Queensland (USQ) Animal Ethics committee 
before the commencement of any experimentation. 
 
3.2 Experimental Animals 
Male C57BL/10ScSn (C57) mice and mutant C57BL/10ScSn mdx (mdx) mice were 
used. Mice were used in the age range of 12-14 weeks, and were age matched for all 
comparisons. Where possible, experiments alternated the use of mdx and C57 to avoid 
systematic bias in data acquisition. Mdx mice were obtained either from the USQ 
breeding colony or from the Animal Resource Centre, Nedlands, Western Australia. 
Since the two colonies were initiated from the same breeding stock, genetic variation 
was minimal. All C57 mice were purchased from the Animal Resource Centre. 
Animals were fed standard mouse chow with water ad libitum and housed at 21-24°C 
under a 12 hour light-dark cycle (6am-6pm).  
 
3.3 Apparatus Calibration and Protocol Optimisation 
Throughout all experimentation any apparatus that required calibration was calibrated 
prior to the commencement of the experimentation. For tissue bath experiments where 
force transducers were utilised, the transducers were calibrated with 1, 2 and 10mN 
weights to ensure accuracy. Before experimentation in the radioligand binding 
studies, the beta radiation-counter and pipettes used were calibrated. Tissue baths 
were cleaned thoroughly with concentrated nitric acid prior to the commencement of a 
Chapter 3 – Materials and Methods 
 62
new protocol, and cleaned after every experiment utilising contaminant drugs. Nitric 
acid residues were thoroughly washed out with water purified by reverse osmosis (Ro 
water). Tissue and perfusion baths were also washed and scrubbed daily with Ro 
water.  
 
Where a protocol had not been undertaken previously in our laboratory, extensive 
literature searches were undertaken initially, then the protocol was developed and 
optimised with and without preliminary use of animals as required. 
 
3.4 Dissection of Cardiac Tissues 
After being weighed, mice were anaesthetised by CO2 inhalation and then euthanased 
by exsanguination (except where otherwise indicated). The heart was removed and the 
left and right atria were rapidly dissected free while beating in cold (4°C) pre-
carbogenated (95% O2:5% CO2) Tyrode physiological salt solution (TPSS) (mM: 
NaCl 136.9, KCl 5.4, MgCl2.H2O 1.0, NaH2PO4.2H2O 0.4, NaHCO3 22.6, CaCl2.2H2O 
1.8, glucose 5.5, ascorbic acid 0.3, Na2EDTA 0.05).  
 
The ventricular chambers were then separated if required, and either prepared for 
homogenisation, placed in RNAlater™ or blotted and weighed if not used further. 
Ventricular tissue was either frozen at –70°C and later used for the radioligand 
binding protocol, or placed in RNAlater™ and stored at –20°C for RT-PCR. Atrial 
tissues, when dissected free, were either immediately utilised for the functional 
studies (ie the tissue bath studies, microelectrode studies, the oxygen consumption 
experiments), or placed in RNAlater™ and stored at –20°C for subsequent RT-PCR 
experiments. 
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3.4.1 Papillary Muscles 
Attempts were made to use mdx papillary muscles in functional protocols, but their 
higher incidence of contracture or arrhythmias relative to atrial preparations prevented 
their continued use. These difficulties are presumably due to elevated intracellular 
calcium exacerbated by cutting injury occurring during dissection. Calcium chelators 
and butanedione monoxime (BDM) were also trialled in the dissection medium to 
reduce calcium-induced tissue injury, but mdx papillary muscles, which contracted 
initially, became non-functional before experimentation could be completed. In 
contrast, our laboratory found that C57 papillary muscles worked quite reliably and 
consistently, providing further evidence that the inherent calcium overload in mdx 
may be the causative factor. No reports using multicellular isolated mdx ventricular 
preparations have been published thus far. In contrast, several publications have 
reported significant findings using mdx atrial preparations (Lu & Hoey 2000a & b, 
Sapp et al., 1996). 
 
3.5 Tissue Bath Experiments 
Tissue baths (25mL double jacketed) were used for several studies, including the 
concentration-response curves to Bay K 8644 and nifedipine, the force-frequency 
studies, and the experiments utilising rapid cooling contractures. Initially the same 
protocol was used for each of these procedures as follows. A stainless steel hook was 
placed in one end of each atrium to connect the atrium to the tissue holder made from 
a length of stainless steel (right atria) or plastic with electrode leads attached (left 
atria). A silk thread was tied to the other end of the atrium to connect it to a force 
transducer (FT-102, CB Sciences, Milford, MA, USA) to measure force of 
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contraction. Atria were subsequently suspended in warm (35±1°C), carbogenated 
TPSS in tissue baths. Data were recorded via a PowerLab system (AD Instruments) 
using Chart 3.5.6. Left atria were field stimulated by placing the atria between two 
platinum electrodes on the tissue holder (AMPI Master 8 stimulator; 1 Hz, 5 ms 
duration, 20% above threshold) and maintained under optimal preload, the length of 
tissue which produces the maximal contractile force. Tissues were allowed 45 min to 
equilibrate with repetitive washes by draining and refilling the bath; before the advent 
of the relevant test protocol. At the completion of all experiments, the atria were 
removed, blotted and weighed.  
 
3.5.1 Concentration Response Curves for L-type Calcium 
Channel Drugs 
Concentration-response curves were obtained by cumulative addition of the test 
compounds. Concentration-response curves were generated to calcium chloride to 
determine the maximum force of contraction attainable by the tissue. The tissues were 
then washed repetitively over 30 min to return the contractility to normal. 
Subsequently a concentration-response curve to the DHP antagonist nifedipine or 
agonist Bay K 8644 was generated.  Similarly concentration-response curves were 
generated to diltiazem and verapamil. 
 
As DHP drugs are sensitive to light with wavelengths below 450nm, all handling and 
experiments with Bay K 8644 and nifedipine were carried out under protection from 
light. In order to avoid indirect receptor-mediated effects of endogenous noradrenaline 
possibly released by Bay K 8644, tissues were incubated with the β-adrenoceptor 
blocker (±)-propranolol and α-adrenoceptor blocker prazosin for 30 min before the 
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concentration-response curve to Bay K 8644 was generated. After experiments with 
Bay K 8644, the tissue baths were cleaned with nitric acid to eliminate contamination 
of glassware and then flushed repeatedly with distilled water. 
 
3.5.2 Rapid Cooling Contracture Experiments 
3.5.2.1 Preliminary Studies 
Preliminary studies for the rapid cooling protocol evaluated the response of the left 
atria to rapidly exchanging warm TPSS with ice-cold calcium-free TPSS. The 
solution was exchanged by draining the warm TPSS and replacing TPSS at 0°C with a 
syringe. Each rapid change elicited a contracture as expected. Temperature was 
monitored continuously through the preliminary studies to determine the time-course 
of the rapid cooling effect, that the temperature reached 0°C in the tissue bath, and the 
time-course of the return of the TPSS in the tissue bath to 35°C. The preliminary 
studies also evaluated the capability of the myocardium to return to normal force after 
each rapid cooling contracture (RCC) and evaluated the responsiveness of the tissue 
to subsequent exposure to cyclopiazonic acid. 
 
3.5.2.2 Comparison of mdx and C57 left atria 
The left atria were suspended in a 5mL tissue bath maintained at 35±0.5°C and fresh 
TPSS was exchanged every 10 min while the tissue equilibrated. The atria were field 
stimulated (5-10V, 0.5ms duration, 1Hz). RCCs were undertaken by cessation of 
stimulation, rapidly exchanging warm TPSS with ice-cold calcium-free TPSS (as per 
TPSS without calcium). The tissue was then rewarmed to 35˚C over a 3 min period by 
replacing with warm TPSS. After 3 min, this procedure was repeated a second and 
third time with each RCC labelled as RCC1, RCC2 and RCC3 respectively. The 
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tissue was rewarmed after RCC3 and stimulated to contract for a period of 2 min 
during which the twitch force returned to normal. This entire protocol was then 
repeated 2 more times. The RCC1 for the 1st, 2nd and 3rd replicate was averaged, and 
similarly with RCC2 and RCC3 to give an average for each RCC (see Fig. 3.1). After 
completion of the third replicate, the tissue was allowed to equilibrate again until 
force of contraction returned to values measured prior to the RCC protocol. A 
concentration response curve (0.5 - 40mM) to the SERCA-specific inhibitor 
cyclopiazonic acid (CPA) was then undertaken. 
Stim
RCC1 RCC2
RCC3
Rewarm Rewarm
Replicate 1
1m
N * *
*
3 min
 
Figure 3.1: Rapid Cooling Contracture Protocol. Three rapid cooling contractures were elicited 
(RCC1, RCC2 & RCC3) per replicate. Between each RCC the atria was rewarmed over 3min. A 
wash is indicated by *. 
 
3.5.3 Force-Frequency Experiments 
The tissues were maintained under physiological conditions in 25mL water-jacketed 
tissue baths (35±0.5°C) at optimum preload, and allowed 30 min to equilibrate with 
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washes every 10 min. In preliminary control experiments, after the equilibration 
period a force-frequency curve was elicited (5 min at each of 0.05, 0.2, 1, 2 and 5 Hz 
with 1Hz between each change to restore force to control values; see Figure 3.2 for an 
example). This was repeated a second and third time to determine the extent of decay 
of force without the effects of any drug. Having confirmed no difference between the 
first, second and third force-frequency curves, subsequent experiments were 
conducted with the second and third curves being generated in the presence of 
increasing concentrations of the drug of interest (no more than two concentrations per 
tissue). The tissues were removed from the tissue baths, blotted and weighed.  
 
1m
N
5 min
0.05Hz
1Hz 1Hz 1Hz 1Hz 2Hz 1Hz 5Hz
0.2Hz
 
Figure 3.2 A typical force-frequency chart in the absence of drug. Each frequency was tested for 
5min, with the tissue being stimulated at 1Hz in between the test frequencies until force returned 
to basal. 
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3.6 Microelectrode and Contractility Experiments 
Left atria were dissected as described above in section 3.4. Tissues were placed in 
warm, carbogenated TPSS (35±1ºC) in a 1 mL chamber perfused at 3 mL/min, field 
stimulated (Grass SD9 isolated stimulator; 1 Hz, 0.5 ms duration, 20% above 
threshold) and allowed to equilibrate for 45 min. Force of contraction was recorded by 
a modified AE-801 SensoNor element. Tissues were impaled concurrently with a 3 M 
KCl filled microelectrode (resistance 2.5-20 MΩ) to record electrophysiological 
activity using a World Precision Instruments Cyto 721. All data was acquired at 
1000Hz and analysed via a PowerLab system (AD Instruments) using Chart 3.5.6. 
 
The tissues were initially exposed to the IC50 concentration of a calcium channel 
antagonist (as determined in the tissue bath studies) until the equilibrium response 
was attained and then exposed to the concentration of antagonist required to produce 
the maximum effect. The time interval for drug additions for all three calcium 
antagonists tested was 30 min and was sufficient to obtain an equilibrium response. 
As nifedipine and verapamil are sensitive to light, all handling and experiments with 
these agents were carried out under protection from light. 
 
3.7 Radioligand Binding Experiments 
3.7.1 Assay Development 
Since this assay had not been used previously in our laboratory, several preliminary 
experiments were undertaken to optimize the protocol. Initially the incubation 
temperature was tested at 20°C and 35°C. Secondly, the optimal amount of incubation 
time was determined by removing incubation tubes at 0, 5, 15, 30, 60, 90, 120 and 
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150 min. Third, nifedipine was tested for displacement of the [3H]-PN 200-110, and 
the optimal concentration to determine non-specific binding. The saturation 
concentration of [3H]-PN 200-110 was also trialled, with 10nM being the highest 
concentration used in the trials, and 2nM determined to be high enough for saturation. 
Filters were tested for filtration of the membranes after incubation with and without 
pre-wetting. Similarly, the number of washes of the filters was trialled at 2, 5 and 10 
washes. A 50mM Tris, a 50mM HEPES buffer, a 10mM Tris, and a 10mM HEPES 
(all with in mM EGTA 5, EDTA 1, MgCl2 4, Ascorbic Acid 1) buffer were trialled for 
incubation of the homogenate with the radioligand (all made to pH 7.4 with NaOH). 
Various dilutions of membrane protein were also trialled. Finally, fresh tissues and 
frozen ventricles were compared to confirm that receptor affinity and density were not 
significantly altered by freezing and storing the tissues.  
 
3.7.2 Experimental Protocol 
For each experiment two ventricles were pooled to obtain sufficient membrane for 
five points on a saturation curve. Two ventricles were thawed and then homogenized 
at 24 000 rpm by a Heidolph DIAX 600 in modified Tris incubation buffer (in mM 
Tris HCl 50, EGTA 5, EDTA 1, MgCl2 4, Ascorbic Acid 1, Trizma Base 50; pH 7.4 
adjusted with NaOH). The homogenate was centrifuged at 1000g, and pellet 
discarded. The supernatant was centrifuged at 10 000g and the supernatant discarded. 
After resuspension in Tris incubation buffer, the membrane protein content was 
determined by Bradford assay using bovine serum albumin as the standard. The 
membrane was then diluted to 1mg/mL protein. Membrane (200µg) was incubated 
with increasing concentrations of [3H]-PN 200 110 (0.1-2nM) and non-specific 
binding was determined by the addition of 0.1mM nifedipine. Samples were incubated 
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for 60 min at 35°C, and halted with the addition of 4mL ice-cold Tris incubation 
buffer. Samples were vacuum filtered over Whatman GFB filters and washed four 
times with ice-cold Tris wash buffer (in mM Tris 50, pH 7.4). Filters were incubated 
overnight with scintillant and counted the next morning. Prism was used to calculate 
non-linear curve fits and scatchard analyses of the data. Bmax was calculated using 
Prism and is defined as the density of the ligand receptor. Kd was also calculated 
using Prism and is defined as the affinity of the ligand [3H]-PN 200 110 for the 
DHPR. 
 
3.8 Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) Experiments 
3.8.1 Preliminary Experiments 
Preliminary experiments were undertaken with each primer used in the study to 
determine whether the mRNA would be amplified. The assay was run as per the 
protocol below, but the solutions were run through a maximum number of 
amplification cycles to check for primer dimers and successful amplification of the 
bands (size of the band was checked against the ladder to ensure the correct location). 
Once each primer had successfully amplified the mRNA, the procedure was repeated 
until 20 cycles, then the solutions removed every 2 cycles to determine the optimal 
number of cycles. 
 
3.8.2 Experimental Protocol 
Animals were euthanased with an overdose of sodium pentobarbitone and the hearts 
rapidly excised. The ventricles were dissected free in cold TPSS and placed in 
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RNAlater™ (Ambion) RNA stabilisation reagent for storage at -20 °C. RNA 
extraction was performed with the QIAGEN RNeasy® Mini Kit, utilising no more 
than 30 mg of tissue per sample obtained from the apex of the left ventricle. The 
tissue was lysed using a polytron rotor-stator homogeniser in a proprietary buffer 
containing guanidinium thiocyanate to liberate RNA prior to the extraction procedure. 
Lysates were then incubated with QIAGEN Proteinase K (>60 mAU/mL) for 10 min 
at 55 °C to ensure sample disruption was complete. RNA was consequently isolated 
via binding to a silica-gel-based membrane during a number of centrifugation 
procedures as recommended by the manufacturer’s instruction. Total RNA samples 
were then stored at -80 °C in 2 µL aliquots until RT-PCR could be performed. 
 
RT-PCR was performed by the two-tube method using QIAGEN Omniscript™ 
Reverse Transcriptase and QIAGEN HotStarTaq™ DNA Polymerase. Total RNA 
samples were thawed on ice and added to a reverse transcription reaction mixture, 
with a final volume of 20 µL and comprised of: 1x Buffer RT (supplied by QIAGEN); 
0.5 mM dATP; 0.5 mM dCTP; 0.5 mM dGTP; 0.5 mM dTTP; 1 µM oligo dT(15); 10 
units RNAsin® RNAse inhibitor (Promega); and 4 units Omniscript™ Reverse 
Transcriptase. Tubes containing the reaction mixture were incubated in a 
thermocycler (Corbett Research PC-960C) for 60 min at 37 °C to facilitate cDNA 
synthesis, followed by an inactivation step of 5 min at 93 °C and subsequent rapid 
cooling on ice. PCR reaction mixtures were consequently prepared using 2 µL of the 
reverse transcription product as template, with a final volume of 50 µL and comprised 
of: 1x PCR buffer (supplied by QIAGEN); 200 µM dATP; 200 µM dCTP; 200 µM 
dGTP; 200 µM dTTP; 0.2 µM each DHPR primer (TCC AGT TTA TAC TAC TTT 
GGC TGG T sense; ACT GAG GGC TCA TGT TTT GG antisense), SERCA 
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primer (GGT GCT GAA AAT CTC CTT GC sense; CTT TTC CCC AAC CTC AGT 
CA antisense), GAPDH primer (TTA GCA CCC CTG GCC AAG G sense; CTT 
ACT CCT TGG AGG CCA TG antisense) or β-Actin (AGC CAT GTA CGT AGC 
CAT CC sense; TCT CAG CTG TGG TGG TGA AG antisense); and 2.5 units 
HotStarTaq™ DNA Polymerase. All reactions were performed with 1.5 mM MgCl2 
contained in the 1x PCR buffer. Using the thermocycler, tubes were incubated 
initially for 15 min at 95°C to activate the HotStarTaqTM DNA Polymerase. Reaction 
tubes initially underwent 40 cycles to determine effectiveness of the primer. 
Subsequently, new reaction tubes underwent a number of cycles of amplification 
(empirically determined to be within the linear range of amplification), consisting of 
15 s at 94 °C, 30 s at 55 °C and 60 s at 72 °C. A final program of 10 min at 72 °C was 
conducted to ensure all amplified product was fully extended. PCR product was 
visualised following gel electrophoresis by ethidium bromide staining and UV 
transillumination in an AlphaImager 2200 MultiImage cabinet. Spot densitometry was 
performed using the supplied software and the ratio of SERCA or DHPR band 
intensity to GAPDH band intensity for each sample calculated to allow a semi-
quantitative comparison. The ubiquitous β-actin was also used as a housekeeper gene. 
 
3.8.3 Primer Design 
Where possible, primers were obtained from previously published articles. The 
primers were then tested using BLAST on the pubmed website. If primers were not 
obtained from published articles, the RNA gene sequence was identified using Entrez 
Nucleotide (http://www.ncbi.nlm.nih.gov:80/entrez/query.fcgi?db=Nucleotide), and 
run through a primer design program. The designed primers were tested for binding 
accuracy using BLAST (http://www.ncbi.nlm.nih.gov:80/BLAST/). Primers were 
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ordered from Invitrogen Life Technologies (Musgrave, Victoria, Australia), were 
desalted purity and had a 55% GC content. 
 
3.9 Data Analysis 
Raw data was first compiled in Microsoft Excel 97, collated and any mathematical 
transformations applied to the data. Final results were expressed as mean ± SEM. 
Means and SEM were transferred to a data plotting program (Sigma Plot or Prism) 
used for graphical purposes or further analyses. Either a two-tailed, unpaired 
Student’s t-test was used for statistical comparisons, or a two-way ANOVA where 
indicated. A P level of <0.05 was considered to be statistically significant. For 
contractile and action potential data, a single stimuli was used from each dosage or 
time point to obtain this data. An EC50 or IC50 was calculated as the concentration that 
produces 50 % of the maximal response (EC for a positive inotropic response, IC for a 
negative inotropic response). A pD2 was calculated as the negative log of the EC50 or 
IC50. The strain potency used to compare potencies and affinities of drugs in both 
strains was calculated by dividing the EC50, IC50, Kd, Bmax or pixel intensity/unit 
area for mdx mice by the corresponding C57 value. 
 
3.10 Drugs and Chemicals 
All laboratory chemicals were purchased from Sigma Chemical Company, St. Louis, 
MO, USA except where otherwise indicated. Bay K 8644 (Bayer, Leverkusen) was 
dissolved in 100% ethanol at a stock concentration of 10-2 M and diluted once further 
in 50% ethanol and subsequently in milliQ water. Nifedipine was dissolved in 100% 
DMSO at a stock concentration of 10-2 M, and diluted once further in 50% DMSO 
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and subsequently in milliQ water. (±)−Verapamil hydrochloride and diltiazem 
hydrochloride were dissolved in milliQ water. Hot [3H] PN 200-110 (Amersham 
Pharmacia Biotech, Buckingham Shire, England) had an activity of 71 Ci/mMol 
which was taken into account when expressing counts per minute as fmol/mg. 
Cyclopiazonic Acid was dissolved in DMSO as a 10mM solution, and further 
dilutions made in milliQ water. Ryanodine was dissolved in ethanol as a 1µM stock 
and further dilutions made in milliQ water; Caffeine was dissolved 0.1M HCl as a 
0.5M solution and further dilutions made in milliQ water; Dantrolene was dissolved in 
milliQ water in a stock concentration of 1µM and further dilutions made with milliQ 
water from this stock. All RT-PCR reagents were purchased from Qiagen.  
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CHAPTER 4 – RESULTS 
4.1 Morphometry 
Whole mouse mass was significantly higher in C57, which is not surprising given the 
nature of the myopathy in mdx. Left atrial mass was not significantly different 
between the strains, but ventricular mass was heavier in C57 (P<0.001). Masses of 
tissues were still significantly higher when normalised for body mass.  Ventricular 
tissues were used only for radioligand or molecular biology experiments. In the 
radioligand experiments, the amount of protein was standardised, so consideration of 
the difference in weight was not necessary. Similarly, for RT-PCR experiments 
mRNA was normalised to a housekeeper gene. The number of mdx used in the current 
study is much higher than C57, because mdx tissues were routinely used for assay 
development since the mdx were more readily available. Table 4.1 shows numbers of 
each species of mass and associated body and heart masses. 
 
Table 4.1 Number and masses of mice used throughout the dissertation 
 n Whole mouse 
mass (g) 
Left atrial 
mass (mg) 
Ventricle 
mass (g) 
mdx 215 25.0±0.3 18.5±0.9 0.135±0.002 
C57 138 26.1±0.3* 19.1±0.8 0.157±0.003** 
*P<0.01; **P<0.001 mdx compared to C57 
 
4.2 Calcium Influx Mechanisms 
In this section the mechanisms of calcium influx into the myocardium in mdx were 
examined through a series of microelectrode and contractility experiments. These 
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experiments examined the action potentials in mdx and C57 and contractile responses 
to the L-type calcium channel drugs that act at the dihydropyridine, phenylalkylamine 
and benzothiazepine receptors. A series of radioligand experiments were undertaken 
to determine the affinity of a radiolabelled DHPR antagonist for its receptor and the 
number of DHPRs present. Finally RT-PCR experiments were utilised to determine 
DHPR mRNA expression. 
 
4.2.1 Calcium Channel Agonist and Antagonist Concentration-
Response Curves 
4.2.1.1 Basal Measurements 
Figure 4.1 shows an indicative recording of a single contraction in the absence of any 
drug. In mdx left atria, the basal force of contraction was lower in mdx 
(1.50±0.17mN) compared to C57 (1.91±0.18mN; P<0.05) with a subsequent 
concentration-response curve to calcium chloride revealing a reduced efficacy (mdx 
3.44±0.21 mN, C57 4.11±0.3 mN; P<0.005 Fig 4.2A) and potency (pD2 values mdx 
3.40±0.08, C57 3.15±0.10; P<0.05). A longer relaxation time (Time to 90% 
relaxation; TR90) was also evident in left atria from mdx mice (mdx 45.3±1.6ms 
(n=24); C57 39.0±1.7ms (n=24): Table 4.2 P<0.01), with no difference in time to 
peak force and dF/dt observed between mdx and C57 mice at basal forces.  
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Figure 4.1 An indicative contraction from a C57 mouse. Mdx contractions had the same shape 
and approximate timecourse. 
 
4.2.1.2 Response to the Calcium Channel Antagonists 
All calcium channel antagonists reduced the force of contraction in left atria as 
expected. Nifedipine reduced the force of contraction similarly in left atria from both 
mdx and C57 but the potency was significantly reduced in left atria from mdx (pD2 
values: mdx 7.46±0.07; C57 7.75±0.10, P<0.05 Fig. 4.2). As expected the reduction in 
force was associated with a significant reduction in dF/dt upon exposure to the 
maximum concentration of nifedipine (mdx Basal 11.45±1.68 mN/s; max. effect 
3.83±0.72 mN/s, P<0.01: C57 Basal 8.74±1.35 mN/s; max. effect 3.24±0.67 mN/s, 
P<0.05) without affecting the time to peak force. Nifedipine caused a further delay in 
relaxation in mdx only (Table 4.2). A strain potency ratio was calculated by dividing 
the potency of mdx by the potency for C57. The strain potency ratio for nifedipine 
was 1.9. 
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Figure 4.2 The effects of nifedipine on left atria, and the effects of extracellular calcium. A 
Response to extracellular calcium (n=24). B Effect of nifedipine on left atria contractile force. 
Basal force of contraction for mdx 1.50±0.17mN (n=10); for C57 1.91±0.18mN (n=8) measured 
prior to the CRC to nifedipine.  
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Figure 4.3 The effects of verapamil on left atria, and the effects of extracellular calcium. A 
Response to extracellular calcium (n=24). B Effect of verapamil on left atria contractile force. 
Basal force of contraction for mdx 1.84±0.07mN (n=10); for C57 1.76±0.09mN (n=8) measured 
prior to the CRC to verapamil.  
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Figure 4.4 The effects of diltiazem on left atria, and the effects of extracellular calcium. A 
Response to extracellular calcium (n=24). B Effect of diltiazem on left atria contractile force. 
Basal force of contraction for mdx 1.37±0.09mN (n=5); for C57 1.49±0.12mN (n=8) measured 
prior to the CRC to diltiazem.  
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In contrast, there was an increase in sensitivity for verapamil in left atria from mdx 
compared to C57 (pD2 mdx 7.50±0.10, pD2 C57 7.03±0.08; P<0.05), with no 
difference in efficacy (Fig. 4.3). This increase in potency is due to a significant 
difference at only one concentration in the concentration-response curve that occurred 
at 50% of the maximum effect. The reduction in force was associated with a reduction 
in dF/dt upon exposure to the maximum concentration of verapamil, without any 
affect on relaxation time. In comparison, no difference in potency was observed for 
diltiazem in left atria between mdx and C57 (pD2 mdx 7.11±0.35, pD2 C57 
6.71±0.20), although a lower efficacy was evident (Figure 4.4). Diltiazem produced a 
significant reduction in force that was associated with a reduction in dF/dt upon 
exposure to the maximum concentration, and a significant prolongation of relaxation 
time (Table 4.2). 
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Figure 4.5 Response to Bay K 8644 in isolated mdx (c) and C57 (z) left atria. Concentration-
response curve to Bay K 8644 in left atria (n=8) as a change in force of contraction. pD2 for mdx 
6.10±0.03, pD2 for C57 6.53±0.05 (P<0.05). See text for basal forces.  
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Table 4.2 Effect of L-type calcium channel antagonists on Time to 90% Relaxation (TR90 in ms) 
in the tissue bath studies. 
 C57 mdx 
 Basal Antagonist Basal Antagonist 
Nifedipine 39.8±2.1 44.9±1.7 41.9±1.7 49.9±3.8* 
Diltiazem 38.6±1.8a 49.2±4.1* 46.8±1.3 55.8±2.1* 
Verapamil 38.7±1.2b 41.8±2.5 47.2±1.8 47.6±1.8 
* P<0.05 antagonist vs. basal within strain, a P<0.05 mdx vs. C57 basal, b P<0.01 mdx vs. C57 
basal; n=6-8. Antagonists values are shown at their maximally effective concentrations, with 
respect to inhibition of force of contraction. 
 
4.2.1.3 Response to Bay K 8644 
Bay K 8644 elicited a strong positive inotropic effect in both strains producing a 
similar efficacy to calcium. Although the efficacy (as a percent of calcium chloride) 
was not different between the two strains, a reduced potency (pD2 values mdx 
6.10±0.03; C57 6.53±0.05, P<0.05 Fig 4.5) was again evident in mdx. The strain 
potency ratio for Bay K 8644 was 2.7, which is similar to the ratio obtained for 
nifedipine. Importantly, a similar potency difference was evident if the positive 
inotropic response was not normalised as a percentage of calcium chloride. The TR90, 
time to peak force & dF/dt at the maximum concentration of Bay K 8644 were not 
significantly different (Table 4.3) between the strains. At the maximum concentration 
of Bay K 8644, mdx time to peak force was significantly longer (P<0.05). Time to 
peak force in C57 left atria was unaffected by the maximum concentration of Bay K 
8644. Relaxation time in the presence of the highest concentration of Bay K 8644 was 
not significantly different to relaxation time in the absence of drug in either strain, 
despite a trend towards this parameter being longer in mdx with Bay K 8644 present. 
The solvent ethanol elicited a weak negative inotropic effect at the maximum solvent 
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concentration, but this was overcome completely by the pronounced positive inotropic 
effect of Bay K 8644. 
 
4.2.2 Microelectrode and Contractility Experiments 
4.2.2.1 Basal Measurements 
There was no significant difference in basal force of contraction in left atria between 
mdx and C57 mice in the microelectrode and contractility series of experiments. 
While no difference was evident in time to peak force and dF/dt (data not shown), a 
longer relaxation time (measured as time to 90% relaxation) was evident in left atria 
from mdx mice (C57 39.0±1.7ms (n=24); mdx 45.3±1.6ms (n=24): P<0.01). 
 
Table 4.3 Contractile parameters in response to Bay K 8644 1x10-4.5M. 
 TR90 (ms) TTPF (ms) 
 Basal Max Basal Max 
mdx 28.8±0.7 31.4±1.6 30.4±0.6 32.9±0.8a 
C57 28.3±1.0 28.1±0.9 30.5±1.1 31.4±1.4 
No parameters were significantly different between the strains (n=8 for both mdx and C57). 
aTTPF (Time to peak force) was significantly prolonged by the maximum concentration of Bay K 
8644 in mdx only. 
 
Prior to the administration of drugs, there was no difference between mdx and C57 in 
the amplitude of the action potentials or the resting membrane potential (Table 4.4). 
The action potential duration (APD) at 20% (APD20) and 50% (APD50) repolarisation 
were not significantly different between mdx and C57 left atria, although at 90% 
(APD90) repolarisation action potentials were shorter in the mdx left atria in the 
diltiazem group only (P<0.05). 
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4.2.2.2 Response to the Calcium Channel Antagonists 
All calcium channel antagonists reduced force of contraction in a concentration and 
time-dependent manner (Fig 4.6, 4.7, 4.8) as expected. This was associated with a 
significant reduction in dF/dt upon exposure to the maximum concentration of drug 
tested (Table 4.2). 
 
The reduction in force of contraction was statistically significant (P<0.01) for the 
concentration of antagonist required to produce the maximum negative inotropic 
effect for all three antagonists. None of the antagonists, at either the equipotent IC50 
or concentration for maximum response, produced significantly different negative 
inotropic responses between mdx and C57 left atria when expressed as a percentage 
reduction in force of contraction. Diltiazem delayed relaxation in mdx and C57 mice, 
evident by an increased TR90 (P<0.05), whereas nifedipine delayed relaxation in mdx 
only (P<0.05) (Table 4.2). None of the antagonists affected time to peak force (Table 
4.5) in either mdx or C57 mice at any concentration. 
 
Nifedipine decreased APD20 in C57 but not mdx (P<0.05), however APD50 and APD90 
remained unaltered in mdx and C57 (Fig. 4.6). The reduction in APD20 was only 1 ms 
and so can not be clearly observed in Fig. 4.6 due to the current line thickness. The 
reproducibility of the data resulted in such a small difference reaching statistical 
significance. Verapamil did not significantly alter APD20, APD50 or APD90 in either 
mdx or C57 (Fig. 4.7), whereas diltiazem prolonged the APD at 20, 50 and 90% of 
repolarisation in both strains (P<0.05), with no difference evident between the strains 
(Fig. 4.8). 
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Figure 4.6 The effects of nifedipine on left atrial force of contraction and action potential 
duration. AB Reduction of force as percent of basal (n=6-8). CD Action potential duration at 20, 
50 and 90% repolarisation. EF Original recording of a representative action potential during 
control period and 20 min after initial exposure to the concentration for maximum effect (*). 
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Figure 4.7 The effects of verapamil on left atrial force of contraction and action potential 
duration. AB Reduction of force as percent of basal (n=6-8). CD Action potential duration at 20, 
50 and 90% repolarisation. EF Original recording of a representative action potential during 
control period and 20 min after initial exposure to the concentration for maximum effect (*). 
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Figure 4.8 The effects of diltiazem on left atrial force of contraction and action potential 
duration. AB Reduction of force as percent of basal (n=6-8). CD Action potential duration at 20, 
50 and 90% repolarisation. EF Original recording of a representative action potential during 
control period and 20 min after initial exposure to the concentration for maximum effect (*). 
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Table 4.4 Basal electrophysiological parameters 
 RMP (mV) APA (mV) Force (mN) dF/dt (mN/ms) TTPF (ms) 
mdx -73.7±0.5 91.8±0.9 0.9±0.1 8.7±0.7 40.9±0.3 
C57 -74.9±0.5 93.3±1.1 1.1±0.1 9.0±0.6 38.9±0.3 
 
 
 
Table 4.5 Comparison of Ca2+ channel antagonist effects on contraction time course parameters 
in mdx and C57 left atria 
 dF/dt (mN/ms) TTPF (ms) 
 Mdx C57 Mdx C57
NFD IC50 8.04±1.21 7.00±1.65 38.00±1.68 38.00±1.93
NFD Max 3.83±0.72** 3.24±0.67* 38.43±1.57 36.29±1.02
DTZ IC50 10.57±2.19 9.44±2.59 43.00±1.45 42.83±3.14
DTZ Max 4.09±0.96** 4.80±1.13* 42.67±1.26 39.67±1.58
VRL IC50 6.29±1.22* 11.93±2.18 40.17±1.46 40.14±1.32
VRL Max 4.93±0.42** 7.91±1.19* 37.00±0.69* 40.57±1.85
Control mean 11.49±1.36 11.74±1.51 40.19±0.69 38.79±1.00
n=6-8 *P<0.05, **P<0.01 basal vs. Maximum effect 
 
 
4.2.3 Radioligand Binding Experiments 
4.2.3.1 Assay Development 
Since the radioligand assay had not been previously undertaken in our laboratory, a 
series of preliminary experiments were undertaken to optimise the assay. Incubation 
time was the first parameter evaluated. Tissues were incubated with a constant 
amount of radioligand (2nM [3H]-PN 200 110 ± nifedipine for non-specific binding), 
and tubes removed at selected time intervals and counted (Fig 4.9). An incubation 
period of 60 min was determined to be sufficient as equilibrium was evident at 30 min 
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and remained relatively stable up to 150 min. Nifedipine was evaluated 
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Figure 4.9 Determination of incubation time (2 separate counts from n=2). A constant 
concentration of [3H]-PN 200 110 (2nM) was used for each of the time periods. An incubation 
time of 60min was determined to be sufficient to obtain a clear equilibrium response. 
 
NFD 1mM NFD 0.1mM NFD 10µM
0
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1500
Figure 4.10 Determination of antagonist concentration for non-specific binding. Specific Binding 
in response to decreasing concentrations of nifedipine used to displace [3H]-PN 200 110 (2 
separate counts from n=2). 
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for displacement of the radioligand for non-specific binding (Fig 4.10) by two 
experiments using three different concentrations of nifedipine to displace the [3H]-PN 
200 110. A final concentration of 0.1mM nifedipine was determined to be the optimal 
concentration to displace the non-specifically bound radioligand. The temperature of 
incubation was evaluated. Room temperature (25°C) was compared to approximate 
physiological temperature (35°C) for an incubation period of 1hr (Fig 4.11). The 
specific binding was much higher at 35°C, so this temperature was used for further 
studies. Overnight incubation with scintillant was also considered, the trial revealing 
that overnight incubation greatly improved penetration of the scintillant into the filter, 
and higher counts of the radioligand. The amount of final membrane protein used in 
the incubation was also trialled, with 1mg/mL determined to be optimal protein for 
the final protocol. 
0.0 0.5 1.0 1.5 2.0 2.5
-250
0
250
500
750
1000
[[3H]-PN 200 110] (nM)
Figure 4.11 Determination of incubation temperature. Specific Binding at 25°C (ν) compared to 
35°C (σ) n=4. Specific binding was much greater at 35°C with higher concentrations of PN200-
110, so this temperature was used for incubation. 
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4.2.3.2 Comparison of mdx and C57 Ventricular Homogenates 
Radioligand binding experiments revealed a significantly greater number of DHPRs 
in mdx (Bmax 99.2±7.0 fmol/mg) compared to C57 (Bmax 74.5±9.4 fmol/mg; Fig. 4.12, 
P<0.05) with a strain ratio (Bmax mdx /Bmax C57) of 1.3. The affinity of [3H]-PN 200 
110 was also significantly reduced in mdx (Kd 0.3897±0.07nM) compared to C57 (Kd 
0.2572±0.09nM) (Fig. 4.12, P<0.05). The strain potency ratio (Kd mdx /Kd C57) was 
2.0, a similar ratio to that observed in the functional tissue bath studies utilising 
nifedipine and Bay K 8644 (Table 4.6). 
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Figure 4.12 Saturation binding curve showing the mean of all experiments from mdx and C57 
ventricular homogenates in response to increasing concentrations of [3H]-PN 200 110 (0.1-2nM). 
Non-specific binding was determined by the addition of 0.1M nifedipine. Inset: Scatchard 
analysis of the saturation curve revealed a Bmax of 107.4±6.5 fmol/mg and a Kd of 0.3897±0.07 
nM (n = 15 experiments; 30 ventricles) for mdx and a Bmax of 78.6±10.6 fmol/mg and a Kd of 
0.2572±0.09 nM (n = 19 experiments; 38 ventricles) for C57. There is a significant difference 
between mdx and C57 in both Bmax (P<0.05) and Kd (P<0.05). 
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Figure 4.13 Kd and Bmax from the scatchard plots in Figure 4.11. Both Kd and Bmax were 
significantly different between mdx and C57. 
 
4.2.4 RT-PCR 
4.2.4.1 Comparison of mdx and C57 Dihydropyridine mRNA 
Ventricular DHPR mRNA was significantly higher (P<0.005) in mdx compared to 
C57 (Fig. 4.14) when corrected for the amount of total mRNA by using the GAPDH 
samples. The original gel photos are presented in figures 4.15 and 4.16. The strain 
ratio for ventricular mRNA was 2.3 (Table 4.6). The left atrial DHPR mRNA was 
also higher in mdx compared to C57, although this did not quite reach statistical 
significance (P=0.07). The strain ratio for atrial mRNA for DHPRs was 2.0. The 
ubiquitous β-Actin was also used as a housekeeper gene and produced qualitatively 
similar data. The mRNA for DHPR was not statistically different between mdx atria 
and ventricles nor C57 atria and ventricles. 
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Figure 4.14 RT-PCR results from mdx (open; n=4) and C57 (filled; n=4) dihydropyridine 
receptor mRNA from ventricles and left atria. Band intensity was normalised to the amount of 
mRNA present by comparing each DHPR sample to its corresponding GAPDH sample. 
Ventricular mRNA was significantly higher in mdx (P<0.05) compared to C57. Analysis by two-
way ANOVA revealed the mdx data set to be significantly different (P<0.05) to the C57 data set. 
 
 
Figure 4.15 Max and linear range gel electrophoresis photos inverted so that mRNA bands are 
black. A Primers after 40 cycles to test binding to RNA. Primers shown are ladder, GAPDH and 
SERCA. B Linear range gel for DHPR. A linear range was undertaken with a combination of 
mdx and C57 samples mixed, so that a number of cycles could be determined where differences 
in expression could be detected. 
B A 
 94
 
Figure 4.16 DHPR gel electrophoresis with colours inverted so bands are black. A DHPR mRNA 
in ventricles. B DHPR mRNA from mdx and C57 atria.  
 
Table 4.6 Strain Potency Ratios for L-type calcium channel data 
 Tissue  Mdx/C57 
Potency Atrial NFD EC50 1.9 
 Atrial Bay K 8644 EC50 2.7 
 Ventricular RLB Kd 1.5 
Density Ventricular RLB Bmax 1.3 
 Atria DHPR RT-PCR  2.0 
 Ventricular DHPR RT-PCR  2.3 
The strain potency ratio was calculated by dividing the mdx EC50, Kd, Bmax or total mRNA by 
the C57 EC50, Kd, Bmax or total mRNA respectively. The strain ratio shows that each of the 
indicators of DHPR regulation is increased in mdx. 
 
 4.3 SR Calcium Release 
To determine the role of the SR and active sequestration and extrusion mechanisms in 
dystrophin-deficient myocardium, rapid cooling contractures were undertaken. The 
rapid cooling contracture experiments evaluated SR function, SERCA function and 
NCX extrusion from dystrophin-deficient atria and compared that to control atria. A 
concentration-response curve was also undertaken to cyclopiazonic acid, a compound 
that blocks the activity of SERCA. A series of force-frequency experiments examined 
the function of the RyR and the SR in mdx compared to C57. 
A B 
C57 mdx 
C57 mdx 
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Figure 4.17 Rapid Cooling Contractures from left atria of mdx and C57. A Rapid cooling 
contractures as a percentage of normal twitch force. The calcium content of the SR was released 
by rapidly exchanging warm TPPS with ice-cold calcium free TPPS. The C57 (z; n=10) data set 
was significantly different to mdx (c; n=9: P<0.05) using two-way ANOVA. The RCC data set 
was highly significant (P<0.0001) using two-way ANOVA. B RCC2 and RCC3 are presented as a 
percentage of the RCC1, thus providing a. measure of SERCA function. RCC3 is non-
significantly higher in mdx (n=10), compared to C57 (n=9; P=0.06).  
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4.3.1 Rapid Cooling Contractures 
4.3.1.1 Basal Measurements 
All basal measurements were recorded at the commencement of the experiment, 
before the rapid cooling contractures and in the absence of any drug. Basal 
contractility was lower in mdx (1.33±0.08mN) relative to C57 (1.56±0.16mN; 
P=0.05). Basal time to 90% relaxation (TR90) was not significantly different between 
mdx (44.8±3.0ms) and C57 (41.5±3.0ms), although a higher mean TR90 was observed 
in mdx.  
 
0.05 0.20 1.00 2.00 5.00
0
1
2
3
mdx no drug
C57 no drug
*** ***
Frequency (Hz)
** **
**
 
Figure 4.18 Basal contractility of mdx and C57 left atria at increasing frequencies (data pooled 
from control experiments and is shown in Fig 4.19, 4.20, 4.21). Contractility was measured at 
0.05, 0.2, 1, 2 and 5 Hz. Mdx (n=21) consistently showed a significant reduction in force 
production compared to C57 (n=31) left atria. ***=P<0.001, **=P<0.01. 
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4.3.1.2 Rapid Cooling Contractures 
The first rapid cooling contracture (RCC) was significantly smaller in mdx 
(1.53±0.26mN) compared to C57 (2.21±0.24mN: P<0.01) as shown in Figure 4.17 as 
a percentage of basal twitch force. The second RCC was not significantly different 
between the strains (Figure 4.17), but the third RCC when taken as a percentage of the 
first (therefore a measure of SERCA function) was larger in mdx. 
 
4.3.2 Force-Frequency Relationships 
At all frequencies tested, in the absence of any drug, the mdx left atria produced 
significantly less force than the C57 left atria (P<0.01; Fig. 4.18). However, addition 
of increasing concentrations of ryanodine progressively eliminated any difference in 
force between the mdx and C57s over all of the frequencies tested. With the blockade 
of sarcoplasmic reticulum calcium release by the addition of 1nM ryanodine, a 
positive staircase developed, with no difference in force production between strains 
(Fig. 4.19), in spite of a normally lowered efficacy and potency to calcium in mdx 
(see Fig. 4.2). The forces produced in the presence of ryanodine are quite low, 
indicating that the drug is successfully blocking SR release, as expected. The force 
frequency curve in the presence of dantrolene (Fig. 4.20) always maintained a 
negative staircase. The significantly lower force of contraction by the mdx 
myocardium in the absence of dantrolene, was maintained with the addition of 
dantrolene 0.1, 1 and 10µM at 0.05 and 0.20Hz. However, at the higher frequencies 
(1, 2 and 5Hz) this significant difference was lost. 
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Figure 4.19 Force-
frequency relationship in 
the presence of 
ryanodine. A force-
frequency relationship in 
the absence of any drug 
mdx n=21, C57 n=31. 
***=P<0.001; **=P<0.01. 
B Force-frequency in the 
presence of 0.1nM 
ryanodine. The mdx data 
set is significantly 
different to the C57 data 
set (P<0.005) using two-
way ANOVA. C Force-
frequency in the 
presence of 0.5nM 
ryanodine. D Force-
frequency in the 
presence of 1nM 
ryanodine.  
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 Figure 4.20 Force-frequency 
relationship in the presence of 
dantrolene. A is in the absence of 
any drug. In the presence of 
dantrolene 0.1 (B), 1 (C) and 10µM 
(D), both 0.05 and 0.2Hz were 
significantly different between mdx 
(n=8) and C57 (n=8). *P<0.05, 
**P<0.005, ***P<0.001. 
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 Figure 4.21 Force-frequency relationship in the presence of caffeine. The only significant difference between mdx (n=6) and C57 (n=8) in the presence of caffeine 
was at 5Hz with 3mM caffeine present. A negative staircase was observed at all concentrations of caffeine applied, although the staircase began to plateau at 10mM 
caffeine. B In the presence of 0.3mM caffeine the mdx data set is significantly different to the C57 data set using two-way ANOVA (P<0.005). C In the presence of 
1mM caffeine the mdx data set is significantly different to the C57 data set using two-way ANOVA (P<0.005). D In the presence of 3mM caffeine the mdx data set is 
significantly different to the C57 data set using two-way ANOVA (P<0.0001). E In the presence of 10mM caffeine the mdx data set was significantly different to the 
C57 data set using two-way ANOVA (P<0.0005). 
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Force of contraction was reduced in the presence of higher concentrations of caffeine 
(Fig. 4.21), indicating that caffeine was blocking SR release and/or uptake. The 
negative staircase property of the left atria was maintained with all the concentrations 
of caffeine, although at 10mM caffeine, the force was not significantly different at 
0.05Hz compared to 5Hz in either strain. Interestingly, there was a trend for the mdx 
to produce higher force than the C57 with caffeine present. This became significant at 
5Hz with 3mM caffeine present. 
 
4.4 Calcium Sequestration and/or Reuptake 
4.4.1 Cyclopiazonic Acid  
The efficacy of CPA was not significantly different between the strains (Fig. 4.22A) 
while the mdx showed a non-significant decrease in potency (EC50s: mdx 
12.3±3.1mM, C57 6.8±2.0mM; P=0.08). CPA significantly lengthened relaxation 
time in both mdx and C57, as was expected due to its inhibition of SERCA. Time to 
90% relaxation (TR90) was significantly greater in mdx (45.5±0.3ms) compared to 
C57 (38.5±0.3ms) at the lowest concentrations of CPA tested (P<0.05), but this effect 
disappeared at higher concentrations as inhibition of SERCA prolonged relaxation in 
both mdx and C57 (Fig. 4.22B). 
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Figure 4.22 Left atrial force of contraction and time to 90% relaxation in response to 
cyclopiazonic acid. A Mdx (c, n=10) response was reduced compared to C57 (z, n=9), although 
the difference was not significant. Potency and efficacy were not significantly different between 
the two strains, although CPA tended towards a lower potency in mdx. B Time to 90% relaxation 
in response to CPA. Due to an inhibition of SERCA, relaxation time was prolonged and this was 
particularly evident in mdx (c, n=10) at 0.3, 1 and 5 mM CPA compared to C57 (z, n=9) 
(P<0.05). The mdx data set are significantly different to the C57 data set using two-way ANOVA 
(P<0.0005). 
 
 103
4.4.2 SERCA RT-PCR 
RT-PCR experiments from ventricle revealed a significantly higher expression of 
SERCA mRNA in dystrophic tissue (mdx 2.47±0.3 intensity/pixel unit area; n=5; C57 
1.15±0.05 intensity/pixel unit area; n=5: P<0.05 see Figure 4.23). The original gel 
photos are shown in Figure 4.24. 
*
mdx C57
0
1
2
3
 
Figure 4.23 SERCA mRNA expression as pixel intensity per unit area. The intensities were 
normalised to GAPDH protein levels for each sample. The intensities were also normalised to be 
per pixel, so that variations in band size were taken into account. The mRNA for SERCA in mdx 
(n=5) is upregulated compared to control mice (n=5) P<0.05. 
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Figure 4.24 SERCA gel electrophoresis of mRNA with colours inverted so that bands are black. 
A GAPDH expression. B SERCA mRNA expression.  
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CHAPTER 5 – DISCUSSION 
5.1 Functional differences between mdx and C57 
cardiac tissues 
At the completion of the equilibration period for each experiment basal measurements 
were taken to compare drug responses to those in the absence of drug. This allowed 
basal measurements of the myopathy of mdx at 12-14 weeks of age to be assessed. In 
the tissue bath experiments a calcium concentration-response curve was undertaken 
immediately after the equilibration period, so that the maximum force production for 
each atrium could be determined. These experiments revealed that the initial basal 
force of contraction and the potency of and efficacy to calcium were reduced in left 
atria of mdx mice, in spite of an elevation of intracellular calcium (Dunn & Radda, 
1991). This reduction in myocardial contractile force has been shown previously in 
our laboratory (Lu & Hoey 2000a) and in others (Sapp et al., 1996). A possible 
mechanism for the reduction in potency and capacity to generate force in response to 
extracellular calcium represents a reduction in myofilament sensitivity to calcium. 
Such weakness may be a protective mechanism against the weaker sarcolemmal 
membrane (Kanai et al., 2001), since dystrophin has now been shown to play a 
mechanical stabilization role in cardiomyocytes (Hainsey et al., 2003) similar to its 
established role in skeletal muscle. Chronically elevated calcium, to a similar level as 
that observed in dystrophic cardiomyocytes, can cause a significant reduction in 
myofilament sensitivity (Holt & Christensen, 1997), although this has not yet been 
shown for dystrophin-deficient cardiomyocytes. 
 
Chapter 5 - Discussion 
  106
Action potentials of mdx are reported as being shorter in mdx mice (Pacioretty et al., 
1992; Perloff et al., 1984), however the current study was unable to verify this 
phenomena. Differences in experimental methodologies such as the horizontal 
placement of the atria in the microelectrode apparatus may contribute to this finding.  
The resting membrane potential, action potential amplitude and maximum upstroke 
velocity were unaffected by a lack of dystrophin. A shorter action potential indicates 
that either the calcium channels are unlikely to remain open for a longer period of 
time, or that repolarisation is markedly increased. The shorter cardiac action potential 
has been attributed to activation of a large transient outward potassium current 
(Alloatti et al., 1995). The mechanisms underlying such a large transient outward 
current are unclear, although an increase in resting intracellular calcium may cause a 
larger transient K+ current, which in turn may promote premature repolarisation of the 
action potential, leading to earlier inactivation of the voltage dependent L-type 
calcium channel (Sperelakis et al., 1996).  
 
A delayed relaxation of the mdx left atria has been observed in the current study and 
previously (Sapp et al., 1996). This prolonged relaxation may be due to an increase in 
intracellular calcium due to dysfunctional sequestration, or extrusion of calcium from 
the cytosol. However, delayed relaxation time and the longer action potential duration 
that are usually seen but not observed in mdx may be linked, as K+ channels may play 
a role in both of these observations (Cingolani et al., 1990).  
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5.2 Contractility and Microelectrode Studies 
The tissue bath studies examined the left atria of mdx and C57, their force of 
contraction, and their responses to drugs that alter L-type calcium channel function. 
The tissue bath protocols were well established in our laboratory, and data generated 
by these protocols had been published previously (Lu and Hoey, 2000a and b) 
indicating the reliability and suitability of these methods. 
 
In the microelectrode studies the contractility of mdx and C57 left atria, along with the 
action potential characteristics were measured concurrently. Three different classes of 
calcium channel antagonists and one class of agonist were tested to determine their 
effect on the cardiac action potential in the mdx model of dystrophin-deficiency. 
 
5.2.1 Concentration-Response Curve to Bay K 8644 
Bay K 8644 exerts positive inotropic actions by binding to the cardiac DHPR of the 
L-type calcium channel to enhance sarcolemmal calcium influx that in turn triggers 
greater CICR (Schramm et al., 1983). In the current study a marked positive inotropic 
effect was observed in response to Bay K 8644 in both mdx and C57, indicating that 
the drug was effective in depolarising the L-type calcium channel. Bay K 8644 
produced a similar efficacy to extracellular calcium in both mdx and C57, showing 
that it is an efficient positive inotrope.  
 
Although the efficacy as a percentage of calcium chloride was not different between 
mdx and C57, the left atria from mdx were less sensitive to Bay K 8644 compared to 
C57. There was also a significantly lower potency observed in mdx. This was the first 
indication that there may have been a conformational change in the DHPR that 
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affected its affinity for DHPR drugs. The strain potency ratio was 2.7, indicating a 
change in affinity of the drug for the receptor. This potency shift was also observed 
when the positive inotropic response was not normalised as a percent of calcium (ie 
absolute force), indicating that this potency change was due to modification of the 
DHPR, and not the lowered force production in mdx. Time to peak force was 
significantly longer in mdx in the presence of Bay K 8644 than the time to peak force 
without the drug present. This is merely a reflection of the larger force production in 
the cardiac tissue with the positive inotrope present. The time to peak force was not 
significantly longer in the presence of Bay K 8644 in C57 than without the drug being 
present, despite a trend towards this occurring. 
 
One study has used Bay K 8644 previously in dystrophic myocardium (Sadeghi et al., 
2002). Sadeghi (2002) measured Ca2+ currents from neonatal cardiomyocytes and 
observed  that calcium channels in mdx myocytes were stimulated 2.3-fold more by 
Bay K 8644 than channels in control myocytes. The authors suggest that this increase 
is due to allosteric changes in the channel (Sadeghi et al., 2002) allowing the channel 
to be open longer. This increase is similar to the potency change observed in the 
current study and suggestive of a conformational change of the DHPR. 
 
5.2.2 Effects of the Calcium Channel Antagonists 
The L-type calcium channel antagonists reduce the influx of calcium by blocking the 
α1-subunit of the channel. The calcium channel antagonists were effective in reducing 
the influx of calcium via the L-type calcium channel. This is demonstrated by a 
negative inotropic response to each of the calcium channel antagonists, in a time- and 
dose-dependent manner. The tissue bath studies revealed differences in potency and 
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efficacy for the calcium channel antagonists in left atria between mdx and C57 mice. 
In the microelectrode studies, the drugs were tested at equipotent doses, the IC50s 
were calculated from the tissue bath studies and used to determine the effects of these 
drugs on the action potential in mdx cardiac tissue. The concentration that produced 
the maximum effects in the tissue bath studies was also used. Therefore, for all of the 
drugs used in the microelectrode study, higher doses were used for mdx left atria 
compared to C57. When these equipotent doses were administered, there was no 
difference in action potential attributes (except for diltiazem), or the negative 
inotropic effect of the calcium channel antagonists.  
 
In the tissue baths, the left atria displayed a decrease in sensitivity to the DHPR 
antagonist nifedipine that was similar to the reduction in potency to the DHPR agonist 
Bay K 8644. There are various explanations for this effect, such as: i) modulation of 
the DHPR results from the long-term exposure to an intracellular calcium overload 
(Dunn & Radda, 1991), or ii) in response to nifedipine there is an increase in activity 
of a putative sarcolemmal leak channel as has been observed in skeletal muscle 
(Turner et al., 1991). If sarcolemmal leak channels are present in cardiomyocytes, and 
if these channels behave similarly, it is possible that influx of calcium via these 
channels may cause earlier inactivation of the L-type channels. Sadeghi et al., (2002) 
observed that inactivation of the L-type calcium channel from mdx neonatal 
cardiomyocytes was delayed. This therefore suggests that the first hypothesis is more 
probable, however the physiological behaviour of neonatal cardiomyocytes may not 
necessarily mimic adult cardiomyocytes. Nifedipine also caused a further delay in 
relaxation of the mdx left atria. This effect cannot be accounted for via the effect on 
the L-type calcium channel, as blockade of the channel reduces intracellular calcium 
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levels, therefore relaxation should occur earlier. This effect may be due to an 
influence on the potassium channels. Another DHPR antagonist nicardipine has been 
shown to inhibit the repolarising potassium current and the Na+/Ca2+ exchange that 
extrudes calcium from the cell post-contraction (Richard et al., 1988). Since the 
structure of nifedipine closely resembles nicardipine, it is possible that it affected 
these mechanisms similarly.   
 
There was an increase in sensitivity to verapamil in the left atria from mdx compared 
to C57, although this was only due to one point on the curve, so it is of questionable 
physiological significance. There was no parallel dextral shift of the curve to signify a 
change in potency of the phenylalkylamine receptor. It is known that nifedipine can 
block the calcium current regardless of whether the channel is in the open or the 
inactivated state (steady depolarisation, without requiring pulses), and as such is 
considered more voltage-dependent than use-dependent (Bers & Perez-Reyes, 1999). 
Verapamil, on the other hand, appears to block the channel preferentially in the open 
state (ie requiring depolarising pulse) and as such is use-dependent. Thus, these 
differences in mechanism may also explain the observed differences in response to the 
two agents. 
 
Although the binding sites for all three classes of calcium channel antagonists are 
found on the α1-subunit of the L-type calcium channel (Catterall & Striessnig, 1992), 
the DHPR seems to be exclusively extracellular (Kass & Arena, 1989; Kass et al., 
1991) whilst the phenylalkylamine and benzothiazepine sites have both intracellular 
(Hescheler et al., 1982) and extracellular (Wegener & Nawrath, 1995; Adachi-
Akahane et al., 1993) components in ventricular myocytes and functional interaction 
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has been reported between sites (Kanda et al., 1998). It is also possible that a 
difference in receptor location on the L-type calcium channel in mdx myocardium 
may explain the lowered potency for nifedipine.  
 
The marked increase in APD observed in response to diltiazem may be due to an 
action of the drug on K+ channels. While the APD is shortened by diltiazem in rabbit 
ventricular tissues that naturally have a longer APD (Miyazaki et al., 1996), no 
reports could be found on its electrophysiological effects in mouse or rat cardiac 
tissues that have a much shorter APD. In contrast, phenylalkylamines have been 
shown to inhibit the cardiac delayed rectifier potassium current and the sodium-
activated potassium current, which would provide a basis for prolongation of the APD 
(Waldegger et al., 1999; Berger et al., 1991; Mori et al., 1998), although only slight 
prolongation was evident in response to verapamil in our studies. This prolongation 
may be due to an inhibition of NCE (mitochondrial sodium/potassium exchange), 
which would reduce the ATP available for SERCA for relaxation of the myocardium 
(Schwartz, 1992). Diltiazem is unique in the calcium channel antagonists in inhibiting 
the NCE in this manner. Kuo et al., (2002) have shown improvement in 
cardiomyopathy by blocking overactive NCE in the cardiomyopathic hamster. The 
function of the NCE in mdx is unknown. 
 
 An in vivo study to determine the efficacies of nifedipine, diltiazem and verapamil in 
γ-sarcoglycan deficient dystrophic hamsters observed that only diltiazem halted 
morbidity and mortality associated with dystrophic pathobiology (Johnson & 
Bhattacharya, 1993). In the same study, diltiazem effectively reduced the intracellular 
calcium overload in cardiac tissues, although effects on contractility or action 
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potential duration of myocardium were not examined. A reduction in calcium deposits 
in dystrophic hamster myocardium post treatment with diltiazem has also been 
observed histologically (Bhattacharya et al., 1982). It is probable that this protection 
is due to an effect on the NCE as well as the reduction in calcium influx through 
blockade of the L-type calcium channel. Therefore there may be therapeutic potential 
from administration of calcium channel antagonists in conditions of calcium overload, 
including the dystrophinopathies. 
 
5.3 Radioligand Binding Studies 
To date, no previous studies have measured DHPR density or affinity in mdx 
myocardium. Given the change in potency in the tissue bath studies to the DHPR 
drugs, it was an important set of experiments to determine whether this change was 
due to a change in the density of the channels, or a conformational change of the 
receptor, or both. In the radioligand studies, the mdx mice showed a significant 
increase in DHPRs, which could account for an increased influx of calcium into the 
cell, although the functionality of the receptors remains to be determined. The mdx 
mouse had a significantly reduced affinity for the DHPR agonist [3H]-PN 200 110. 
These results are clearly consistent with a reduced potency of nifedipine and Bay K 
8644 in the organ bath experiments, and suggest that both upregulation of the 
receptors occurs, and a conformational change of the receptor reducing its affinity for 
DHPR drugs. 
 
Receptor regulation is a commonly observed phenomenon in cardiovascular disease 
states. For example, congestive heart failure is associated with a reduction in β-
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adrenoceptor affinity, concurrent with β-adrenoceptor downregulation, as evidenced 
by an increased Kd and lower Bmax measured in radioligand binding studies (Brodde, 
1991). Similarly, regulation of the L-type calcium channel occurs in response to other 
disease processes. Hyperthyroidism has been shown to downregulate the L-type 
calcium channel (Watanabe et al., 2003), and electrical remodelling involving the L-
type calcium channel is an early manifestation of arrhythmia (Bosch et al., 2003). The 
DHPRs have been shown to downregulate in end stage heart failure (Takahashi et al., 
1992). As radioligand binding studies utilizing antagonists are not dependent on 
receptor stimulus and agonist efficacy, the Kd is determined solely by receptor affinity 
and is unaffected by the receptor density (Bmax). The increased Kd observed with [3H]-
PN200 110 in the current study shows a lowered receptor affinity and thus 
presumably altered conformation that would explain the lowered potency observed 
with Bay K 8644 and nifedipine. 
 
A possible mechanism that could affect the affinity of DHPRs is changes in the cell 
membrane potential, with depolarisation of the cardiac resting membrane potential 
causing an increase in DHPR affinity and thus presumably hyperpolarisation causing 
a decrease in DHPR affinity (Bean, 1984). However, microelectrode studies in left 
atria of mdx and C57 mice utilising the same conditions as those in the tissue bath 
studies, did not show any difference in resting membrane potential, eliminating this as 
a basis for the difference in DHPR affinity in the tissue bath studies. Furthermore, the 
difference in receptor affinity was maintained in the radioligand binding studies, 
where the influence of the membrane potential is eliminated. This provides clear 
evidence that a change in receptor affinity is not due to changes in membrane 
potential. 
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Another influence affecting DHPR affinity is the concentration of free calcium. Using 
[3H]-PN 200 110 in radioligand binding studies, Peterson and Catterall (1995) showed 
that divalent ions cause a biphasic effect on the affinity of DHPRs, with a low free 
calcium causing an increase in affinity, while a high free calcium causes a significant 
decrease in affinity. It is therefore, highly feasible that the calcium overload observed 
in mdx myocytes is a mediator responsible for the lowered affinity state of the DHPRs 
observed in the atrial contractility studies. However, in DHPR radioligand binding 
studies, calcium is not added to the incubation buffer and chelators such as EGTA are 
also present. This then eliminates any acute effects of calcium on modifying the 
affinity state of the DHPRs within such studies. Given that a lowered affinity for [3H]-
PN 200 110 was still observed, this may suggest that the chronic in vivo elevation of 
intracellular calcium and/or the primary lack of dystrophin may cause a more rigid 
conformational change in DHPRs, that is subsequently maintained in isolated 
membranes.  
 
5.4 Dihydropyridine Receptor RT-PCR 
Given the increase in DHPR density shown in radioligand binding studies, it is 
important to measure mRNA levels of the DHPR. These experiments showed a 2 fold 
and a 2.3 fold increase in atria and ventricles respectively, which supports the 
radioligand binding data. DHPRs have been shown to become upregulated in other 
conditions, including chronic adrenergic stimulation (Maki et al., 1996). While a 
comparison to previous values in mdx myocardium is not possible, Pereon et al., 
(1997) showed an elevation in DHPR mRNA expression in mdx diaphragm, however, 
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this was not associated with an elevation in DHPR protein expression measured by 
[3H]-PN 200-110 binding. This anomaly was explained by elevated protein 
degradation in mdx diaphragm, a muscle that shows marked deterioration (Stedman et 
al., 1991). In comparison, adult rat ventricular myocytes incubated in the presence of 
high intracellular calcium showed a two-fold increase in DHPR mRNA, providing 
evidence that a dystrophin-deficiency mediated increase in intracellular calcium could 
be the basis for the increased DHPR expression (Davidoff et al., 1997). 
 
5.5 Upregulation of the L-type Calcium Channel  
This dissertation provides strong evidence for upregulation of the L-type calcium 
channel, resulting in an increase in channel density. This change is associated with a 
conformational change of the receptor that lowers its affinity for DHPR drugs. An 
increase in L-type calcium current has been shown in mdx smooth muscle, where this 
increase is responsible for sustained tone in mdx colon (Mule & Serio, 2001). In other 
models of cardiomyopathy that are not due to dystrophin-deficiency (myocardial 
infarction induced by left coronary artery ligation), an elevation of intracellular 
calcium and an increased number of L-type calcium channels has been observed 
(Gopalakrishnan et al., 1991). Furthermore, in the presence of an intracellular calcium 
overload, mRNA for the channel subunit containing the DHPR binding site has been 
reported to increase twofold (Davidoff et al., 1997). Like the mdx mouse, heart failure 
in the γ-sarcoglycan deficient cardiomyopathic hamster is due to a loss of the 
dystrophin associated glycoprotein complex (Palmieri et al., 1981) and intracellular 
calcium is also elevated (Wagner et al., 1989), further indicating a causal relationship 
between dystrophin dysfunction and an intracellular calcium overload. Studies on the 
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hamster, however, are divided on whether there is a change in the affinity or density 
of cardiac L-type calcium channels. An increase in numbers of DHPR and 
phenylalkylamine binding sites has been reported (Wagner et al., 1989), although 
contrasting reports (Howlett & Gordon 1987; Sen et al., 1990) observe no change in 
density or affinity of these sites. The data for the influence of the L-type calcium 
channel in the pathogenesis of the cardiomyopathic hamster remain divided. 
 
The current study is the first to show a decrease in the affinity of the DHPR binding 
site, along with a significant increase in DHPR binding sites in mdx cardiomyocytes, 
both of which may explain the accompanying functional data which revealed a 
decrease in potency to nifedipine and Bay K 8644 in isolated atria. While indirect 
consequences of dystrophin deficiency causing an intracellular calcium overload may 
explain the alteration in DHPR affinity and density, it is also possible that the 
dystrophin deficiency may result directly in altered receptor conformation. Brand et. 
al. (1985) showed that DHPRs are located in transverse tubules (T tubules) of the 
myocyte, which is also the site where the majority of the cardiac dystrophin is located 
(Bers, 1991; Peri et al., 1994). Furthermore, dystrophin has been suggested to play a 
role in anchoring cardiac DHPRs, or modulating their activity (Meng et al., 1996). 
Therefore, the deficiency of dystrophin could result in a direct defect in the DHPR 
that in turn may contribute to the observed reduction of potency of DHP drugs in mdx 
cardiac tissues and a compensatory increase in DHPRs. Davidoff et al., (1997) 
observed a direct relationship between an intracellular calcium overload in rat 
cardiomyocytes, and an increase in DHPRs. Those experiments showed that elevated 
extracellular calcium in the incubation medium of the cardiomyocytes, caused a 
marked increase in DHPR mRNA, binding sites for [3H]-PN 200 110, an increased 
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Kd, and an increase in L-type calcium current after three days of intracellular calcium 
overload (Davidoff et al., 1997). These findings mirror those of the current study, of a 
reported intracellular calcium overload leading to an increase in DHPR mRNA, 
binding sites for [3H]-PN 200 110, an increased Kd, along with further functional 
changes. It therefore seems logical to hypothesise that a lack of dystrophin leads to 
intracellular calcium overload as an initiating event for the observed changes in the 
current study.  
 
Clearly, if an elevation of DHPRs is evident, then an alteration in the L-type calcium 
current should occur concurrently. It has already been shown that cultured neonatal 
cardiac myocytes from 1 to 4 day old mdx mice show a reduction in inactivation of 
the L-type calcium current, a change that could potentially elevate intracellular 
calcium, although no difference in peak current was evident in that particular study 
(Sadeghi et al., 2002). However, there are significant differences in T-tubule 
development and ion channel function between cultured neonatal cardiomyocytes and 
adult myocytes (Nuss & Marban, 1994), and such differences could be further 
exacerbated in mdx mice, as the mdx do not show significant pathology until about 21 
days of age (McArdle et al., 1995). To date only Alloatti et al., (1995) has published 
details on the adult mdx cardiac L-type calcium current, in which no significant 
differences in current were observed, however the authors did not provide details on 
perfusion or pipette solutions to indicate if the concentration of intracellular calcium 
was regulated during the experiment, yet this can have a major impact on current 
(Xiao et al., 1994).  
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Following a moderate increase in calcium bound to the calcium-binding protein 
calmodulin, the association between the inhibitory domain of the L-type channel and 
the catalytic subunit is disrupted to allow the catalytic subunit to phosphorylate a wide 
range of substrates. Also elevation of intracellular calcium causes the L-type calcium 
channel β-subunit (Jahn et al., 1988) to be phosphorylated by the calcium-
/calmodulin-dependent protein kinase II (CaM kinase) which results in an increased 
influx of calcium through the channel (Armstrong et al., 1988). Through these 
processes the calcium current can be increased by small increases in intracellular 
calcium, but at greater levels of increased resting intracellular calcium such as those 
observed in DMD, inhibition of influx predominates. Thus the calcium current can be 
differentially regulated depending on the level to which intracellular calcium is 
elevated. Furthermore, when intracellular calcium is elevated, calcium entry via the L-
type calcium channel will be further reduced largely due to a decrease in the 
electrochemical driving force for calcium entry (Sperelakis et al., 1996). Further study 
is required to elucidate the L-type calcium channel kinetics of mature mdx mice and 
how this may affect both APD and intracellular calcium levels.  
 
5.6 Differences in calcium handling between ventricles 
and atria 
Dystrophic ventricular tissue shows hypertrophy whereas atria either do not show 
enlargement or there are scant reports to support these kinds of changes. The atria 
workload is minimal compared to ventricular as they are only required to pump blood 
to the ventricles. Any systemic disease state that affects the volume or pressure of 
circulation will have an affect on the ventricular tissue, but not necessarily atria.  
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In comparison with ventricular cardiomyocytes, atrial cells are characterised by the 
absence of a t-tubular system (Minajeva et al., 1997). They contain only peripheral 
junctional SR connected to the sarcolemma and a higher proportion of corbular SR 
within the cytoplasm. Because corbular SR is not connected to the sarcolemmal 
membrane, calcium release from these stores must be triggered by a diffusible agent 
(Minajeva et al., 1997). Atrial and ventricular fibres do, however, exhibit the same 
sensitivity to calcium (Minajeva et al., 1997), and although they exhibit a lower 
density of ryanodine receptors, atrial cells have a very similar Kd and IC50 for 
ryanodine, and EC50 for calcium (Cote et al., 2000). A 30% higher level of SERCA 
mRNA has been observed in atria (Minajeva et al., 1997) compared to ventricle, and a 
lower expression of phospholamban. However, the structures necessitated by a 
functional SR network are present: Cl- selective channels, Ca2+-Mg2+-ATPase and 
other calcium regulating proteins (Cote et al., 2000). Both atria and ventricles of mdx 
exhibit fibrosis, focal degeneration and fatty infiltration (Bridges, 1986).  
 
5.7 Function of the Sarcoplasmic Reticulum 
The sarcoplasmic reticulum as the major store of calcium in the cardiomyocyte may 
contribute to the intracellular calcium overload. The rapid cooling contracture 
experiments enable comparison of SR calcium between dystrophic and normal tissues 
via the relative size of the contracture produced.  
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5.7.1 Altered Relaxation  
The reduced contractility of mdx isolated cardiac muscle appears to be in some part 
due to defective intracellular calcium homeostasis (Alloatti et al., 1995). The mdx left 
atria displayed a longer relaxation time in this study as previously reported (Sapp et 
al., 1996), which is indicative of a reduction in calcium sequestration, storage and/or 
extrusion from the cell. The two main pathways for removal of calcium are SERCA 
and the NCX. In the cardiomyopathic hamster, which exhibits a cardiac sarcoglycan 
deficiency, the NCX is increased secondary to the intracellular calcium overload 
(Wagner et al., 1989). Theoretically this would increase calcium extrusion at the 
resting membrane potential, and thus cannot be the basis for the elevation of 
intracellular calcium that is observed in mdx. A delayed relaxation is often associated 
with delayed repolarisation, however in mdx tissues, relaxation is delayed in spite of a 
shorter action potential.  
 
5.8 Force-Frequency Experiments 
At lower frequencies of stimulation, SR sequestration and function can be examined. 
As frequency is increased, active sequestration mechanisms have less time to restore 
calcium to the SR, but the voltage-dependent calcium channels are stimulated more 
frequently causing greater opening of the L-type calcium channels and hence greater 
net calcium influx. A negative staircase was observed in the murine myocardium with 
an impaired capacity to generate force being observed in mdx over a range of 
stimulation frequencies in the force-frequency experiments. Previously Alloatti et al., 
(1996) demonstrated a decline in force of contraction in response to increasing 
frequencies that was more marked in mdx compared to C57 left atria. The current 
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study showed a similar relationship in mdx, with the left atria unable to produce 
similar forces to C57 atria over a range of frequencies. A similar negative staircase in 
rat cardiac tissue is related to a myofilament desensitisation mechanism (Morii et al., 
1996). Possible mechanisms to explain this include a reduced time for SR calcium 
loading or a loss of myofilament sensitivity to calcium as reported in rat cardiac tissue 
(Morii et al., 1996). Mechanisms for a loss of myofilament sensitivity include altered 
responsiveness due to effects of ions and chemicals such as Mg2+, H+, 
phosphocreatine and inorganic phosphate (Donaldson, et al., 1978; Fabiato & Fabiato, 
1978; Kentish, 1986). In particular, an increase in stimulation frequency may cause an 
decrease in intracellular pH (Bountra et al., 1988).  
 
5.8.1 Response to Ryanodine 
When low concentrations of ryanodine were applied to the tissues, no difference in 
force of contraction relative to basal for each strain was evident, suggesting no 
difference in calcium release. When high doses of ryanodine were applied, SR release 
of calcium was inhibited, as evident by lower forces produced by the left atria. In this 
situation, L-type calcium current becomes that major pathway for calcium to activate 
the contractile apparatus. Under these conditions the L-type calcium current can be 
observed by the contractile properties of the tissue, because L-type calcium current is 
the only source of calcium available to the cell. In ryanodine treated animals where 
the cardiac tissue was stimulated at low frequencies, calcium from the SR has been 
shown to leak from the SR back into the cytoplasm from where it is extruded via 
NCX, which results in lower steady-state forces (Meyer et al., 2001). This 
phenomenon was observed in the current study. In species with a negative force-
frequency relationship such as mouse, ryanodine has been shown to convert the force-
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frequency relationship to a positive staircase, indicating that unmasking the 
sarcolemma contribution to the force-frequency relationship isolates a positive force-
frequency relationship in all species (Prabhu, 1998). Thus, on the addition of 
ryanodine, force-frequency relationship amplification is consistent with an increased 
importance of sarcolemmal calcium influx (Prabhu, 1998). 
 
When 1nM Ryanodine was added to the tissue bath to remove the contribution of the 
SR in releasing calcium for contractions, the force-frequency curve shows a positive 
staircase, indicative of L-type calcium influx becoming the predominant pathway to 
elevate cytosolic calcium. Low force of contraction is also observed in the presence of 
1nM Ryanodine, as there is no SR contribution to contractility of the myocardium. 
Force in the presence of 1nM Ryanodine was restored to equivalent of C57, indicating 
a greater influx of calcium via the L-type calcium channels in mdx, since the mdx 
myocardium cannot contract with similar force at the same level of cytosolic calcium. 
This functional finding once again lends support to the notion that the L-type calcium 
channels are upregulated in mdx myocardium. 
 
5.8.2 Response to Caffeine 
Caffeine was effective in inhibiting calcium release from the SR, as is evident from a 
decreased contractile force in both the control and mdx tissues. On the addition of 
caffeine, SR calcium release was inhibited, therefore L-type calcium current became 
the predominant source of calcium for contraction of the left atria. On the addition of 
the lowest concentration of caffeine, the mdx began to produce forces similar to those 
in C57, despite a normally reduced response to extracellular calcium. This is 
indicative of a greater flow of calcium through the L-type calcium channels. Because 
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caffeine is a methylxanthine, it also inhibits the enzyme phosphodiesterase allowing 
accumulation of cyclic AMP. Cyclic AMP increases the open time of the L-type 
calcium channels, thereby increasing sarcolemmal influx, as well as inhibiting SR 
calcium release. This effect is observed at the highest concentration of caffeine used 
where there is a trend for the mdx to produce greater force than the C57. This provides 
further functional data to support that mdx have a greater density of L-type calcium 
channels.  
 
5.8.3 Response to Dantrolene 
The force of contraction produced in both mdx and C57 with dantrolene present is 
indicative of the compound not blocking SR calcium release. Forces are maintained at 
levels observed in the absence of any drug, even in the presence of the highest 
concentration of dantrolene. A negative staircase remained, suggesting that L-type 
influx is not necessarily predominating at higher frequencies. There is a similar force-
frequency relationship in the presence of the highest concentration of dantrolene to 
the force-frequency relationship in the absence of drug, indicating that dantrolene did 
not block SR release. In other studies, dantrolene has been shown to be ineffective in 
blocking the cardiac ryanodine receptor (Zhao et al., 2002), but concentrations five 
times higher than the concentration used in the current study have shown a mild 
negative inotropic effect (Meissner et al., 1996). In rat myocardium dantrolene has 
been shown to produce a negative inotropic response in a low extracellular calcium 
solution, but not in high calcium (Fratea et al., 1997). The high calcium levels in 
dystrophic myocardium may thus be affecting the response to dantrolene. Dantrolene 
did not alter the force-frequency effect in rat myocardium or any SR calcium 
modulation mechanisms (uptake, release, postrest recovery) (Fratea et al., 1997). It is 
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plausible that a similar lack of effect was observed in the current study. The only 
study that observed the effects of dantrolene on murine myocardium showed that 
dantrolene was not effective in suppressing arrhythmia in a murine model (Brooks et 
al., 1989) which may suggest that dantrolene is not effective in blocking SR calcium 
release in murine myocardium. 
 
Dantrolene has been used in a clinical trial in boys with DMD. No cardiac changes 
were observed, however dantrolene reduced serum creatine kinase in the trial 
(Bertorini et al., 1991). The skeletal muscles showed a trend towards “a lessening of 
muscle deterioration” however no statistical differences were observed (Bertorini et 
al., 1991). The trial used only 7 patients with varying ages from 6 to 13 years of age, 
and one concentration of dantrolene was used. The study used 2 years prior to 
treatment as control. This study may have provided more clear evidence had the trial 
been placebo based and blinded. 
 
5.9 Rapid Cooling Contractures 
The amplitude of RCCs is a useful indicator of releasable SR calcium in intact cardiac 
muscle (Bers & Bridge, 1989). The first RCC in mdx is significantly smaller than 
control, when expressed in absolute force (mN), and when expressed as a percentage 
of normal twitch force. This indicates that either: i) the SR in mdx is releasing less 
calcium, ii) that the SR is leaky and/or cannot sequester and store calcium effectively, 
or iii) that the myocardium is unable to contract in response to a similar amount of 
calcium released as the C57. The tissue bath experiments in the current study have 
shown that the third hypothesis is most probable, as mdx left atria are unable to 
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contract with similar forces to control in response to extracellular calcium. RCC2 and 
RCC3 are smaller than RCC1 in both mdx and C57, but not significantly different 
between the strains. Using the SERCA specific inhibitor, the potency of CPA was not 
significantly different between the strains suggesting that SERCA function is 
comparable between the dystrophic and normal left atria. Therefore sequestration 
does not appear to be dysfunctional in mdx left atria. The difference between RCC1 
and RCC2 is attributed to the activity of the NCX (Bers & Bridge, 1989). In the 
current study, the percent change between mdx and C57 is almost identical when the 
decreased force production of mdx is taken into consideration. This suggests that 
NCX is functioning normally in mdx left atria.  
 
5.10 CPA Concentration-Response Curve 
Relaxation time is increased in mdx atria (Sapp et al., 1996) and DMD ventricles 
(Kovick et al., 1975; Goldberg et al., 1980). The current study showed no functional 
change in the level of SERCA, therefore the increased relaxation time may be 
attributed to changes in sarcolemmal calcium extrusion, or calcium binding proteins. 
Interestingly, Kargacin & Kargacin (1996) found no change in SERCA or the 
sensitivity of SERCA for calcium in skeletal muscle of mdx mice. They did, however, 
suggest that some SERCA units may be non-functional in dystrophic muscle. This 
could occur if some of the pump protein is partially degraded in the face of elevated 
calcium levels in dystrophin-deficient muscle or the continual degeneration and 
regeneration of dystrophic muscle causes expression of immature non-functional 
protein to be expressed in the SR membrane (Kargacin & Kargacin, 1996). Mule & 
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Serio (2001) observed no differences in SERCA by CPA-induced inhibition in colon 
of mdx.  
 
Phospholamban has been shown to significantly lengthen relaxation time in 
cardiomyocytes (Zvaritch et al., 2000) and to decrease SERCA affinity for calcium 
(Kimura et al., 1996). The level of expression of the intraluminal SR calcium binding 
proteins is altered in mdx myocardium. In mdx skeletal muscle SR, Culligan et al., 
(2002) observed a 20% reduction in the calcium binding capacity due to a reduction in 
calsequestrin-like binding proteins. Thus it is plausible that the lusitropic effect 
observed in mdx cardiac tissues may be due to changes in intraluminal SR calcium 
binding proteins. While active sequestration by SERCA appears to be functioning 
normally in mdx myocardium, if the binding proteins were not retaining the calcium in 
the SR, this calcium may contribute to the calcium overload and loss of sensitivity of 
the contractile proteins. 
 
5.11 SERCA RT-PCR 
SERCA in cardiac muscle of the laminin deficient dystrophic (dy/dy C57BL6J) 
mouse has been shown to be unchanged compared to control cardiomyocytes (Lucas-
Heron et al., 1987). Where SERCA mRNA has been successfully upregulated in 
mouse overexpression models, protein level was only moderately changed above the 
endogenous expression (Periasamy & Huke, 2001). The authors suggest that there 
may be powerful post-transcriptional mechanisms working to maintain a 
physiological SERCA level. In the current study, SERCA mRNA was increased, 
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although no functional evidence supported this change. It appears that mRNA changes 
observed in mdx SERCA are not translated into functional changes. 
 
In mdx heart, a study has shown decreased SERCA mRNA in 5 month old mice 
(Rohman et al., 2003). Given that changes in intracellular calcium lead to regulation 
of calcium handling proteins (Davidoff et al., 1997), it is not surprising that changes 
such as these are observed. SERCA mRNA levels have been shown to be increased 
(De Boer et al., 2001) and decreased (Mittman et al., 1998) in various models of 
cardiomyopathy, but protein levels in failing myocardium have been shown to be 
unchanged (Schwinger et al., 1995; Munch et al., 1998). The current study using mdx 
at 12-14 weeks of age showed an increase in SERCA mRNA but no functional 
change. It is postulated that mRNA is increased in response to the high intracellular 
calcium at this age, but protein levels remain unchanged. 
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CHAPTER 6 – IMPLICATIONS AND 
CONCLUSIONS 
6.1 Conclusions From the Current Study 
The current study aimed to elucidate potential mechanisms for the intracellular 
calcium overload that contributes to the pathogenesis of the myocardium in 
dystrophin-deficient conditions. The major findings from the current study were 
alterations in the potency, affinity and density of the DHPRs in mdx. Drugs active at 
the DHPR were approximately 2-fold less potent in mdx myocardium. In contracting 
left atrial preparations using both a DHPR agonist and antagonist, a potency 
difference of 2.7 and 1.9 respectively was evident. This finding was reinforced in 
purified ventricular membranes using radioligand binding studies which gave a 
similar potency difference of 2.0 and indicated an upregulation of DHPRs by 1.3 fold. 
RT-PCR studies provided further supportive evidence of receptor upregulation by 
increased mRNA expression in both atria and ventricles by 2.0 and 2.3 fold 
respectively. At various levels of complexity, utilising a range of techniques, clear 
evidence is provided to show that dystrophin deficiency in the mdx mouse results in 
DHPR upregulation in the myocardium and a reduction in receptor affinity. 
 
It is postulated that this increase in calcium channels is a contributor to the calcium 
overload in dystrophic myocardium. Yet the major calcium regulating mechanism, 
sequestration of calcium into the SR, appears to be unaffected in mdx. This is an 
interesting finding considering the delayed relaxation observed in this study and 
others (Sapp et al., 1996). A shorter action potential in mdx previously (Alloatti et al., 
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1995) would suggest that prolonged L-type Ca2+ influx is not responsible for delayed 
relaxation either. Therefore it is probable that this effect is due to alternate 
mechanisms, such as SR storage. Since the calcium binding proteins of the SR have 
been shown to be dysfunctional in dystrophic skeletal muscle, future cardiac studies 
should examine these particular proteins. SERCA mRNA was shown to be 
upregulated, a finding that was not supported with any functional changes. There was 
a trend towards there being a greater amount of SERCA in the CRC to CPA, but this 
was not statistically significant. The RCCs suggested that SERCA function was 
equivalent in mdx to that in C57. The consensus of data supports mdx SERCA levels 
being equivalent to C57 in the heart. It is probable that mRNA changes are not 
translated to protein. 
 
Interestingly, the potency of calcium is also lowered when conducting a 
concentration-response curve to extracellular calcium. This reduction in potency to 
calcium and capacity to generate force is indicative of a reduced sensitivity of the 
contractile proteins to calcium. One possible explanation for this is that a chronically 
elevated intracellular calcium such as that observed in dystrophic muscles could cause 
a significant reduction in myofilament sensitivity (Holt & Christensen, 1997). 
 
6.2 Implications of the Findings 
The current study has shown a significant defect in myocardial calcium handling that 
could contribute significantly to the pathogenesis of dystrophin-deficient disorders. 
The L-type calcium channels are upregulated in mdx myocardium, and as such 
represent a pathway for calcium overload which contributes to necrosis of 
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cardiomyocytes. The study has also shown a potency shift to DHP compounds due to 
a proposed conformational change in the dihydropyridine receptor. Thus treatment 
protocols need to be adjusted according to these findings.  
 
Currently boys with DMD are routinely administered positive inotropic drugs to 
increase cardiac output. Based on the findings of the current study indicating inherent 
calcium overload, this practice may be detrimental to the patient. Skeletal myopathy 
is the overt clinical sign in DMD, yet cardiac and respiratory insufficiency account for 
almost all mortality associated with the disease. The current study would suggest that 
administration of a calcium channel antagonist when cardiomyopathy is first apparent, 
or even earlier may be of some benefit in reducing calcium-dependent pathogenesis. 
Similarly, the calcium channel antagonists have the added advantage of reducing the 
incidence of arrhythmias, which may become life-threatening in DMD. A reduction in 
intracellular calcium may also be of advantage in terms of skeletal muscle myopathy, 
since an increase in intracellular calcium seems to be an important step in the 
pathogenesis associated with the development of the myopathy. Previously, an in vivo 
trial of diltiazem improved dysfunctional calcium handling in a mouse model of 
hypertrophic cardiomyopathy due to a disruption of the sarcomere (Semsarian et al., 
2002). Early administration of diltiazem restored calcium handling protein levels to 
normal and prevented development of pathology (Semsarian et al., 2002). Therefore 
the early administration of drugs that reduce intracellular calcium overload may have 
therapeutic potential in dystrophin-deficient conditions.   
 
Administration of a calcium channel blocker prior to cardiomyopathy may be able to 
inhibit the observed increase in density of the DHPR. Further studies are warranted to 
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determine whether this event can be inhibited, and at what age these changes occur. 
Similarly, a reduction in intracellular calcium may be linked with prevention of 
apoptosis and cellular necrosis. The potential for prevention of the pathogenesis in 
DMD needs to be elucidated. 
 
6.3 Future Research Directions 
6.3.1 Longitudinal Study 
A longitudinal study needs to be undertaken in mdx to confirm the age at which 
cardiac changes are observed, and to correlate these changes with alterations in 
calcium handling. The current study has observed a particular pathobiology at one age 
only. It is unknown when the onset of these changes occur, and whether these changes 
are maintained as the animal ages. Similarly, it remains unknown whether the primary 
defect of a lack of dystrophin causes changes in the L-type calcium channels, or 
whether these changes are secondary to other changes that lead to an intracellular 
accumulation of calcium. The lack of sarcolemmal integrity associated with the loss 
of dystrophin must lead to mechanical changes of the myocardium. It is unknown at 
what age the mdx begins to manifest cardiomyopathy associated with dystrophin-
deficiency. Similarly, it is unknown to what extent utrophin is able to upregulate in 
mdx cardiac tissues, and to what degree of function utrophin is able to compensate. 
The mdx mouse remains a poorly understood model of dystrophin-deficiency, 
especially in terms of pathogenesis of cardiac abnormalities. 
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6.3.2 Calcium Channel Antagonists 
Future work should entail a controlled drug trial of the calcium channel antagonists in 
the mdx model of dystrophin-deficiency. With the observed upregulation of the L-
type calcium channel in mdx, it is expected that an antagonist to this channel would be 
beneficial in reducing the calcium dependent proteolysis in the myocardium. Calcium 
channel blockers have further advantages in reducing the possibility of arrhythmia in 
boys with DMD, and reducing cardiac workload, thus delaying heart failure 
associated with dystrophin-deficiency and respiratory insufficiency. Since the current 
study has observed an upregulation of the DHPR utilising several different techniques 
and at different levels of complexity, it is hypothesised that an in vivo controlled drug 
trial of a DHPR antagonist would reduce the intracellular calcium overload associated 
with dystrophin-deficiency. Given that this in turn may restore sensitivity of the 
contractile proteins, a marked reduction in contractility caused by the calcium channel 
antagonists may not occur. Similarly, since calcium overload is an initiating event in 
terms of cellular necrosis and apoptosis, a reduction in this calcium may have the 
potential to reverse or at least delay this pathogenesis. 
 
6.3.3 Patch Clamp and L-type Calcium Current 
Patch clamp data needs to be obtained for mdx and C57 cardiomyocytes at 12-14 
weeks of age to confirm that the L-type current is increased compared to normal at 
this age. This study attempted to obtain L-type calcium currents by patch clamping 
dystrophin-deficient and normal cardiomyocytes (see Appendix) but was 
unsuccessful. Future work should examine the current magnitude from mdx and C57 
cardiomyocytes for comparison and examine open probability, conductance and 
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inactivation of the L-type calcium channel. An antagonist to the DHPR should also be 
tested, to determine the potency of these drugs in reducing the L-type current. Based 
on the observations of the current study, it is hypothesised that the L-type current is 
larger in mdx compared to C57, and that a higher concentration of DHPR antagonist 
would be required to reduce the current in mdx by a similar extent to that observed in 
C57 cardiomyoctes. It would also be interesting to combine the longitudinal study 
with a patch clamp study, to observe changes in L-type current by age. 
 
6.3.4 The Sodium/calcium Exchanger as a Potential 
Contributor to Calcium Overload 
The role of the sodium/calcium exchanger in dystrophic myocardium is as yet 
unknown. As the primary mechanism mediating calcium efflux from the cytoplasm, it 
deserves attention as a potential contributor to calcium overload in dystrophin-
deficient myocardium. Also, since the protein is located on the sarcolemma, where 
dystrophin is absent, there is potential for dysfunction of the NCX in the absence of 
dystrophin. Similarly, in the presence of an intracellular calcium overload, there is a 
potential for changes in expression of the NCX in an attempt to maintain homeostasis. 
 
6.3.5 Calcium Binding Proteins 
In mdx skeletal muscle, the calcium sequestration proteins of the SR have been shown 
to be dysfunctional (Culligan et al., 2002). The function of the calcium sequestration 
proteins in cardiac SR has not been reported. Data from the current study support 
functional SERCA, and a leaky SR. A study needs to evaluate the function of the 
cardiac SR calcium binding proteins.  
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6.3.6 Myofilament Sensitivity to Calcium 
The current study and previous studies (Lu & Hoey 2000 a & b; Sapp et al., 1996) 
have observed a decrease in force production by the myocardium of dystrophin-
deficient mice. This reduced ability to produce force exists despite an increased 
intracellular calcium concentration. It is hypothesised that a chronic calcium overload 
produces conformational changes in Troponin to reduce the sensitivity of the 
myofilaments to calcium. A study of skinned cardiac myofilaments could determine 
whether or not the myofilaments are desensitised.  
 
6.4 Conclusion 
The current study has shown substantial evidence to support both a decrease in 
affinity of the DHPR in mdx due to a conformational change of the DHPR, and an 
increase in DHPR density. The decrease in affinity is supported by tissue bath data 
using an agonist and antagonist at the DHPR, and radioligand binding studies using 
[3H]-PN 200 110. An increase in receptor density is supported by radioligand binding 
studies, and DHPR mRNA levels. Both of these changes are also supported in 
functional data, whereby blocking SR calcium release and causing L-type calcium 
current to become the primary source of intracellular calcium caused a restoration of 
force in mdx atria, despite a usually impaired force of contraction.  
 
A decrease in affinity of the DHPR may be due to a conformational change due to an 
interaction with the DAGPC. Alternatively, a loss of sarcolemmal integrity due to the 
absence of dystrophin may be the primary cause of intracellular calcium overload, and 
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an increase in DHPRs occurs secondary to this calcium overload. A conformational 
change of the DHPR could represent a calcium-induced change due to initial calcium 
overload. If this hypothesis is correct, the lack of dystrophin may be the initial event 
in a cycle of abnormal calcium handling, whereby the myocardium attempts to 
maintain intracellular calcium homeostasis by increasing L-type calcium channels, 
however this leads to further dysfunctional calcium handling. Eventually calcium-
dependent proteolytic enzymes are activated and cellular necrosis begins to diminish 
the function of the myocardium. 
 
The reduced force of contraction observed in mdx myocardium may represent a 
diminished calcium sensitivity of the myofilaments, caused by chronic calcium 
overload, a hypothesis that needs to be tested. 
 
The delayed relaxation observed in mdx can not be attributed to dysfunctional 
SERCA. The current study has shown a trend towards the upregulation of SERCA, 
rather than a downregulation which could account for a delayed relaxation. The 
potential mechanisms for this observation remain a loss of the SR calcium binding 
proteins, a mechanism that has been observed in skeletal muscle, a leaky SR or a 
leaky sarcolemma which is also feasible given the location of dystrophin. 
 
Regardless of the basis for the delayed relaxation, the use of calcium channel 
antagonists in treating dystrophinopathy-related cardiomyopathy requires further 
research. Calcium influx via the calcium channels in mdx appears to be a substantial 
contributor to the lack of calcium homeostasis and resultant calcium overload. 
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APPENDICES 
Appendix A – Oxygen Consumption Assay and 
Apparatus Development  
A series of oxygen consumption experiments were undertaken to determine whether 
potential futile calcium handling led to metabolic changes in the myocardium of mdx. 
However, these experiments were variable due to the small left atrial tissue size and 
the sensitivity of the oxygen consumption apparatus. 
 
The Requirement For Oxygen Usage Studies 
Dysfunctional calcium handling should be observed metabolically by changes in 
oxygen consumption. A series of oxygen consumption experiments evaluated energy 
usage in the mdx compared to C57 mice. 
 
During quiescence of the cardiac muscle, energy expenditure is related to 
extracellular ionic composition (Ponce-Hornos et al., 1987; 1990; 1992). The 
SERCA, along with the NCX contribute significantly to basal metabolism and are the 
active processes required for relaxation of the myocardium. SERCA expends energy 
directly at the rate of 1 ATP/2 calcium, and NCX indirectly and at twice the metabolic 
cost of 1 ATP/1 calcium (reflecting the 3:1 and 3:2 ionic stoichiometries of the NCX 
and Na+-K+ pump, respectively) (Cooper et al., 2001). SERCA contributes 
approximately 30% of oxygen consumption (Loiselle, 1987), whereas the Na+/K+ 
pump contributes less than 10% to cardiac resting metabolism (Schramm et al, 1994). 
During contraction, actomyosin ATPase activity of cross-bridges contributes to 
energy usage (Cooper et al., 2001). Cardiac energy demand increases in response to 
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increasing intracellular calcium concentrations (Fiolet et al., 1995). Calcium is also an 
important regulator of mitochondrial function. Impaired oxidative phosphorylation 
has been observed in dystrophin-deficient muscle cells (Even et al., 1994; Braun et 
al., 2001), although no mitochondrial abnormalities have been observed in cardiac 
muscle from 4-6 month old female mdx (Kuznetsov et al., 1998). At this age skinned 
mdx cardiac fibres have almost identical respiratory parameters as control in several 
different substrates (Kuznetsov et al., 1998). Kanai et al., (2001) proposed that 
elevated calcium activated mitochondrial NOS production, increasing local 
mitochondrial NO production, which inhibits mitochondrial ATP synthesis to inhibit 
contractility. Two studies of mitochondrial activity in DMD patients observed 
mitochondrial calcium overload due to the activity of proteolytic enzymes, and a 
decrease in ATP synthesis (Lucas-Heron 1996). Robert et al., (2001) observed that 
the mitochondria in skeletal muscle of mdx are responsible for both the apoptosis and 
impaired calcium homeostasis. 
 
Energy usage in dystrophin-deficient skeletal muscle is altered. It is unknown whether 
energy usage of the myocardium is unchanged, and whether changes in calcium 
handling contribute to altered metabolism of the myocardium.  
 
Oxygen Consumption Methodology 
A small stainless steel hook was placed in one end of the left atria, and a length of 
thread that was subsequently attached to the ergometer, (Model 300B, Aurora 
Scientific Inc., Canada) was attached to the other. The atrium was progressively 
stretched to the optimum preload and allowed 30 min to equilibrate in a 1.5mL 
chamber in 35±0.5°C TPSS saturated with carbogen. Oxygen consumption was 
continually monitored by an electrode in the base of the chamber while the TPSS was 
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constantly mixed by a magnetic stirrer (Dual Digital Model 20, Rank Brothers LTD). 
Initial experiments revealed that oxygen consumption was stabilised after 30 min. 
 
The left atrium was field stimulated (1Hz, 10V, 5ms duration; Grass SD9 isolated 
stimulator) for four sets of 10 min periods, with cessation of stimulation for three 30 
min periods for quiescent measurements. Subsequently 40mM KCl TPSS (as for 
TPSS except in mM: NaCl 102.3, KCl 40) was added for one 30 min period (Fig 
A.1). Oxygen consumption and contractility were measured concurrently for the 
duration of the experiment. Prior to each exchange of TPSS the solution was aerated 
with carbogen until saturation. All data was recorded using Chart 4.0 on a 
Powerlab/4SP (AD Instruments, Australia) and captured on an Apple iMac. The 
oxygen electrode was calibrated by measuring 100% dissolved oxygen, 20% 
dissolved oxygen (compressed air) and 0% dissolved oxygen by the addition of 
sodium dithionite. A linear plot was constructed and values for oxygen consumption 
calculated back from the plot (personal communication from the manufacturer 
indicated linearity of the oxygen electrode). Atria were blotted and weighed. Oxygen 
consumption was normalised as per tissue weight.  
 
 
 
Figure A.1 Oxygen consumption protocol. 1,2,3,4 are 10 min stimulation equilibration periods, 
ABC are 30min periods of quiescence. Subsequent to quiescence 40mM KCl was added for a 30 
min period. 
 
Depolarisation and L-type Calcium Channel Blockade 
At the conclusion of the stimulation period, the myocardium was depolarised by the 
addition of 40mM KCl for a 30 min period. Subsequently, nifedipine was added in 
40mM KCl TPSS to remove the effect of L-type calcium influx on the oxygen 
1 2 3 4 A B C KCl 
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consumption of the tissue. Depolarisation and addition of the dihydropyridine drug 
produced unusually high results, so diltiazem was used as an alternative L-type 
calcium channel blocker. However, diltiazem produced similarly high values. Finally, 
experiments were undertaken without tissue present to determine whether the KCl 
and/or the L-type calcium channel antagonists were affecting the oxygen electrode. 
 
Oxygen consumption data 
Preliminary Experiments 
Since oxygen consumption in cardiac tissue had not been previously undertaken in 
our laboratory, preliminary experiments focussed on evaluating the methodology. The 
oxygen electrode consumes oxygen, so experiments were conducted without tissue 
(Fig A.2) to measure the amount of oxygen consumed for the duration of the 
experimental protocol. Preliminary experiments also evaluated the oxygen 
consumption from immediately subsequent to dissection to determine when oxygen 
consumption stabilised (Fig A.2). Since oxygen consumption changed markedly for 
the first 10 – 20min, only the final 10min of the 40 min stimulated equilibration 
period was used for data comparison. A 30min period was determined to be optimal 
for the quiescent experiments, since oxygen consumption by the myocardium during 
quiescence is much lower. Finally, the effects of KCl, nifedipine and diltiazem on the 
oxygen electrode were evaluated (Fig. A.3). Oxygen consumption was increased 
markedly without tissue present, in the presence of the L-type Ca2+ channel 
antagonists. The drugs were made up in the final required concentration in TPSS to 
remove the effect of the solvent on the electrode. The oxygen consumption continued 
to be high. Because the drugs interfered with the oxygen electrode, they could not be 
used for any further experiments. 
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Comparison of Oxygen Consumption in mdx and C57 
Whole mouse mass was not significantly different between mdx (25.3±0.5g, n=14) 
and C57 (26.4±0.8g, n=8). Left atrial mass was not significantly different between 
mdx (22.8±1.2mg, n=14) and C57 (21.9±1.5mg, n=8). Force of contraction during the 
stimulation period was significantly smaller (P<0.05) in mdx (0.89±0.12) compared to 
C57 (1.28±0.17; Fig A.4). The oxygen usage data was unreliable, with quiescent 
periods sometimes using more oxygen than stimulation periods. Based on this finding 
the data was not used further. The variability in the oxygen usage data was 
presumably due to the small size of the murine atria using too little oxygen for the 
sensitivity of the apparatus. Hence, this data did not have sufficient rigour and was 
not included in the main thesis dissertation. 
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Figure A.2 Determination of oxygen consumption in the absence of tissue. A The oxygen 
consumption electrode uses oxygen from the solution, so to determine the amount of oxygen used 
during each experiment, control experiments were conducted without tissue. The data for the 10 
minute stimulation periods and the 30 minute quiescent periods are presented here. Due to the 
nature of the curve, final oxygen consumption for the stimulation period was taken only from the 
final 10min (n=5 for tissue, n=3 for no tissue). 
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Figure A.3 Comparison of the effects of KCl, nifedipine and diltiazem on oxygen consumption 
with and without tissue. Preliminary studies examined the effect of KCl (n=3 with and without 
tissue), nifedipine (NFD; n=4 with tissue, n=1 without tissue) and diltiazem (DTZ; n=4 with 
tissue, n=2 without tissue) on oxygen consumption in left atrial tissue, and in the absence of any 
tissue. Because nifedipine and diltiazem greatly increased oxygen consumption in the absence of 
any tissue, the drugs were not used in further studies.  
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Figure A.4 Contractility of mdx (n=9) and C57 (n=8) mice for all of the oxygen consumption 
experiments. 
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Appendix B - Patch Clamp Assay and Apparatus 
Development in our Laboratory 
The patch clamp apparatus and protocol had not been used previously in our 
laboratory, therefore considerable time was spent on development of apparatus, a 
myocyte isolation protocol and patch methodology. 
 
Initially assay development focussed on isolating functional murine cardiomyocytes. 
The mouse was euthanased by excess inhalation of carbon dioxide, and the heart 
rapidly excised and placed into cold, carbogenated TPSS. The aorta was placed on a 
canula (modified from a 26 gauge needle), with the use of a micro vessel clip (0.75 x 
4mm; SSR Cat No. 17-4000) to hold the aorta in place until a length of thread was 
tied around the aorta and canula. The canula was scarred approximately 2mm from 
the tip so that the aorta did not slip. The canula was then attached directly to the 
perfusion apparatus without further handling of the aorta or heart.  
 
A Gilson peristaltic pump was used to deliver carbogenated (95% O2, 5% CO2) TPSS 
(mM: NaCl 136.9, KCl 5.4, MgCl2.H2O 1.0, NaH2PO4.2H2O 0.4, NaHCO3 22.6, 
CaCl2.2H2O 1.8, glucose 5.5, ascorbic acid 0.3, Na2EDTA 0.05) through a water-
jacketed column at 3mL/min prior to mounting of the heart on the apparatus. The 
temperature of the perfusate was maintained at 37±0.5°C. Once attached to the 
apparatus, TPSS was perfused for 2 min to ensure appropriate perfusion and the heart 
was contracting normally. If the perfusion was satisfactory, the excess blood in the 
coronary vessels of the heart was removed causing the heart to change to a more 
pinkish colour, and the heart would beat consistently. The TPSS was then changed to 
a calcium free solution (in mM: NaCl 120, KCl 4.7, KH2PO4 1.2, MgSO4.7H2O 1.2, 
Glucose 15, NaHCO3 25, EDTA 0.5) for 10 min. Finally, collagenase (Life 
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Technologies Collagenase Type I, lypholized, 220 units/mg) was perfused through the 
heart for 10 min. The ventricles were then cut free from the atria and minced with 
scissors. A number of cells would be examined under the microscope at this point, 
and a small portion of the cells stored. The remaining cardiac tissue was placed in 
fresh collagenase and put in a 37±0.5°C shaking water bath (2Hz) for 10 min, before a 
fraction of cells was removed and collagenase added. This was repeated once more 
for a third fraction of cells. Each of the fractions were diluted in calcium-free solution 
(with 0.4mM CaCl2 added) containing BSA (1mg/mL) for 10 min. After the cells 
settled to the bottom of the tube, the supernatant was removed and replaced with a 
calcium-free solution (with 0.8mM CaCl2 added) containing BSA (1mg/mL). This 
was repeated another time with calcium-free solution (with 1.2mM CaCl2 added) 
containing BSA (1mg/mL).  
 
Initial cell yields from the isolation were poor, but provided cells with normal 
morphology. However, the myocytes were not calcium tolerant, and contracted when 
the patch pipette contacted them. To improve cell yield and stability for patches 
several alterations to the isolation protocol were trialled. 
 
The first alteration to the protocol was to lengthen the time that the myocardium was 
exposed to collagenase. Initially the time was extended to 15 min perfusion, however 
cell morphology became abnormal when exposed to collagenase for this extended 
period of time. Therefore the time the cardiomyocytes were exposed to collagenase in 
the perfusion was reduced to 5 min. The cell yields were improved, however the cells 
were not stable in the bath solution, nor when contacted by the patch pipette. This led 
to the use of several different extracellular (bath) and intracellular (pipette) solutions. 
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Glucose in the calcium free solutions was reduced from 15 to 5mM, and sodium 
bicarbonate was reduced from 50 to 25mM, in case the calcium free solution may be 
hyperosmotic. Intracellular solutions that were trialled include: ICa Solution 1 in mM: 
CaCl2 1.0, CsCl 120, EGTA 10, MgCl2 6, Na2ATP 5; Solution 2 in mM: CsCl 140, 
EGTA 10, MgCl2.6H2O 4, Hepes 10, ATP-Na2 4. The bath solution (in mM KCl 4.7, 
NaCl 120, KH2PO4 1.2, MgSO4.7H2O 1.2, Glucose 15, NaHCO3 25, EDTA 0.5, 
CaCl2 1.75) was calculated to be 303.4 mOsm, and the intracellular solution 1 (as 
above) calculated to be 289 mOsm. At this point a glass pipette was used to titrate the 
cells from the cardiac tissue. While the cell yield was improved, cells continued to 
contract on application of the patch pipette. 
 
A cleaning solution (0.1M HCl, 0.1M EDTA, pH 7.0 with KOH) was used for the 
isolation apparatus, and all containers that had solutions for the perfusion, or used for 
cells. All solutions were made with MilliQ water to reduce the possibility of 
contaminants affecting the perfusion. A 0.45 µM Millex HA filter was used in line to 
filter all solutions. 
 
Several different protocols were also used to produce pipettes, usually with a 
resistance of 1-20MΩ. Pippettes with a resistance higher than 10MΩ were discarded 
and only pipettes with a resistance of 1-2MΩ were used on the cardiomyocytes. A fire 
polisher was designed and made in our laboratory to polish the tips of the pipettes. 
 
A report by Sadeghi et al., (2002) was published at this point, a paper that 
successfully recorded L-type currents from mdx neonatal cardiomyocytes. Their 
solutions were trialled: extracellular (in mM TEA-Cl 145, BaCl2 10, MgCl2 1, 
HEPES, 10; pH 7.4) and intracellular (in mM N-methyl-D-glucamine 130, EGTA 10, 
HEPES 60, MgATP 2, MgCl 1; MSA to adjust pH 7.3). Another intracellular solution 
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was also trialled (in mM Na2ATP 3, EGTA 10, CsCl 120, HEPES 10, MgCl2 2; pH 
7.3). 
 
Rat cells were also used, to observe whether yield and contracture problems 
continued. The yield was much greater with rat heart (possibly due to more tissue and 
the absence of calcium overload), and cells were more stable, but a gigaseal was not 
obtained.  
 
Protease (0.12mg/mL) was used in the isolation in the collagenase solution. Also a 
portion of the cells was centrifuged in 1.2mM Ca2+ and the cells removed from the 
BSA albumin to ensure that the BSA was not affecting the gigaseal. 
 
A gigaseal was still not obtained, so the amount and time in collagenase was reduced. 
Colleagues who routinely patch murine cardiomyocytes were contacted for assistance 
and correspondence continued for several weeks. 
 
A simple intracellular solution containing EGTA, CsCl, MgCl2 and HEPES was used. 
The rate of the perfusion was tested, and trialled at two different rates. The pH of all 
solutions was observed throughout the perfusion and oxygen and carbogen were both 
tried and compared for pH changes to the solutions.  
 
Temperature was also measured as a potential source of the problem. The earth 
electrode was also re-chlorided.  
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Appendix C - Patch Clamp Assay and Apparatus 
Development at the University of Adelaide 
External expertise in patch clamping cardiomyocytes was sought since the protocol 
was unsuccessful in our laboratory. At the University of Adelaide, rat cardiomyocytes 
were routinely patch clamped.  
 
Initially perfusion was ineffective, so a soft plastic canula was made, similar to 
canula’s used in their laboratory for rat, except of a smaller diameter. The first 
extracellular solution used consisted of in mM: TEA-Cl 145, MgCl2 1, BaCl2 10, 
HEPES 10, adjusted to pH 7.4 with CsOH; and the first intracellular solution in mM: 
CsCl2 130, EDTA 10, HEPES 60, MgCl2 3, K2ATP 2, adjusted to pH 7.3 with CsOH. 
The collagenase used for the isolation was Type 1 from Gibco-BRL (220 units/mg), 
and was successful in isolating rat cardiomyocytes previously. The mouse was given 
an injection of heparin five minutes prior to euthanasia. Sodium currents were 
obtained from these murine cardiomyocytes, but not calcium currents. The 
extracellular solution caused crystals and the cells contracted spontaneously and then 
burst. Several different solutions were sought from the literature to produce L-type 
currents in heart cells (Hamplova-Peichlova et al., 2002; Vandecasteele et al., 2001; 
De Paoli et al., 2002; DuBell et al., 2002; Chen et al., 2001). Following this a simple 
extracellular solution was made consisting of in mM Tris 140, BaCl2 10. Cells still 
contracted spontaneously and imploded on contact with the pipette.  
 
A heavily buffered intracellular solution with low free calcium was attempted, as 
follows in mM: CsCl 130, EGTA 20, HEPES 60, K2ATP 2, MgCl2 3, pH 7.4 with 
CsOH. A rat heart was used since mice numbers were becoming low. Calcium 
currents were obtained from this rat that was injected with heparin prior to euthanasia. 
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The heart was placed on the plastic canula and a 1.5 mM calcium Tyrodes solution 
bubbled with O2 was run through the heart at 3mL/min for 5min. The Ca2+-free 
tyrodes was circulated through the heart for 20min, and then collagenase (Type 1 
Gibco-BRL 220 units/mg) was circulated for 20min and the heart removed, abrased 
with scissors tearing the ventricular tissue and placed into a BSA storage solution. 
The cells were then put through a series of Ca2+-containing solutions to raise the Ca2+ 
tolerance.  
 
25 ms
Figure C.1 Superimposed current records from mdx cardiomyocytes. Each current was elicited 
by voltage-clamp steps from a holding potential from –40mV to potentials between –40 and 
+120mV (in 5mV increments). 
 
The calcium currents produced by the rat cardiomyocytes were completely abolished 
on the addition of diltiazem, proving that these currents were from the L-type calcium 
channels.  
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The next mdx mouse produced a good yield of healthy looking cells. The heart was 
digested for 10min, and extracellular Calcium brought up to 0.5mM over 20min. 
Calcium currents were produced by these cardiomyocytes, though the seals were 
leaky, and the cells often died immediately after a calcium current was produced. 
After the completion of these studies an n of 2 for mdx and 0 for C57 were obtained. 
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Figure C.2 A calcium current IV curve from a 12 week old mdx. 
